[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fwT0FWhiBPYYNSrJEPoxaHzMvi4WSmVCJlt5zfVQyPbw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":86,"rows":93},"SWOG Cancer Research Network",[4],336,false,55,91,180820,115,49,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Breast Cancer",41,{"name":18,"count":19},"Lymphoma",34,{"name":21,"count":22},"Lung Cancer",30,{"name":24,"count":25},"Leukemia",27,{"name":27,"count":28},"Prostate Cancer",16,{"name":30,"count":31},"Colorectal Cancer",14,{"name":33,"count":34},"Head and Neck Cancer",13,{"name":36,"count":34},"Multiple Myeloma",[38,43,48,53,58,63,67,72,77,82],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT00070564","S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer","2015-01","pegfilgrastim",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT02785952","Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers","2019-12-19","Ipilimumab",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT01674140","S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer","2022-12-01","anastrozole",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT03654768","Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia","2024-07-01","Bosutinib",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT03939481","Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer","2025-04-08","Chemotherapy",{"nctId":64,"briefTitle":65,"date":66,"intervention":62},"NCT05633602","Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study","2025-11-26",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT03091660","S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer","2025-12-31","BCG Solution",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT05642572","Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)","2026-05-31","Capmatinib",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT04205968","Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers","2026-08-01","Fluorouracil",{"nctId":83,"briefTitle":84,"date":80,"intervention":85},"NCT04315324","Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)","AKR1C3-activated Prodrug AST-3424",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,138,156,293,767,909,960,1248,1465,1596,1733,1790,1835,1865,1982,2130,2191,2241,2282,2329,2362,2384,2406,2478,2551,2605,2647,2681,2764,2805,2860,2897,2930,2965,2987,3009,3031,3053,3098,3116,3134,3152,3170,3188,3206,3232,3258,3276,3294,3319,3347,3372,3390,3408,3435,3453,3471,3489,3507,3525,3543,3561,3579,3597,3615,3633,3651,3669,3687,3705,3723,3741,3759,3777,3795,3813,3831,3868,3989,4065,4120,4223,4258,4285,4312,4339,4357,4375,4393,4411,4429,4447,4465,4489,4513,4531,4549,4567,4585,4612,4630,4648,4666,4684,4702,4720,4738,4756,4774,4792,4814,4842,4860,4878,4896,4931,5076,5176,5272,5342,5421,5487,5535,5582,5616,5650,5693,5727,5757,5787,5813,5839,5874,5924,5950,5972,5994,6016,6038,6060,6082,6104,6126,6148,6170,6201,6223,6246,6264,6282,6308,6326,6344,6362,6385,6403,6421,6447,6465,6483,6507,6531,6549,6567,6585,6612,6630,6648,6666,6684,6702,6720,6747,6765,6783,6801,6819,6837,6859,6877,6895,6919,6937,7024,7070,7100,7130,7162,7198,7220,7250,7272,7294,7323,7351,7379,7401,7423,7445,7473,7500,7518,7536,7557,7585,7603,7621,7644,7662,7683,7701,7719,7737,7755,7773,7798,7819,7841,7859,7877,7895,7918,7940,7958,7976,7994,8012,8030,8048,8066,8084,8105,8126,8149,8167,8185,8203,8221,8239,8257,8275,8312,8330,8348,8366,8384,8402,8420,8438,8459,8477,8495,8513,8531,8549,8567,8585,8603,8621,8639,8657,8679,8697,8719,8737,8755,8778,8796,8818,8836,8938,8996,9048,9095,9139,9169,9199,9229,9259,9309,9338,9371,9393,9415,9437,9459,9481,9507,9529,9551,9573,9595,9613,9631,9649,9667,9690,9714,9732,9750,9768,9786],{"intervention":95,"totalTrials":96,"cells":97},"Ruxolitinib",2,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":118,"PHASE4":120,"NA":136},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":117,"soonestReadout":56},[105],{"nctId":54,"briefTitle":55,"status":106,"phases":107,"primaryCompletion":56,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":113},"ACTIVE_NOT_RECRUITING",[89],"2028-07-01","2018-10-24",81,[112],"Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",[57,114,115,95,116],"Dasatinib","Nilotinib","Imatinib",1,{"trials":119,"activeCount":100},[],{"trials":121,"activeCount":117,"soonestReadout":127},[122],{"nctId":123,"briefTitle":124,"status":125,"phases":126,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":134},"NCT07498205","Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts","NOT_YET_RECRUITING",[91],"2029-08-08","2031-08-08","2026-08-08",268,[132,133],"Myelofibrosis","Myelofibrosis (MF)",[135,95],"Momelotinib",{"trials":137,"activeCount":100},[],{"intervention":135,"totalTrials":117,"cells":139},{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":148,"NA":154},{"trials":141,"activeCount":100},[],{"trials":143,"activeCount":100},[],{"trials":145,"activeCount":100},[],{"trials":147,"activeCount":100},[],{"trials":149,"activeCount":117,"soonestReadout":127},[150],{"nctId":123,"briefTitle":124,"status":125,"phases":151,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":152,"interventions":153},[91],[132,133],[135,95],{"trials":155,"activeCount":100},[],{"intervention":157,"totalTrials":158,"cells":159},"Ramucirumab",9,{"EARLY_PHASE1":160,"PHASE1":162,"PHASE2":164,"PHASE3":253,"PHASE4":289,"NA":291},{"trials":161,"activeCount":100},[],{"trials":163,"activeCount":100},[],{"trials":165,"activeCount":252,"soonestReadout":75},[166,179,196,204,223,238],{"nctId":167,"briefTitle":168,"status":169,"phases":170,"primaryCompletion":171,"completion":171,"start":172,"enrollment":173,"conditions":174,"interventions":177},"NCT06031688","Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)","RECRUITING",[89],"2028-05-31","2024-08-08",56,[175,176],"Recurrent Lung Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8",[157,178],"Tepotinib",{"nctId":78,"briefTitle":79,"status":169,"phases":180,"primaryCompletion":80,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":190},[89],"2027-08-01","2020-06-01",94,[185,186,187,188,189],"Metastatic Small Intestinal Adenocarcinoma","Stage III Small Intestinal Adenocarcinoma AJCC v8","Stage IIIA Small Intestinal Adenocarcinoma AJCC v8","Stage IIIB Small Intestinal Adenocarcinoma AJCC v8","Stage IV Small Intestinal Adenocarcinoma AJCC v8",[81,191,192,193,194,195,157],"Irinotecan","Irinotecan Hydrochloride","Leucovorin","Leucovorin Calcium","Paclitaxel",{"nctId":73,"briefTitle":74,"status":169,"phases":197,"primaryCompletion":75,"completion":198,"start":199,"enrollment":200,"conditions":201,"interventions":202},[89],"2027-05-31","2023-05-05",66,[175,176],[76,203,157],"Osimertinib",{"nctId":205,"briefTitle":206,"status":207,"phases":208,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":213,"interventions":216},"NCT03971474","Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)","COMPLETED",[89],"2022-04-14","2024-01-01","2019-05-28",166,[175,176,214,215],"Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8",[217,218,219,220,221,222,157],"Docetaxel","Gemcitabine","Gemcitabine Hydrochloride","Pembrolizumab","Pemetrexed","Pemetrexed Disodium",{"nctId":224,"briefTitle":225,"status":207,"phases":226,"primaryCompletion":227,"completion":228,"start":229,"enrollment":230,"conditions":231,"interventions":236},"NCT03694002","Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery",[89],"2024-12-01","2025-03-03","2019-03-20",21,[232,233,234,235],"Locally Advanced Thymic Carcinoma","Metastatic Thymic Carcinoma","Recurrent Thymic Carcinoma","Unresectable Thymic Carcinoma",[237,195,157],"Carboplatin",{"nctId":239,"briefTitle":240,"status":241,"phases":242,"primaryCompletion":243,"completion":244,"start":245,"enrollment":100,"conditions":246,"interventions":249},"NCT04267913","Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)","WITHDRAWN",[89],"2025-10-31","2026-10-31","2020-09-05",[247,248,176,214,215],"Lung Squamous Cell Carcinoma","Recurrent Lung Carcinoma",[250,217,157,251],"Dexamethasone","Sapanisertib",3,{"trials":254,"activeCount":252,"soonestReadout":66},[255,271,282],{"nctId":256,"briefTitle":257,"status":106,"phases":258,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":263,"interventions":269},"NCT05096663","Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)",[89,90],"2027-06-30","2027-12-01","2022-03-15",82,[264,175,265,266,267,268,176,214,215],"Advanced Lung Non-Small Cell Carcinoma","Stage III Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8",[250,217,218,270,220,221,157],"Nogapendekin Alfa",{"nctId":272,"briefTitle":273,"status":169,"phases":274,"primaryCompletion":275,"completion":276,"start":277,"enrollment":278,"conditions":279,"interventions":280},"NCT06616584","Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)",[89,90],"2027-12-31","2028-12-31","2025-05-22",378,[175,176],[281,250,217,157],"Cemiplimab",{"nctId":64,"briefTitle":65,"status":106,"phases":283,"primaryCompletion":66,"completion":284,"start":285,"enrollment":286,"conditions":287,"interventions":288},[90],"2028-03-15","2023-03-14",838,[175,176],[62,220,157],{"trials":290,"activeCount":100},[],{"trials":292,"activeCount":100},[],{"intervention":294,"totalTrials":295,"cells":296},"cyclophosphamide",38,{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":319,"PHASE3":602,"PHASE4":763,"NA":765},{"trials":298,"activeCount":100},[],{"trials":300,"activeCount":100},[301],{"nctId":302,"briefTitle":303,"status":207,"phases":304,"primaryCompletion":305,"completion":306,"start":307,"enrollment":308,"conditions":309,"interventions":315},"NCT01925131","S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia",[88],"2022-01-01","2023-01-01","2014-06-13",50,[310,311,312,313,314],"Acute Leukemias of Ambiguous Lineage","B-cell Adult Acute Lymphoblastic Leukemia","Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia","Recurrent Adult Acute Lymphoblastic Leukemia","Recurrent Adult Burkitt Lymphoma",[294,316,317,318],"vincristine sulfate","prednisone","inotuzumab ozogamicin",{"trials":320,"activeCount":117,"soonestReadout":447},[321,338,352,365,376,386,403,416,427,443,465,476,487,497,507,518,527,537,548,558,568,577,590],{"nctId":322,"briefTitle":323,"status":207,"phases":324,"primaryCompletion":325,"completion":326,"start":327,"enrollment":173,"conditions":328,"interventions":329},"NCT00041132","S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma",[89],"2007-11","2011-06","2002-09",[18],[330,331,294,332,333,334,335,336,337],"filgrastim","rituximab","cytarabine","dexamethasone","doxorubicin","leucovorin","methotrexate","vincristine",{"nctId":339,"briefTitle":340,"status":207,"phases":341,"primaryCompletion":342,"completion":343,"start":344,"enrollment":345,"conditions":346,"interventions":347},"NCT00070018","S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma",[89],"2010-11","2015-01-08","2004-02",46,[18],[331,348,349,317,316,350,351],"Cyclophosphamide","doxorubicin hydrochloride","Yttrium-90 ibritumomab tiuxetan","Indium-111 ibritumomab tiuxetan",{"nctId":353,"briefTitle":354,"status":207,"phases":355,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":360,"interventions":361},"NCT00040937","S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma",[89],"2008-10","2015-10","2002-06",147,[36],[330,362,294,333,363,317,364],"sargramostim","melphalan","thalidomide",{"nctId":366,"briefTitle":367,"status":207,"phases":368,"primaryCompletion":369,"completion":370,"start":371,"enrollment":372,"conditions":373,"interventions":375},"NCT00064337","S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis",[89],"2012-05","2015-11","2004-01",104,[36,374],"Plasma Cell Myeloma",[330,294,333,363,364],{"nctId":377,"briefTitle":378,"status":207,"phases":379,"primaryCompletion":380,"completion":381,"start":382,"enrollment":383,"conditions":384,"interventions":385},"NCT01359592","S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma",[89],"2020-06-03","2023-12","2011-09",159,[18],[331,294,349,317,316],{"nctId":387,"briefTitle":388,"status":207,"phases":389,"primaryCompletion":390,"completion":391,"start":392,"enrollment":308,"conditions":393,"interventions":396},"NCT00002665","SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia",[89],"2001-12","2003-12","1995-07",[24,394,395],"Neutropenia","Thrombocytopenia",[397,294,332,398,333,349,399,400,401,336,317,402,316],"asparaginase","daunorubicin hydrochloride","etoposide","leucovorin calcium","mercaptopurine","thioguanine",{"nctId":404,"briefTitle":405,"status":207,"phases":406,"primaryCompletion":407,"completion":408,"start":409,"enrollment":410,"conditions":411,"interventions":413},"NCT00002657","SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant",[89],"2003-11","2011-07","1995-05",20,[18,412],"Multiple Myeloma and Plasma Cell Neoplasm",[414,415,294,332,349,399,336,317,316],"bleomycin sulfate","recombinant interferon alfa",{"nctId":417,"briefTitle":418,"status":207,"phases":419,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":424,"interventions":425},"NCT01412879","S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma",[89],"2016-02","2021-03","2011-11",53,[18],[331,426,294,332,333,349,400,336,316],"bendamustine hydrochloride",{"nctId":428,"briefTitle":429,"status":207,"phases":430,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":435,"interventions":437},"NCT00822120","S0816 Fludeoxyglucose F 18-PET\u002FCT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma",[89],"2016-04-30","2022-06-30","2009-07",371,[18,436],"Nonneoplastic Condition",[414,330,438,439,294,440,349,399,317,441,442,316],"ABVD regimen","BEACOPP regimen","dacarbazine","procarbazine hydrochloride","vinblastine sulfate",{"nctId":444,"briefTitle":445,"status":169,"phases":446,"primaryCompletion":447,"completion":447,"start":448,"enrollment":449,"conditions":450,"interventions":458},"NCT05633615","Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma",[89],"2030-06-30","2023-06-12",396,[451,452,453,454,455,456,457],"Diffuse Large B-Cell Lymphoma","Grade 3b Follicular Lymphoma","Primary Mediastinal (Thymic) Large B-Cell Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Transformed Follic Lymph to Diff Large B-Cell Lymphoma","Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma",[459,348,460,461,462,463,464],"Axicabtagene Ciloleucel","Fludarabine","Lisocabtagene Maraleucel","Mosunetuzumab","Polatuzumab Vedotin","Tisagenlecleucel",{"nctId":466,"briefTitle":467,"status":207,"phases":468,"primaryCompletion":469,"completion":470,"start":471,"enrollment":472,"conditions":473,"interventions":474},"NCT00376961","S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",[89],"2012-12","2017-09","2006-08",68,[18],[331,475,294,349,317,316],"bortezomib",{"nctId":477,"briefTitle":478,"status":207,"phases":479,"primaryCompletion":357,"completion":480,"start":481,"enrollment":482,"conditions":483,"interventions":484},"NCT00856492","S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer",[89],"2015-12","2010-04",215,[15],[485,42,294,349,486],"bevacizumab","paclitaxel albumin-stabilized nanoparticle formulation",{"nctId":488,"briefTitle":489,"status":207,"phases":490,"primaryCompletion":491,"completion":492,"start":493,"enrollment":494,"conditions":495,"interventions":496},"NCT00005089","S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma",[89],"2004-11","2014-04","2000-04",71,[18],[331,294,349,317,316],{"nctId":498,"briefTitle":499,"status":241,"phases":500,"primaryCompletion":501,"start":502,"enrollment":100,"conditions":503,"interventions":504},"NCT00723658","S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia",[89],"2010-05","2008-09",[18],[331,475,505,506,294,332,333,349,399,363,364],"carmustine","cisplatin",{"nctId":508,"briefTitle":509,"status":207,"phases":510,"primaryCompletion":511,"completion":512,"start":513,"enrollment":514,"conditions":515,"interventions":516},"NCT00107276","S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer",[89],"2008-03","2009-08","2005-08",112,[15],[517,294],"capecitabine",{"nctId":519,"briefTitle":520,"status":207,"phases":521,"primaryCompletion":522,"completion":480,"start":523,"enrollment":524,"conditions":525,"interventions":526},"NCT00107380","S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma",[89],"2013-11","2005-11",86,[18],[331,294,349,317,316],{"nctId":528,"briefTitle":529,"status":207,"phases":530,"primaryCompletion":531,"start":532,"enrollment":533,"conditions":534,"interventions":535},"NCT00003784","S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma",[89],"2003-01","1999-05",102,[18],[536,294,349,317,316],"CHOP regimen",{"nctId":538,"briefTitle":539,"status":207,"phases":540,"primaryCompletion":541,"completion":542,"start":543,"enrollment":544,"conditions":545,"interventions":546},"NCT00770224","S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma",[89],"2017-04","2019-08","2009-04",87,[18],[331,547,294,334,317,337],"tositumomab",{"nctId":549,"briefTitle":550,"status":207,"phases":551,"primaryCompletion":552,"completion":553,"start":554,"enrollment":555,"conditions":556,"interventions":557},"NCT00233987","S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma",[89],"2014-11","2017-12","2005-10",98,[18],[505,294,399,363],{"nctId":559,"briefTitle":560,"status":207,"phases":561,"primaryCompletion":407,"completion":408,"start":562,"enrollment":563,"conditions":564,"interventions":565},"NCT00002571","SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma",[89],"1994-06",52,[18],[414,330,294,332,349,399,400,336,317,566,316,567],"trimethoprim-sulfamethoxazole","Intrathecal cytarabine",{"nctId":569,"briefTitle":570,"status":241,"phases":571,"primaryCompletion":408,"completion":408,"start":408,"enrollment":100,"conditions":572,"interventions":573},"NCT01055301","S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma",[89],[36,374],[475,506,294,333,349,399,574,363,364,575,576],"lenalidomide","gene expression analysis","microarray analysis",{"nctId":578,"briefTitle":579,"status":207,"phases":580,"primaryCompletion":342,"completion":552,"start":581,"enrollment":582,"conditions":583,"interventions":584},"NCT00109837","S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",[89],"2005-04",79,[24],[330,294,332,585,333,334,335,401,336,586,587,317,402,337,588,589],"daunorubicin","mitoxantrone","Asparaginase","allopurinol","bactrim",{"nctId":591,"briefTitle":592,"status":207,"phases":593,"primaryCompletion":594,"completion":531,"start":595,"enrollment":596,"conditions":597,"interventions":599},"NCT00003549","S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer",[89],"2001-09","1998-10",80,[598],"Neuroendocrine Carcinoma of the Skin",[600,294,601,336],"CMF regimen","fluorouracil",{"trials":603,"activeCount":762,"soonestReadout":41},[604,612,624,634,650,659,670,680,698,707,720,732,742,749],{"nctId":39,"briefTitle":40,"status":106,"phases":605,"primaryCompletion":41,"completion":606,"start":407,"enrollment":607,"conditions":608,"interventions":609},[90],"2027-01",3294,[15],[42,610,294,349,611],"AC regimen","paclitaxel",{"nctId":613,"briefTitle":614,"status":207,"phases":615,"primaryCompletion":513,"completion":616,"start":617,"enrollment":618,"conditions":619,"interventions":620},"NCT00929591","SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer",[90],"2010-03","1989-05",1558,[15],[294,349,621,622,601,623],"endocrine therapy","endocrine-modulating drug therapy","tamoxifen citrate",{"nctId":625,"briefTitle":626,"status":207,"phases":627,"primaryCompletion":628,"completion":629,"start":630,"enrollment":631,"conditions":632,"interventions":633},"NCT00002548","SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma",[90],"2003-10","2006-11","1994-01",899,[36],[415,505,294,333,349,363,317,316],{"nctId":635,"briefTitle":636,"status":169,"phases":637,"primaryCompletion":638,"completion":639,"start":640,"enrollment":641,"conditions":642,"interventions":648},"NCT05929768","Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer",[90],"2033-03-31","2033-04","2023-09-15",2400,[643,644,645,646,647],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Early Stage Triple-Negative Breast Carcinoma",[237,348,217,649,195,220],"Doxorubicin",{"nctId":651,"briefTitle":652,"status":207,"phases":653,"primaryCompletion":382,"completion":654,"start":655,"enrollment":656,"conditions":657,"interventions":658},"NCT00006721","S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma",[90],"2025-12","2001-03",571,[18],[331,294,334,317,337],{"nctId":660,"briefTitle":661,"status":662,"phases":663,"primaryCompletion":344,"completion":344,"start":664,"enrollment":665,"conditions":666,"interventions":667},"NCT00002772","S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer","TERMINATED",[90],"1996-07",602,[15],[330,668,505,506,294,349,611,623,669],"carboplatin","thiotepa",{"nctId":671,"briefTitle":672,"status":207,"phases":673,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":678,"interventions":679},"NCT00004031","SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma",[90],"2008-06-01","2013-10-31","1997-07",397,[18],[331,536,505,294,349,399,317,316],{"nctId":681,"briefTitle":682,"status":125,"phases":683,"primaryCompletion":684,"completion":685,"start":686,"enrollment":533,"conditions":687,"interventions":691},"NCT07220187","Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial",[90],"2035-10-01","2036-10","2026-05-02",[688,689,690],"Richter Syndrome","Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma","Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma",[348,692,693,694,695,696,697],"Doxorubicin Hydrochloride","Pirtobrutinib","Prednisone","Rituximab","Rituximab and Hyaluronidase Human","Vincristine",{"nctId":699,"briefTitle":700,"status":662,"phases":701,"primaryCompletion":702,"completion":702,"start":493,"enrollment":703,"conditions":704,"interventions":705},"NCT00005090","S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease",[90],"2005-05",11,[18],[414,505,294,440,349,399,706],"vinblastine",{"nctId":708,"briefTitle":709,"status":207,"phases":710,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":715,"interventions":717},"NCT00005866","S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia",[90],"2004-03","2006-03","2000-02",240,[24,716],"Myelodysplastic Syndromes",[718,294,719,336],"busulfan","cyclosporine",{"nctId":721,"briefTitle":722,"status":207,"phases":723,"primaryCompletion":724,"completion":725,"start":628,"enrollment":726,"conditions":727,"interventions":730},"NCT00068601","S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer",[90],"2014-01","2016-09",257,[15,728,729],"Infertility","Menopausal Symptoms",[294,731],"goserelin acetate",{"nctId":733,"briefTitle":734,"status":207,"phases":735,"primaryCompletion":736,"completion":737,"start":738,"enrollment":739,"conditions":740,"interventions":741},"NCT00016406","S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer",[90],"2006-09","2012-02","2001-05",399,[15],[330,294,334,611],{"nctId":743,"briefTitle":744,"status":662,"phases":745,"primaryCompletion":407,"completion":325,"start":493,"enrollment":746,"conditions":747,"interventions":748},"NCT00005834","S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma",[90],19,[36],[330,506,294,333,399,364],{"nctId":750,"briefTitle":751,"status":169,"phases":752,"primaryCompletion":753,"completion":754,"start":56,"enrollment":755,"conditions":756,"interventions":758},"NCT06022939","Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis",[90],"2030-07-29","2030-10-29",338,[757],"AL Amyloidosis",[759,348,760,250,761],"Bortezomib","Daratumumab and Hyaluronidase-fihj","Melphalan",4,{"trials":764,"activeCount":100},[],{"trials":766,"activeCount":100},[],{"intervention":333,"totalTrials":230,"cells":768},{"EARLY_PHASE1":769,"PHASE1":771,"PHASE2":773,"PHASE3":866,"PHASE4":905,"NA":907},{"trials":770,"activeCount":100},[],{"trials":772,"activeCount":100},[],{"trials":774,"activeCount":100},[775,779,783,796,800,804,814,818,822,837,846,850,854,858],{"nctId":322,"briefTitle":323,"status":207,"phases":776,"primaryCompletion":325,"completion":326,"start":327,"enrollment":173,"conditions":777,"interventions":778},[89],[18],[330,331,294,332,333,334,335,336,337],{"nctId":353,"briefTitle":354,"status":207,"phases":780,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":781,"interventions":782},[89],[36],[330,362,294,333,363,317,364],{"nctId":784,"briefTitle":785,"status":207,"phases":786,"primaryCompletion":787,"completion":788,"start":789,"enrollment":790,"conditions":791,"interventions":794},"NCT01903811","S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma",[89],"2017-11-21","2019-03-07","2013-10",143,[792,793],"Recurrent Plasma Cell Myeloma","Refractory Plasma Cell Myeloma",[795,250],"Carfilzomib",{"nctId":366,"briefTitle":367,"status":207,"phases":797,"primaryCompletion":369,"completion":370,"start":371,"enrollment":372,"conditions":798,"interventions":799},[89],[36,374],[330,294,333,363,364],{"nctId":387,"briefTitle":388,"status":207,"phases":801,"primaryCompletion":390,"completion":391,"start":392,"enrollment":308,"conditions":802,"interventions":803},[89],[24,394,395],[397,294,332,398,333,349,399,400,401,336,317,402,316],{"nctId":805,"briefTitle":806,"status":207,"phases":807,"primaryCompletion":808,"completion":809,"start":810,"enrollment":811,"conditions":812,"interventions":813},"NCT00002849","S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis",[89],"1998-12","2000-07","1996-11",93,[36],[415,333],{"nctId":417,"briefTitle":418,"status":207,"phases":815,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":816,"interventions":817},[89],[18],[331,426,294,332,333,349,400,336,316],{"nctId":498,"briefTitle":499,"status":241,"phases":819,"primaryCompletion":501,"start":502,"enrollment":100,"conditions":820,"interventions":821},[89],[18],[331,475,505,506,294,332,333,349,399,363,364],{"nctId":823,"briefTitle":824,"status":207,"phases":825,"primaryCompletion":826,"completion":827,"start":828,"enrollment":829,"conditions":830,"interventions":834},"NCT01668719","S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",[88,89],"2020-02-05","2025-09-22","2012-11",142,[831,832,833],"DS Stage I Plasma Cell Myeloma","DS Stage II Plasma Cell Myeloma","DS Stage III Plasma Cell Myeloma",[759,250,835,836],"Elotuzumab","Lenalidomide",{"nctId":838,"briefTitle":839,"status":662,"phases":840,"primaryCompletion":841,"completion":842,"start":513,"enrollment":843,"conditions":844,"interventions":845},"NCT00124579","S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",[89],"2008-06","2010-06",7,[36],[475,333,364],{"nctId":569,"briefTitle":570,"status":241,"phases":847,"primaryCompletion":408,"completion":408,"start":408,"enrollment":100,"conditions":848,"interventions":849},[89],[36,374],[475,506,294,333,349,399,574,363,364,575,576],{"nctId":239,"briefTitle":240,"status":241,"phases":851,"primaryCompletion":243,"completion":244,"start":245,"enrollment":100,"conditions":852,"interventions":853},[89],[247,248,176,214,215],[250,217,157,251],{"nctId":578,"briefTitle":579,"status":207,"phases":855,"primaryCompletion":342,"completion":552,"start":581,"enrollment":582,"conditions":856,"interventions":857},[89],[24],[330,294,332,585,333,334,335,401,336,586,587,317,402,337,588,589],{"nctId":859,"briefTitle":860,"status":207,"phases":861,"primaryCompletion":862,"completion":371,"start":863,"enrollment":158,"conditions":864,"interventions":865},"NCT00003416","S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia",[89],"2000-08","1998-09",[18],[330,415,333,363],{"trials":867,"activeCount":762,"soonestReadout":259},[868,872,876,884,888,897,901],{"nctId":625,"briefTitle":626,"status":207,"phases":869,"primaryCompletion":628,"completion":629,"start":630,"enrollment":631,"conditions":870,"interventions":871},[90],[36],[415,505,294,333,349,363,317,316],{"nctId":256,"briefTitle":257,"status":106,"phases":873,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":874,"interventions":875},[89,90],[264,175,265,266,267,268,176,214,215],[250,217,218,270,220,221,157],{"nctId":877,"briefTitle":878,"status":207,"phases":879,"primaryCompletion":356,"completion":369,"start":491,"enrollment":880,"conditions":881,"interventions":883},"NCT00064038","S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma",[90],198,[36,882],"Plasma Cell Neoplasm",[333,574],{"nctId":272,"briefTitle":273,"status":169,"phases":885,"primaryCompletion":275,"completion":276,"start":277,"enrollment":278,"conditions":886,"interventions":887},[89,90],[175,176],[281,250,217,157],{"nctId":889,"briefTitle":890,"status":169,"phases":891,"primaryCompletion":892,"completion":892,"start":893,"enrollment":894,"conditions":895,"interventions":896},"NCT05561387","Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment",[90],"2031-05-30","2023-10-12",510,[374],[759,760,250,836],{"nctId":743,"briefTitle":744,"status":662,"phases":898,"primaryCompletion":407,"completion":325,"start":493,"enrollment":746,"conditions":899,"interventions":900},[90],[36],[330,506,294,333,399,364],{"nctId":750,"briefTitle":751,"status":169,"phases":902,"primaryCompletion":753,"completion":754,"start":56,"enrollment":755,"conditions":903,"interventions":904},[90],[757],[759,348,760,250,761],{"trials":906,"activeCount":100},[],{"trials":908,"activeCount":100},[],{"intervention":220,"totalTrials":910,"cells":911},5,{"EARLY_PHASE1":912,"PHASE1":914,"PHASE2":916,"PHASE3":922,"PHASE4":956,"NA":958},{"trials":913,"activeCount":100},[],{"trials":915,"activeCount":100},[],{"trials":917,"activeCount":100},[918],{"nctId":205,"briefTitle":206,"status":207,"phases":919,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":920,"interventions":921},[89],[175,176,214,215],[217,218,219,220,221,222,157],{"trials":923,"activeCount":762,"soonestReadout":66},[924,928,932,952],{"nctId":635,"briefTitle":636,"status":169,"phases":925,"primaryCompletion":638,"completion":639,"start":640,"enrollment":641,"conditions":926,"interventions":927},[90],[643,644,645,646,647],[237,348,217,649,195,220],{"nctId":256,"briefTitle":257,"status":106,"phases":929,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":930,"interventions":931},[89,90],[264,175,265,266,267,268,176,214,215],[250,217,218,270,220,221,157],{"nctId":933,"briefTitle":934,"status":125,"phases":935,"primaryCompletion":936,"completion":937,"start":938,"enrollment":939,"conditions":940,"interventions":945},"NCT07383441","Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer",[90],"2033-01-31","2034-01-31","2026-06-10",718,[941,942,943,944],"Advanced Clear Cell Renal Cell Carcinoma","Metastatic Clear Cell Renal Cell Carcinoma","Stage III Renal Cell Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8",[946,947,948,47,949,950,951,220],"Axitinib","Cabozantinib","Clostridium butyricum CBM 588 Probiotic Strain","Lenvatinib","Nivolumab","Nivolumab and Recombinant Human Hyaluronidase",{"nctId":64,"briefTitle":65,"status":106,"phases":953,"primaryCompletion":66,"completion":284,"start":285,"enrollment":286,"conditions":954,"interventions":955},[90],[175,176],[62,220,157],{"trials":957,"activeCount":100},[],{"trials":959,"activeCount":100},[],{"intervention":961,"totalTrials":962,"cells":963},"docetaxel",28,{"EARLY_PHASE1":964,"PHASE1":966,"PHASE2":988,"PHASE3":1118,"PHASE4":1229,"NA":1231},{"trials":965,"activeCount":100},[],{"trials":967,"activeCount":100},[968,978],{"nctId":969,"briefTitle":970,"status":662,"phases":971,"primaryCompletion":972,"completion":972,"start":973,"enrollment":974,"conditions":975,"interventions":976},"NCT00288054","S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer",[88],"2012-04","2006-04",24,[21],[977,961],"cetuximab",{"nctId":979,"briefTitle":980,"status":241,"phases":981,"primaryCompletion":982,"completion":982,"start":502,"enrollment":100,"conditions":983,"interventions":985},"NCT00937417","S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors",[88],"2009-09",[15,33,21,27,984],"Unspecified Adult Solid Tumor, Protocol Specific",[961,986,987],"vandetanib","proteomic profiling",{"trials":989,"activeCount":100},[990,999,1006,1017,1025,1036,1044,1052,1056,1063,1074,1083,1091,1099,1103],{"nctId":991,"briefTitle":992,"status":207,"phases":993,"primaryCompletion":994,"completion":995,"start":996,"enrollment":472,"conditions":997,"interventions":998},"NCT00003908","S9902 Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer",[89],"2004-06","2007-01","1999-11",[33],[668,961],{"nctId":1000,"briefTitle":1001,"status":207,"phases":1002,"primaryCompletion":325,"start":1003,"conditions":1004,"interventions":1005},"NCT00054054","S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer",[89],"2003-04",[33],[506,961,601],{"nctId":1007,"briefTitle":1008,"status":207,"phases":1009,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":1013,"conditions":1014,"interventions":1015},"NCT00026156","S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer",[89],"2004-07","2008-11","2001-11",125,[21],[961,1016],"vinorelbine tartrate",{"nctId":1018,"briefTitle":1019,"status":662,"phases":1020,"primaryCompletion":523,"completion":523,"start":1021,"enrollment":117,"conditions":1022,"interventions":1024},"NCT00058448","S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED)",[89],"2004-10",[1023],"Penile Cancer",[961],{"nctId":1026,"briefTitle":1027,"status":207,"phases":1028,"primaryCompletion":789,"completion":1029,"start":616,"enrollment":1030,"conditions":1031,"interventions":1035},"NCT00872989","S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",[89],"2014-05",129,[1032,1033,1034],"Fallopian Tube Cancer","Ovarian Cancer","Primary Peritoneal Cavity Cancer",[961,986],{"nctId":1037,"briefTitle":1038,"status":207,"phases":1039,"primaryCompletion":1040,"completion":1040,"start":1041,"enrollment":345,"conditions":1042,"interventions":1043},"NCT00062439","S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors",[89],"2010-12","2003-07",[21],[506,961,399],{"nctId":1045,"briefTitle":1046,"status":662,"phases":1047,"primaryCompletion":1048,"completion":1048,"start":655,"enrollment":1049,"conditions":1050,"interventions":1051},"NCT00014196","S0022:Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer",[89],"2005-03",33,[21],[506,961],{"nctId":205,"briefTitle":206,"status":207,"phases":1053,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":1054,"interventions":1055},[89],[175,176,214,215],[217,218,219,220,221,222,157],{"nctId":1057,"briefTitle":1058,"status":241,"phases":1059,"primaryCompletion":995,"completion":995,"start":1060,"enrollment":100,"conditions":1061,"interventions":1062},"NCT00084435","S0217, Adjuvant Cisplatin and Docetaxel After Complete Resection Stage III or IV Head and Neck Cancer",[89],"2005-07",[33],[506,961],{"nctId":1064,"briefTitle":1065,"status":207,"phases":1066,"primaryCompletion":1067,"completion":1068,"start":327,"enrollment":1069,"conditions":1070,"interventions":1071},"NCT00041067","S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer",[89],"2008-01","2012-01",76,[15],[330,1072,961,1073],"trastuzumab","vinorelbine",{"nctId":1075,"briefTitle":1076,"status":207,"phases":1077,"primaryCompletion":1078,"completion":995,"start":595,"enrollment":1079,"conditions":1080,"interventions":1081},"NCT00003587","S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer",[89],"2001-01",204,[21],[668,506,961,1082,611,1073],"gemcitabine",{"nctId":1084,"briefTitle":1085,"status":662,"phases":1086,"primaryCompletion":1087,"completion":841,"start":1088,"enrollment":25,"conditions":1089,"interventions":1090},"NCT00025493","S0029 Docetaxel in Treating Older Women With Metastatic Breast Cancer",[89],"2007-06","2001-10",[15],[961],{"nctId":1092,"briefTitle":1093,"status":207,"phases":1094,"primaryCompletion":1095,"completion":828,"start":738,"enrollment":1096,"conditions":1097,"interventions":1098},"NCT00015938","S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer",[89],"2005-02",95,[15],[330,961,1073],{"nctId":239,"briefTitle":240,"status":241,"phases":1100,"primaryCompletion":243,"completion":244,"start":245,"enrollment":100,"conditions":1101,"interventions":1102},[89],[247,248,176,214,215],[250,217,157,251],{"nctId":1104,"briefTitle":1105,"status":207,"phases":1106,"primaryCompletion":1107,"completion":1108,"start":737,"enrollment":1109,"conditions":1110,"interventions":1114},"NCT01498289","S1201: Combination Chemo for Patients W\u002FAdvanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",[89],"2018-03","2019-09-19",213,[1111,1112,1113],"Adenocarcinoma of the Gastroesophageal Junction","Esophageal Cancer","Gastric Cancer",[1115,961,601,1116,400,1117],"FOLFOX regimen","irinotecan hydrochloride","oxaliplatin",{"trials":1119,"activeCount":762,"soonestReadout":259},[1120,1130,1134,1138,1151,1160,1164,1181,1205,1215],{"nctId":1121,"briefTitle":1122,"status":662,"phases":1123,"primaryCompletion":1124,"completion":1124,"start":1125,"enrollment":1126,"conditions":1127,"interventions":1128},"NCT00268372","S0427, Combination Chemotherapy & RT in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx",[90],"2007-12","2005-12",6,[33],[506,961,1129],"5-fluorouracil",{"nctId":635,"briefTitle":636,"status":169,"phases":1131,"primaryCompletion":638,"completion":639,"start":640,"enrollment":641,"conditions":1132,"interventions":1133},[90],[643,644,645,646,647],[237,348,217,649,195,220],{"nctId":256,"briefTitle":257,"status":106,"phases":1135,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":1136,"interventions":1137},[89,90],[264,175,265,266,267,268,176,214,215],[250,217,218,270,220,221,157],{"nctId":1139,"briefTitle":1140,"status":207,"phases":1141,"primaryCompletion":1142,"completion":1143,"start":1144,"enrollment":1145,"conditions":1146,"interventions":1149},"NCT02766335","Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers",[89,90],"2018-09","2020-09","2014-07-31",116,[1147,1148],"Recurrent Squamous Cell Lung Carcinoma","Stage IV Squamous Cell Lung Carcinoma AJCC v7",[217,1150],"Durvalumab",{"nctId":1152,"briefTitle":1153,"status":207,"phases":1154,"primaryCompletion":420,"completion":420,"start":471,"enrollment":1155,"conditions":1156,"interventions":1158},"NCT00134056","S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy",[90],1038,[1157,27],"Metastatic Cancer",[1159,961,317],"atrasentan hydrochloride",{"nctId":272,"briefTitle":273,"status":169,"phases":1161,"primaryCompletion":275,"completion":276,"start":277,"enrollment":278,"conditions":1162,"interventions":1163},[89,90],[175,176],[281,250,217,157],{"nctId":1165,"briefTitle":1166,"status":207,"phases":1167,"primaryCompletion":1168,"completion":1169,"start":1170,"enrollment":1171,"conditions":1172,"interventions":1179},"NCT02965378","Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer",[89,90],"2017-01","2019-10","2014-10",43,[1173,1174,1175,1176,1177,1178,1147,1148],"FGFR1 Gene Amplification","FGFR1 Gene Mutation","FGFR2 Gene Amplification","FGFR2 Gene Mutation","FGFR3 Gene Amplification","FGFR3 Gene Mutation",[217,1180],"FGFR Inhibitor AZD4547",{"nctId":1182,"briefTitle":1183,"status":169,"phases":1184,"primaryCompletion":1185,"completion":1186,"start":1187,"enrollment":1188,"conditions":1189,"interventions":1195},"NCT03678025","Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer",[90],"2028-04-01","2031-10-01","2018-09-24",1273,[1190,1191,1192,1193,1194],"Castration Levels of Testosterone","Metastatic Prostatic Adenocarcinoma","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8",[1196,1197,1198,217,1199,1200,1201,1202,1203,694,1204],"Abiraterone","Bicalutamide","Degarelix","Flutamide","Goserelin Acetate","Histrelin Acetate","Leuprolide Acetate","Nilutamide","Triptorelin",{"nctId":1206,"briefTitle":1207,"status":207,"phases":1208,"primaryCompletion":1209,"completion":995,"start":1210,"enrollment":1211,"conditions":1212,"interventions":1213},"NCT00004001","S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy",[90],"2006-07","1999-10",770,[27],[961,1214,586,317],"estramustine",{"nctId":1216,"briefTitle":1217,"status":207,"phases":1218,"primaryCompletion":1219,"completion":1220,"start":1221,"enrollment":423,"conditions":1222,"interventions":1227},"NCT02785939","Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer",[89,90],"2017-06","2019-06","2014-09",[1223,1224,1225,1226,1147,1148],"CCND1 Gene Amplification","CCND2 Gene Amplification","CCND3 Gene Amplification","CDK4 Gene Amplification",[217,1228],"Palbociclib",{"trials":1230,"activeCount":100},[],{"trials":1232,"activeCount":100},[1233],{"nctId":1234,"briefTitle":1235,"status":207,"phases":1236,"primaryCompletion":1237,"completion":1238,"start":1239,"enrollment":1240,"conditions":1241,"interventions":1242},"NCT02154490","Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer",[],"2022-04-01","2022-04-15","2014-07-08",1864,[1147,1148],[217,1150,1243,1180,47,950,1228,1244,1245,1246,1247],"Erlotinib Hydrochloride","Rilotumumab","Talazoparib","Taselisib","Tremelimumab",{"intervention":611,"totalTrials":1249,"cells":1250},26,{"EARLY_PHASE1":1251,"PHASE1":1253,"PHASE2":1255,"PHASE3":1396,"PHASE4":1461,"NA":1463},{"trials":1252,"activeCount":100},[],{"trials":1254,"activeCount":100},[],{"trials":1256,"activeCount":117,"soonestReadout":80},[1257,1267,1271,1279,1290,1299,1307,1319,1328,1337,1345,1353,1357,1361,1369,1377,1387],{"nctId":1258,"briefTitle":1259,"status":207,"phases":1260,"primaryCompletion":1261,"completion":1261,"start":1262,"enrollment":472,"conditions":1263,"interventions":1265},"NCT00003896","S9912 Combination Chemo in Stage III Ovarian Cancer,",[89],"2008-02","1999-09",[1032,1033,1264],"Peritoneal Cavity Cancer",[506,1266,611],"liposomal doxorubicin",{"nctId":78,"briefTitle":79,"status":169,"phases":1268,"primaryCompletion":80,"completion":181,"start":182,"enrollment":183,"conditions":1269,"interventions":1270},[89],[185,186,187,188,189],[81,191,192,193,194,195,157],{"nctId":1272,"briefTitle":1273,"status":207,"phases":1274,"primaryCompletion":371,"completion":995,"start":1275,"enrollment":1276,"conditions":1277,"interventions":1278},"NCT00002969","S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer",[89],"1997-05",60,[21],[611],{"nctId":1280,"briefTitle":1281,"status":207,"phases":1282,"primaryCompletion":842,"completion":408,"start":390,"enrollment":16,"conditions":1283,"interventions":1284},"NCT00028769","S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer",[89],[27],[1285,1214,399,1286,1287,1288,1289,611],"bicalutamide","flutamide","goserelin","leuprolide","nilutamide",{"nctId":1291,"briefTitle":1292,"status":207,"phases":1293,"primaryCompletion":1294,"completion":1124,"start":1295,"enrollment":1296,"conditions":1297,"interventions":1298},"NCT00003158","S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer",[89],"2002-12","1998-02",96,[21],[668,399,611],{"nctId":1300,"briefTitle":1301,"status":207,"phases":1302,"primaryCompletion":982,"completion":1303,"start":655,"enrollment":1304,"conditions":1305,"interventions":1306},"NCT00008138","S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer",[89],"2009-11",62,[1032,1033,1264],[668,611],{"nctId":1308,"briefTitle":1309,"status":207,"phases":1310,"primaryCompletion":1311,"completion":1312,"start":531,"enrollment":1313,"conditions":1314,"interventions":1318},"NCT00045630","S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium",[89],"2008-05","2011-12",77,[1315,1316,1317],"Bladder Cancer","Transitional Cell Cancer of the Renal Pelvis and Ureter","Urethral Cancer",[668,1082,611],{"nctId":1320,"briefTitle":1321,"status":207,"phases":1322,"primaryCompletion":1003,"completion":1010,"start":1295,"enrollment":1323,"conditions":1324,"interventions":1326},"NCT00003127","S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer",[89],57,[1325],"Endometrial Cancer",[1327,668,611],"amifostine trihydrate",{"nctId":1329,"briefTitle":1330,"status":207,"phases":1331,"primaryCompletion":1332,"completion":1332,"start":1333,"enrollment":843,"conditions":1334,"interventions":1335},"NCT00055835","S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium",[89],"2006-06","2002-11",[1315,1317],[668,506,1336,611],"gemcitabine hydrochloride",{"nctId":1338,"briefTitle":1339,"status":207,"phases":1340,"primaryCompletion":1261,"completion":1261,"start":1341,"enrollment":1342,"conditions":1343,"interventions":1344},"NCT00100789","S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer",[89],"2005-01",67,[33],[1082,611],{"nctId":1346,"briefTitle":1347,"status":207,"phases":1348,"primaryCompletion":711,"completion":1011,"start":1210,"enrollment":1349,"conditions":1350,"interventions":1351},"NCT00004137","S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer",[89],88,[21],[330,668,611,1352],"topotecan hydrochloride",{"nctId":1075,"briefTitle":1076,"status":207,"phases":1354,"primaryCompletion":1078,"completion":995,"start":595,"enrollment":1079,"conditions":1355,"interventions":1356},[89],[21],[668,506,961,1082,611,1073],{"nctId":224,"briefTitle":225,"status":207,"phases":1358,"primaryCompletion":227,"completion":228,"start":229,"enrollment":230,"conditions":1359,"interventions":1360},[89],[232,233,234,235],[237,195,157],{"nctId":1362,"briefTitle":1363,"status":662,"phases":1364,"primaryCompletion":841,"completion":408,"start":1365,"enrollment":1366,"conditions":1367,"interventions":1368},"NCT00022633","S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract",[89],"2001-07",65,[1315,1316,1317],[1336,611],{"nctId":1370,"briefTitle":1371,"status":207,"phases":1372,"primaryCompletion":1373,"completion":408,"start":1010,"enrollment":1374,"conditions":1375,"interventions":1376},"NCT00085501","S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[89],"2007-08",242,[21],[977,668,611],{"nctId":1378,"briefTitle":1379,"status":207,"phases":1380,"primaryCompletion":480,"completion":1381,"start":1382,"enrollment":1383,"conditions":1384,"interventions":1385},"NCT00661193","S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[89],"2016-12","2008-12",59,[21],[668,1386,611],"erlotinib hydrochloride",{"nctId":1388,"briefTitle":1389,"status":207,"phases":1390,"primaryCompletion":1391,"completion":1391,"start":1392,"enrollment":1393,"conditions":1394,"interventions":1395},"NCT00006248","S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer",[89],"2005-06","2000-11",78,[33],[506,601,611],{"trials":1397,"activeCount":96,"soonestReadout":41},[1398,1402,1409,1413,1420,1437,1441,1450,1457],{"nctId":39,"briefTitle":40,"status":106,"phases":1399,"primaryCompletion":41,"completion":606,"start":407,"enrollment":607,"conditions":1400,"interventions":1401},[90],[15],[42,610,294,349,611],{"nctId":1403,"briefTitle":1404,"status":207,"phases":1405,"completion":973,"start":1392,"conditions":1406,"interventions":1407},"NCT00006484","Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer",[90],[21],[668,611,1408],"tirapazamine",{"nctId":635,"briefTitle":636,"status":169,"phases":1410,"primaryCompletion":638,"completion":639,"start":640,"enrollment":641,"conditions":1411,"interventions":1412},[90],[643,644,645,646,647],[237,348,217,649,195,220],{"nctId":1414,"briefTitle":1415,"status":241,"phases":1416,"primaryCompletion":1041,"completion":1041,"start":1003,"enrollment":100,"conditions":1417,"interventions":1419},"NCT00057928","S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer",[90],[1418],"Cervical Cancer",[506,1336,611],{"nctId":1421,"briefTitle":1422,"status":662,"phases":1423,"primaryCompletion":1424,"completion":1425,"start":1426,"enrollment":1427,"conditions":1428,"interventions":1434},"NCT00946712","S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and\u002For Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer",[90],"2017-08-31","2022-02-08","2009-07-15",1333,[1429,1430,1147,1431,1432,1433],"Recurrent Large Cell Lung Carcinoma","Recurrent Lung Adenocarcinoma","Stage IV Large Cell Lung Carcinoma","Stage IV Lung Adenocarcinoma","Stage IV Squamous Cell Lung Carcinoma",[1435,237,1436,195],"Bevacizumab","Cetuximab",{"nctId":660,"briefTitle":661,"status":662,"phases":1438,"primaryCompletion":344,"completion":344,"start":664,"enrollment":665,"conditions":1439,"interventions":1440},[90],[15],[330,668,505,506,294,349,611,623,669],{"nctId":1442,"briefTitle":1443,"status":207,"phases":1444,"primaryCompletion":1445,"completion":828,"start":1446,"enrollment":1447,"conditions":1448,"interventions":1449},"NCT00003120","S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission",[90],"2003-06","1997-11",308,[1032,1033,1264],[611],{"nctId":1451,"briefTitle":1452,"status":207,"phases":1453,"primaryCompletion":702,"completion":828,"start":1210,"enrollment":1454,"conditions":1455,"interventions":1456},"NCT00004011","S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer",[90],354,[21],[668,611],{"nctId":733,"briefTitle":734,"status":207,"phases":1458,"primaryCompletion":736,"completion":737,"start":738,"enrollment":739,"conditions":1459,"interventions":1460},[90],[15],[330,294,334,611],{"trials":1462,"activeCount":100},[],{"trials":1464,"activeCount":100},[],{"intervention":317,"totalTrials":974,"cells":1466},{"EARLY_PHASE1":1467,"PHASE1":1469,"PHASE2":1475,"PHASE3":1539,"PHASE4":1592,"NA":1594},{"trials":1468,"activeCount":100},[],{"trials":1470,"activeCount":100},[1471],{"nctId":302,"briefTitle":303,"status":207,"phases":1472,"primaryCompletion":305,"completion":306,"start":307,"enrollment":308,"conditions":1473,"interventions":1474},[88],[310,311,312,313,314],[294,316,317,318],{"trials":1476,"activeCount":100},[1477,1481,1485,1489,1493,1497,1501,1505,1509,1513,1517,1521,1525,1535],{"nctId":339,"briefTitle":340,"status":207,"phases":1478,"primaryCompletion":342,"completion":343,"start":344,"enrollment":345,"conditions":1479,"interventions":1480},[89],[18],[331,348,349,317,316,350,351],{"nctId":353,"briefTitle":354,"status":207,"phases":1482,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":1483,"interventions":1484},[89],[36],[330,362,294,333,363,317,364],{"nctId":377,"briefTitle":378,"status":207,"phases":1486,"primaryCompletion":380,"completion":381,"start":382,"enrollment":383,"conditions":1487,"interventions":1488},[89],[18],[331,294,349,317,316],{"nctId":387,"briefTitle":388,"status":207,"phases":1490,"primaryCompletion":390,"completion":391,"start":392,"enrollment":308,"conditions":1491,"interventions":1492},[89],[24,394,395],[397,294,332,398,333,349,399,400,401,336,317,402,316],{"nctId":404,"briefTitle":405,"status":207,"phases":1494,"primaryCompletion":407,"completion":408,"start":409,"enrollment":410,"conditions":1495,"interventions":1496},[89],[18,412],[414,415,294,332,349,399,336,317,316],{"nctId":428,"briefTitle":429,"status":207,"phases":1498,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":1499,"interventions":1500},[89],[18,436],[414,330,438,439,294,440,349,399,317,441,442,316],{"nctId":466,"briefTitle":467,"status":207,"phases":1502,"primaryCompletion":469,"completion":470,"start":471,"enrollment":472,"conditions":1503,"interventions":1504},[89],[18],[331,475,294,349,317,316],{"nctId":488,"briefTitle":489,"status":207,"phases":1506,"primaryCompletion":491,"completion":492,"start":493,"enrollment":494,"conditions":1507,"interventions":1508},[89],[18],[331,294,349,317,316],{"nctId":519,"briefTitle":520,"status":207,"phases":1510,"primaryCompletion":522,"completion":480,"start":523,"enrollment":524,"conditions":1511,"interventions":1512},[89],[18],[331,294,349,317,316],{"nctId":528,"briefTitle":529,"status":207,"phases":1514,"primaryCompletion":531,"start":532,"enrollment":533,"conditions":1515,"interventions":1516},[89],[18],[536,294,349,317,316],{"nctId":538,"briefTitle":539,"status":207,"phases":1518,"primaryCompletion":541,"completion":542,"start":543,"enrollment":544,"conditions":1519,"interventions":1520},[89],[18],[331,547,294,334,317,337],{"nctId":559,"briefTitle":560,"status":207,"phases":1522,"primaryCompletion":407,"completion":408,"start":562,"enrollment":563,"conditions":1523,"interventions":1524},[89],[18],[414,330,294,332,349,399,400,336,317,566,316,567],{"nctId":1526,"briefTitle":1527,"status":207,"phases":1528,"primaryCompletion":1529,"completion":1530,"start":1531,"enrollment":16,"conditions":1532,"interventions":1533},"NCT01309672","S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy",[89],"2016-11-29","2024-04-11","2011-08-09",[27],[1534,694],"abiraterone acetate",{"nctId":578,"briefTitle":579,"status":207,"phases":1536,"primaryCompletion":342,"completion":552,"start":581,"enrollment":582,"conditions":1537,"interventions":1538},[89],[24],[330,294,332,585,333,334,335,401,336,586,587,317,402,337,588,589],{"trials":1540,"activeCount":252,"soonestReadout":1185},[1541,1545,1556,1560,1564,1568,1572,1584,1588],{"nctId":625,"briefTitle":626,"status":207,"phases":1542,"primaryCompletion":628,"completion":629,"start":630,"enrollment":631,"conditions":1543,"interventions":1544},[90],[36],[415,505,294,333,349,363,317,316],{"nctId":1546,"briefTitle":1547,"status":207,"phases":1548,"primaryCompletion":1549,"completion":1550,"start":1551,"enrollment":1552,"conditions":1553,"interventions":1554},"NCT00004124","S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer",[90],"2017-08-12","2018-05-01","1999-10-15",983,[27],[1285,1287,1555,317],"mitoxantrone hydrochloride",{"nctId":1152,"briefTitle":1153,"status":207,"phases":1557,"primaryCompletion":420,"completion":420,"start":471,"enrollment":1155,"conditions":1558,"interventions":1559},[90],[1157,27],[1159,961,317],{"nctId":651,"briefTitle":652,"status":207,"phases":1561,"primaryCompletion":382,"completion":654,"start":655,"enrollment":656,"conditions":1562,"interventions":1563},[90],[18],[331,294,334,317,337],{"nctId":671,"briefTitle":672,"status":207,"phases":1565,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":1566,"interventions":1567},[90],[18],[331,536,505,294,349,399,317,316],{"nctId":1182,"briefTitle":1183,"status":169,"phases":1569,"primaryCompletion":1185,"completion":1186,"start":1187,"enrollment":1188,"conditions":1570,"interventions":1571},[90],[1190,1191,1192,1193,1194],[1196,1197,1198,217,1199,1200,1201,1202,1203,694,1204],{"nctId":1573,"briefTitle":1574,"status":169,"phases":1575,"primaryCompletion":1576,"completion":1577,"start":1578,"enrollment":1579,"conditions":1580,"interventions":1582},"NCT06470243","Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body",[90],"2029-06-30","2034-04","2024-11-27",528,[1581,1194],"Castration-Resistant Prostate Carcinoma",[1583,237,694],"Cabazitaxel",{"nctId":681,"briefTitle":682,"status":125,"phases":1585,"primaryCompletion":684,"completion":685,"start":686,"enrollment":533,"conditions":1586,"interventions":1587},[90],[688,689,690],[348,692,693,694,695,696,697],{"nctId":1206,"briefTitle":1207,"status":207,"phases":1589,"primaryCompletion":1209,"completion":995,"start":1210,"enrollment":1211,"conditions":1590,"interventions":1591},[90],[27],[961,1214,586,317],{"trials":1593,"activeCount":100},[],{"trials":1595,"activeCount":100},[],{"intervention":668,"totalTrials":1597,"cells":1598},22,{"EARLY_PHASE1":1599,"PHASE1":1601,"PHASE2":1603,"PHASE3":1686,"PHASE4":1729,"NA":1731},{"trials":1600,"activeCount":100},[],{"trials":1602,"activeCount":100},[],{"trials":1604,"activeCount":117,"soonestReadout":1633},[1605,1609,1613,1617,1621,1625,1629,1642,1653,1666,1670,1674,1678,1682],{"nctId":991,"briefTitle":992,"status":207,"phases":1606,"primaryCompletion":994,"completion":995,"start":996,"enrollment":472,"conditions":1607,"interventions":1608},[89],[33],[668,961],{"nctId":1291,"briefTitle":1292,"status":207,"phases":1610,"primaryCompletion":1294,"completion":1124,"start":1295,"enrollment":1296,"conditions":1611,"interventions":1612},[89],[21],[668,399,611],{"nctId":1300,"briefTitle":1301,"status":207,"phases":1614,"primaryCompletion":982,"completion":1303,"start":655,"enrollment":1304,"conditions":1615,"interventions":1616},[89],[1032,1033,1264],[668,611],{"nctId":1308,"briefTitle":1309,"status":207,"phases":1618,"primaryCompletion":1311,"completion":1312,"start":531,"enrollment":1313,"conditions":1619,"interventions":1620},[89],[1315,1316,1317],[668,1082,611],{"nctId":1320,"briefTitle":1321,"status":207,"phases":1622,"primaryCompletion":1003,"completion":1010,"start":1295,"enrollment":1323,"conditions":1623,"interventions":1624},[89],[1325],[1327,668,611],{"nctId":1329,"briefTitle":1330,"status":207,"phases":1626,"primaryCompletion":1332,"completion":1332,"start":1333,"enrollment":843,"conditions":1627,"interventions":1628},[89],[1315,1317],[668,506,1336,611],{"nctId":1630,"briefTitle":1631,"status":169,"phases":1632,"primaryCompletion":1633,"completion":1634,"start":1635,"enrollment":1636,"conditions":1637,"interventions":1641},"NCT05806515","Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation",[89],"2027-07","2031-06","2024-03-01",44,[1638,1639,1640],"Prostate Adenocarcinoma","Stage IIIB Prostate Cancer AJCC v8","Stage IIIC Prostate Cancer AJCC v8",[237],{"nctId":1643,"briefTitle":1644,"status":241,"phases":1645,"primaryCompletion":1646,"completion":1647,"start":1648,"enrollment":100,"conditions":1649,"interventions":1651},"NCT05364645","Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer",[89],"2023-06-27","2029-05-01","2022-07-25",[1650,175,176,214,215],"Lung Non-Small Cell Carcinoma",[237,221,1652],"Selpercatinib",{"nctId":1654,"briefTitle":1655,"status":662,"phases":1656,"primaryCompletion":1657,"completion":1658,"start":1659,"enrollment":1126,"conditions":1660,"interventions":1664},"NCT04871529","Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)",[89],"2023-11-14","2024-06-26","2022-08-10",[1661,1662,1663],"Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall","Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma","Stage II Bladder Cancer AJCC v8",[1665,219,237],"Avelumab",{"nctId":1346,"briefTitle":1347,"status":207,"phases":1667,"primaryCompletion":711,"completion":1011,"start":1210,"enrollment":1349,"conditions":1668,"interventions":1669},[89],[21],[330,668,611,1352],{"nctId":1075,"briefTitle":1076,"status":207,"phases":1671,"primaryCompletion":1078,"completion":995,"start":595,"enrollment":1079,"conditions":1672,"interventions":1673},[89],[21],[668,506,961,1082,611,1073],{"nctId":224,"briefTitle":225,"status":207,"phases":1675,"primaryCompletion":227,"completion":228,"start":229,"enrollment":230,"conditions":1676,"interventions":1677},[89],[232,233,234,235],[237,195,157],{"nctId":1370,"briefTitle":1371,"status":207,"phases":1679,"primaryCompletion":1373,"completion":408,"start":1010,"enrollment":1374,"conditions":1680,"interventions":1681},[89],[21],[977,668,611],{"nctId":1378,"briefTitle":1379,"status":207,"phases":1683,"primaryCompletion":480,"completion":1381,"start":1382,"enrollment":1383,"conditions":1684,"interventions":1685},[89],[21],[668,1386,611],{"trials":1687,"activeCount":96,"soonestReadout":1576},[1688,1692,1696,1700,1704,1713,1717,1721],{"nctId":1403,"briefTitle":1404,"status":207,"phases":1689,"completion":973,"start":1392,"conditions":1690,"interventions":1691},[90],[21],[668,611,1408],{"nctId":635,"briefTitle":636,"status":169,"phases":1693,"primaryCompletion":638,"completion":639,"start":640,"enrollment":641,"conditions":1694,"interventions":1695},[90],[643,644,645,646,647],[237,348,217,649,195,220],{"nctId":1421,"briefTitle":1422,"status":662,"phases":1697,"primaryCompletion":1424,"completion":1425,"start":1426,"enrollment":1427,"conditions":1698,"interventions":1699},[90],[1429,1430,1147,1431,1432,1433],[1435,237,1436,195],{"nctId":660,"briefTitle":661,"status":662,"phases":1701,"primaryCompletion":344,"completion":344,"start":664,"enrollment":665,"conditions":1702,"interventions":1703},[90],[15],[330,668,505,506,294,349,611,623,669],{"nctId":1705,"briefTitle":1706,"status":207,"phases":1707,"primaryCompletion":1087,"completion":408,"start":1708,"enrollment":1709,"conditions":1710,"interventions":1711},"NCT00043082","S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer",[90],"2002-08",61,[1033,1264],[668,1712],"pegylated liposomal doxorubicin hydrochloride",{"nctId":1573,"briefTitle":1574,"status":169,"phases":1714,"primaryCompletion":1576,"completion":1577,"start":1578,"enrollment":1579,"conditions":1715,"interventions":1716},[90],[1581,1194],[1583,237,694],{"nctId":1451,"briefTitle":1452,"status":207,"phases":1718,"primaryCompletion":702,"completion":828,"start":1210,"enrollment":1454,"conditions":1719,"interventions":1720},[90],[21],[668,611],{"nctId":1722,"briefTitle":1723,"status":662,"phases":1724,"primaryCompletion":1333,"completion":629,"start":1725,"enrollment":843,"conditions":1726,"interventions":1727},"NCT00006708","S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",[90],"2000-10",[18],[330,331,668,399,1728],"ifosfamide",{"trials":1730,"activeCount":100},[],{"trials":1732,"activeCount":100},[],{"intervention":836,"totalTrials":1126,"cells":1734},{"EARLY_PHASE1":1735,"PHASE1":1737,"PHASE2":1739,"PHASE3":1765,"PHASE4":1786,"NA":1788},{"trials":1736,"activeCount":100},[],{"trials":1738,"activeCount":100},[],{"trials":1740,"activeCount":117,"soonestReadout":1745},[1741,1757,1761],{"nctId":1742,"briefTitle":1743,"status":169,"phases":1744,"primaryCompletion":1745,"completion":1746,"start":1747,"enrollment":1748,"conditions":1749,"interventions":1753},"NCT05890352","Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment",[89],"2026-12-31","2029-01","2023-09-26",227,[452,1750,1751,454,455,1752],"High Grade B-Cell Lymphoma","High Grade B-Cell Lymphoma With MYC and BCL2 and\u002For BCL6 Rearrangements","Transformed Non-Hodgkin Lymphoma",[836,1754,1755,1756],"Tafasitamab","Tazemetostat","Zanubrutinib",{"nctId":823,"briefTitle":824,"status":207,"phases":1758,"primaryCompletion":826,"completion":827,"start":828,"enrollment":829,"conditions":1759,"interventions":1760},[88,89],[831,832,833],[759,250,835,836],{"nctId":569,"briefTitle":570,"status":241,"phases":1762,"primaryCompletion":408,"completion":408,"start":408,"enrollment":100,"conditions":1763,"interventions":1764},[89],[36,374],[475,506,294,333,349,399,574,363,364,575,576],{"trials":1766,"activeCount":96,"soonestReadout":1775},[1767,1771,1782],{"nctId":877,"briefTitle":878,"status":207,"phases":1768,"primaryCompletion":356,"completion":369,"start":491,"enrollment":880,"conditions":1769,"interventions":1770},[90],[36,882],[333,574],{"nctId":1772,"briefTitle":1773,"status":106,"phases":1774,"primaryCompletion":1775,"completion":1776,"start":1777,"enrollment":1778,"conditions":1779,"interventions":1780},"NCT04071457","S1803, Lenalidomide +\u002F- Daratumumab\u002FrHuPh20 as Post-ASCT Maintenance for MM w\u002FMRD to Direct Therapy Duration",[90],"2029-07-01","2040-07-01","2019-08-13",1100,[36],[836,1781],"Daratumumab\u002FrHuPH20",{"nctId":889,"briefTitle":890,"status":169,"phases":1783,"primaryCompletion":892,"completion":892,"start":893,"enrollment":894,"conditions":1784,"interventions":1785},[90],[374],[759,760,250,836],{"trials":1787,"activeCount":100},[],{"trials":1789,"activeCount":100},[],{"intervention":47,"totalTrials":762,"cells":1791},{"EARLY_PHASE1":1792,"PHASE1":1794,"PHASE2":1796,"PHASE3":1814,"PHASE4":1827,"NA":1829},{"trials":1793,"activeCount":100},[],{"trials":1795,"activeCount":100},[],{"trials":1797,"activeCount":117,"soonestReadout":259},[1798],{"nctId":1799,"briefTitle":1800,"status":169,"phases":1801,"primaryCompletion":259,"completion":259,"start":1802,"enrollment":514,"conditions":1803,"interventions":1811},"NCT04511013","A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases",[89],"2021-01-06",[1804,1805,1806,1807,1808,1809,1810],"Acral Lentiginous Melanoma","Clinical Stage IV Cutaneous Melanoma AJCC v8","Metastatic Cutaneous Melanoma","Metastatic Malignant Neoplasm in the Brain","Metastatic Melanoma","Metastatic Mucosal Melanoma","Pathologic Stage IV Cutaneous Melanoma AJCC v8",[1812,1813,47,950],"Binimetinib","Encorafenib",{"trials":1815,"activeCount":96,"soonestReadout":46},[1816,1823],{"nctId":44,"briefTitle":45,"status":106,"phases":1817,"primaryCompletion":46,"completion":1818,"start":1819,"enrollment":1820,"conditions":1821,"interventions":1822},[90],"2026-04-01","2015-12-29",275,[1147,1148],[47,950],{"nctId":933,"briefTitle":934,"status":125,"phases":1824,"primaryCompletion":936,"completion":937,"start":938,"enrollment":939,"conditions":1825,"interventions":1826},[90],[941,942,943,944],[946,947,948,47,949,950,951,220],{"trials":1828,"activeCount":100},[],{"trials":1830,"activeCount":100},[1831],{"nctId":1234,"briefTitle":1235,"status":207,"phases":1832,"primaryCompletion":1237,"completion":1238,"start":1239,"enrollment":1240,"conditions":1833,"interventions":1834},[],[1147,1148],[217,1150,1243,1180,47,950,1228,1244,1245,1246,1247],{"intervention":950,"totalTrials":762,"cells":1836},{"EARLY_PHASE1":1837,"PHASE1":1839,"PHASE2":1841,"PHASE3":1847,"PHASE4":1857,"NA":1859},{"trials":1838,"activeCount":100},[],{"trials":1840,"activeCount":100},[],{"trials":1842,"activeCount":117,"soonestReadout":259},[1843],{"nctId":1799,"briefTitle":1800,"status":169,"phases":1844,"primaryCompletion":259,"completion":259,"start":1802,"enrollment":514,"conditions":1845,"interventions":1846},[89],[1804,1805,1806,1807,1808,1809,1810],[1812,1813,47,950],{"trials":1848,"activeCount":96,"soonestReadout":46},[1849,1853],{"nctId":44,"briefTitle":45,"status":106,"phases":1850,"primaryCompletion":46,"completion":1818,"start":1819,"enrollment":1820,"conditions":1851,"interventions":1852},[90],[1147,1148],[47,950],{"nctId":933,"briefTitle":934,"status":125,"phases":1854,"primaryCompletion":936,"completion":937,"start":938,"enrollment":939,"conditions":1855,"interventions":1856},[90],[941,942,943,944],[946,947,948,47,949,950,951,220],{"trials":1858,"activeCount":100},[],{"trials":1860,"activeCount":100},[1861],{"nctId":1234,"briefTitle":1235,"status":207,"phases":1862,"primaryCompletion":1237,"completion":1238,"start":1239,"enrollment":1240,"conditions":1863,"interventions":1864},[],[1147,1148],[217,1150,1243,1180,47,950,1228,1244,1245,1246,1247],{"intervention":349,"totalTrials":1866,"cells":1867},23,{"EARLY_PHASE1":1868,"PHASE1":1870,"PHASE2":1872,"PHASE3":1930,"PHASE4":1978,"NA":1980},{"trials":1869,"activeCount":100},[],{"trials":1871,"activeCount":100},[],{"trials":1873,"activeCount":100},[1874,1878,1882,1886,1890,1894,1898,1902,1906,1910,1914,1918,1922,1926],{"nctId":339,"briefTitle":340,"status":207,"phases":1875,"primaryCompletion":342,"completion":343,"start":344,"enrollment":345,"conditions":1876,"interventions":1877},[89],[18],[331,348,349,317,316,350,351],{"nctId":377,"briefTitle":378,"status":207,"phases":1879,"primaryCompletion":380,"completion":381,"start":382,"enrollment":383,"conditions":1880,"interventions":1881},[89],[18],[331,294,349,317,316],{"nctId":387,"briefTitle":388,"status":207,"phases":1883,"primaryCompletion":390,"completion":391,"start":392,"enrollment":308,"conditions":1884,"interventions":1885},[89],[24,394,395],[397,294,332,398,333,349,399,400,401,336,317,402,316],{"nctId":404,"briefTitle":405,"status":207,"phases":1887,"primaryCompletion":407,"completion":408,"start":409,"enrollment":410,"conditions":1888,"interventions":1889},[89],[18,412],[414,415,294,332,349,399,336,317,316],{"nctId":417,"briefTitle":418,"status":207,"phases":1891,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":1892,"interventions":1893},[89],[18],[331,426,294,332,333,349,400,336,316],{"nctId":428,"briefTitle":429,"status":207,"phases":1895,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":1896,"interventions":1897},[89],[18,436],[414,330,438,439,294,440,349,399,317,441,442,316],{"nctId":466,"briefTitle":467,"status":207,"phases":1899,"primaryCompletion":469,"completion":470,"start":471,"enrollment":472,"conditions":1900,"interventions":1901},[89],[18],[331,475,294,349,317,316],{"nctId":477,"briefTitle":478,"status":207,"phases":1903,"primaryCompletion":357,"completion":480,"start":481,"enrollment":482,"conditions":1904,"interventions":1905},[89],[15],[485,42,294,349,486],{"nctId":488,"briefTitle":489,"status":207,"phases":1907,"primaryCompletion":491,"completion":492,"start":493,"enrollment":494,"conditions":1908,"interventions":1909},[89],[18],[331,294,349,317,316],{"nctId":498,"briefTitle":499,"status":241,"phases":1911,"primaryCompletion":501,"start":502,"enrollment":100,"conditions":1912,"interventions":1913},[89],[18],[331,475,505,506,294,332,333,349,399,363,364],{"nctId":519,"briefTitle":520,"status":207,"phases":1915,"primaryCompletion":522,"completion":480,"start":523,"enrollment":524,"conditions":1916,"interventions":1917},[89],[18],[331,294,349,317,316],{"nctId":528,"briefTitle":529,"status":207,"phases":1919,"primaryCompletion":531,"start":532,"enrollment":533,"conditions":1920,"interventions":1921},[89],[18],[536,294,349,317,316],{"nctId":559,"briefTitle":560,"status":207,"phases":1923,"primaryCompletion":407,"completion":408,"start":562,"enrollment":563,"conditions":1924,"interventions":1925},[89],[18],[414,330,294,332,349,399,400,336,317,566,316,567],{"nctId":569,"briefTitle":570,"status":241,"phases":1927,"primaryCompletion":408,"completion":408,"start":408,"enrollment":100,"conditions":1928,"interventions":1929},[89],[36,374],[475,506,294,333,349,399,574,363,364,575,576],{"trials":1931,"activeCount":96,"soonestReadout":41},[1932,1936,1940,1944,1952,1956,1960,1970,1974],{"nctId":39,"briefTitle":40,"status":106,"phases":1933,"primaryCompletion":41,"completion":606,"start":407,"enrollment":607,"conditions":1934,"interventions":1935},[90],[15],[42,610,294,349,611],{"nctId":613,"briefTitle":614,"status":207,"phases":1937,"primaryCompletion":513,"completion":616,"start":617,"enrollment":618,"conditions":1938,"interventions":1939},[90],[15],[294,349,621,622,601,623],{"nctId":625,"briefTitle":626,"status":207,"phases":1941,"primaryCompletion":628,"completion":629,"start":630,"enrollment":631,"conditions":1942,"interventions":1943},[90],[36],[415,505,294,333,349,363,317,316],{"nctId":1945,"briefTitle":1946,"status":207,"phases":1947,"primaryCompletion":1392,"completion":492,"start":1948,"enrollment":1949,"conditions":1950,"interventions":1951},"NCT00002495","SWOG-9133 RT w\u002F or w\u002Fo Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease",[90],"1992-09",348,[18],[349,706],{"nctId":660,"briefTitle":661,"status":662,"phases":1953,"primaryCompletion":344,"completion":344,"start":664,"enrollment":665,"conditions":1954,"interventions":1955},[90],[15],[330,668,505,506,294,349,611,623,669],{"nctId":671,"briefTitle":672,"status":207,"phases":1957,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":1958,"interventions":1959},[90],[18],[331,536,505,294,349,399,317,316],{"nctId":1961,"briefTitle":1962,"status":662,"phases":1963,"primaryCompletion":1964,"completion":1965,"start":1966,"enrollment":1967,"conditions":1968,"interventions":1969},"NCT00005047","4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer",[90],"2011-03","2014-12","1997-08",521,[1315],[506,349,336,706],{"nctId":681,"briefTitle":682,"status":125,"phases":1971,"primaryCompletion":684,"completion":685,"start":686,"enrollment":533,"conditions":1972,"interventions":1973},[90],[688,689,690],[348,692,693,694,695,696,697],{"nctId":699,"briefTitle":700,"status":662,"phases":1975,"primaryCompletion":702,"completion":702,"start":493,"enrollment":703,"conditions":1976,"interventions":1977},[90],[18],[414,505,294,440,349,399,706],{"trials":1979,"activeCount":100},[],{"trials":1981,"activeCount":100},[],{"intervention":601,"totalTrials":1983,"cells":1984},17,{"EARLY_PHASE1":1985,"PHASE1":1987,"PHASE2":1989,"PHASE3":2085,"PHASE4":2126,"NA":2128},{"trials":1986,"activeCount":100},[],{"trials":1988,"activeCount":100},[],{"trials":1990,"activeCount":117,"soonestReadout":80},[1991,2000,2004,2017,2021,2029,2041,2050,2059,2067,2073,2077,2081],{"nctId":1992,"briefTitle":1993,"status":207,"phases":1994,"primaryCompletion":1333,"completion":628,"start":1995,"enrollment":1996,"conditions":1997,"interventions":1998},"NCT00003254","SWOG-S9635 Fluorouracil Plus Ethynyluracil in Advanced Colorectal Cancer Not Responded to Fluorouracil",[89],"1998-04",75,[30],[1999,601],"ethynyluracil",{"nctId":78,"briefTitle":79,"status":169,"phases":2001,"primaryCompletion":80,"completion":181,"start":182,"enrollment":183,"conditions":2002,"interventions":2003},[89],[185,186,187,188,189],[81,191,192,193,194,195,157],{"nctId":2005,"briefTitle":2006,"status":207,"phases":2007,"primaryCompletion":2008,"completion":2009,"start":2010,"enrollment":359,"conditions":2011,"interventions":2014},"NCT02562716","S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery",[89],"2020-05-31","2022-09-26","2016-01-06",[2012,2013],"Pancreatic Adenocarcinoma","Resectable Pancreatic Carcinoma",[81,219,192,2015,2016],"Oxaliplatin","Paclitaxel Albumin-Stabilized Nanoparticle Formulation",{"nctId":1000,"briefTitle":1001,"status":207,"phases":2018,"primaryCompletion":325,"start":1003,"conditions":2019,"interventions":2020},[89],[33],[506,961,601],{"nctId":2022,"briefTitle":2023,"status":207,"phases":2024,"primaryCompletion":512,"completion":2025,"start":2026,"enrollment":555,"conditions":2027,"interventions":2028},"NCT00086996","S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction",[89],"2011-08","2004-09",[1112],[601,1117],{"nctId":2030,"briefTitle":2031,"status":207,"phases":2032,"primaryCompletion":2033,"completion":995,"start":2034,"enrollment":2035,"conditions":2036,"interventions":2038},"NCT00003018","S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer",[89],"2002-01","1997-09",54,[2037],"Pancreatic Cancer",[2039,601,400,2040],"dipyridamole","mitomycin C",{"nctId":2042,"briefTitle":2043,"status":662,"phases":2044,"primaryCompletion":2045,"completion":1048,"start":2046,"enrollment":472,"conditions":2047,"interventions":2048},"NCT00002735","SWOG-9451, Combination Chemo & RT For Patients With Stage III\u002FStage IV Cancer of the Hypopharynx or Tongue",[89],"2004-04","1996-04",[33],[2049,506,601],"Induction chemotherapy",{"nctId":2051,"briefTitle":2052,"status":241,"phases":2053,"primaryCompletion":2054,"start":2055,"enrollment":100,"conditions":2056,"interventions":2057},"NCT00070434","S0304 Induct Chemo Then Chemo-RT in Pts w\u002FLocally Advanced Adenocarcinoma of the Rectum",[89],"2006-02","2004-08",[30],[517,601,1116,400,1117,2058],"Pyridoxine",{"nctId":2060,"briefTitle":2061,"status":207,"phases":2062,"primaryCompletion":995,"completion":995,"start":2063,"enrollment":1366,"conditions":2064,"interventions":2065},"NCT00004233","S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach",[89],"2001-02",[1112,1113],[601,400,2066],"triacetyluridine",{"nctId":2068,"briefTitle":2069,"status":241,"phases":2070,"enrollment":100,"conditions":2071,"interventions":2072},"NCT00002999","S9715, Chemotherapy and Radiation Therapy in Treating Patients With Advanced Cancer of the Nasopharynx",[89],[33],[506,601],{"nctId":1104,"briefTitle":1105,"status":207,"phases":2074,"primaryCompletion":1107,"completion":1108,"start":737,"enrollment":1109,"conditions":2075,"interventions":2076},[89],[1111,1112,1113],[1115,961,601,1116,400,1117],{"nctId":1388,"briefTitle":1389,"status":207,"phases":2078,"primaryCompletion":1391,"completion":1391,"start":1392,"enrollment":1393,"conditions":2079,"interventions":2080},[89],[33],[506,601,611],{"nctId":591,"briefTitle":592,"status":207,"phases":2082,"primaryCompletion":594,"completion":531,"start":595,"enrollment":596,"conditions":2083,"interventions":2084},[89],[598],[600,294,601,336],{"trials":2086,"activeCount":117,"soonestReadout":2105},[2087,2091,2101,2118],{"nctId":613,"briefTitle":614,"status":207,"phases":2088,"primaryCompletion":513,"completion":616,"start":617,"enrollment":618,"conditions":2089,"interventions":2090},[90],[15],[294,349,621,622,601,623],{"nctId":2092,"briefTitle":2093,"status":207,"phases":2094,"primaryCompletion":2095,"completion":1048,"start":2096,"enrollment":2097,"conditions":2098,"interventions":2099},"NCT00002593","S9415 Chemotherapy in Patients With Stage II or III Colon Cancer That Has Been Surgically Removed",[90],"1999-12","1994-12",1135,[30],[601,400,2100],"levamisole hydrochloride",{"nctId":2102,"briefTitle":2103,"status":169,"phases":2104,"primaryCompletion":2105,"completion":2106,"start":2107,"enrollment":183,"conditions":2108,"interventions":2114},"NCT06998940","Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations",[90],"2029-12-31","2030-12","2026-05-13",[2109,2110,2111,2112,2113],"Locally Advanced Pancreatic Adenocarcinoma","Metastatic Pancreatic Adenocarcinoma","Stage III Pancreatic Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8","Unresectable Pancreatic Adenocarcinoma",[81,218,191,2115,193,2116,2117],"Irinotecan Sucrosofate","Nab-paclitaxel","Panitumumab",{"nctId":2119,"briefTitle":2120,"status":207,"phases":2121,"primaryCompletion":471,"completion":356,"start":2122,"enrollment":2123,"conditions":2124,"interventions":2125},"NCT00002551","SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed",[90],"1994-03",1917,[30],[601,400,2100],{"trials":2127,"activeCount":100},[],{"trials":2129,"activeCount":100},[],{"intervention":218,"totalTrials":2131,"cells":2132},8,{"EARLY_PHASE1":2133,"PHASE1":2135,"PHASE2":2137,"PHASE3":2177,"PHASE4":2187,"NA":2189},{"trials":2134,"activeCount":100},[],{"trials":2136,"activeCount":100},[],{"trials":2138,"activeCount":100},[2139,2143,2147,2151,2155,2164],{"nctId":1308,"briefTitle":1309,"status":207,"phases":2140,"primaryCompletion":1311,"completion":1312,"start":531,"enrollment":1313,"conditions":2141,"interventions":2142},[89],[1315,1316,1317],[668,1082,611],{"nctId":1338,"briefTitle":1339,"status":207,"phases":2144,"primaryCompletion":1261,"completion":1261,"start":1341,"enrollment":1342,"conditions":2145,"interventions":2146},[89],[33],[1082,611],{"nctId":205,"briefTitle":206,"status":207,"phases":2148,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":2149,"interventions":2150},[89],[175,176,214,215],[217,218,219,220,221,222,157],{"nctId":1075,"briefTitle":1076,"status":207,"phases":2152,"primaryCompletion":1078,"completion":995,"start":595,"enrollment":1079,"conditions":2153,"interventions":2154},[89],[21],[668,506,961,1082,611,1073],{"nctId":2156,"briefTitle":2157,"status":207,"phases":2158,"primaryCompletion":2159,"completion":492,"start":2160,"enrollment":19,"conditions":2161,"interventions":2162},"NCT00109928","S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma",[89],"2012-06","2005-09",[18],[506,399,1082,2163],"methylprednisolone",{"nctId":2165,"briefTitle":2166,"status":207,"phases":2167,"primaryCompletion":2168,"completion":51,"start":2169,"enrollment":2170,"conditions":2171,"interventions":2172},"NCT02177695","S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",[89],"2020-02","2014-08-28",237,[1315],[218,2173,2174,2175,649,2176],"Cisplatin","Methotrexate","Vinblastine","Filgrastim",{"trials":2178,"activeCount":96,"soonestReadout":259},[2179,2183],{"nctId":256,"briefTitle":257,"status":106,"phases":2180,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":2181,"interventions":2182},[89,90],[264,175,265,266,267,268,176,214,215],[250,217,218,270,220,221,157],{"nctId":2102,"briefTitle":2103,"status":169,"phases":2184,"primaryCompletion":2105,"completion":2106,"start":2107,"enrollment":183,"conditions":2185,"interventions":2186},[90],[2109,2110,2111,2112,2113],[81,218,191,2115,193,2116,2117],{"trials":2188,"activeCount":100},[],{"trials":2190,"activeCount":100},[],{"intervention":475,"totalTrials":2131,"cells":2192},{"EARLY_PHASE1":2193,"PHASE1":2195,"PHASE2":2197,"PHASE3":2227,"PHASE4":2237,"NA":2239},{"trials":2194,"activeCount":100},[],{"trials":2196,"activeCount":100},[],{"trials":2198,"activeCount":100},[2199,2203,2207,2215,2219,2223],{"nctId":466,"briefTitle":467,"status":207,"phases":2200,"primaryCompletion":469,"completion":470,"start":471,"enrollment":472,"conditions":2201,"interventions":2202},[89],[18],[331,475,294,349,317,316],{"nctId":498,"briefTitle":499,"status":241,"phases":2204,"primaryCompletion":501,"start":502,"enrollment":100,"conditions":2205,"interventions":2206},[89],[18],[331,475,505,506,294,332,333,349,399,363,364],{"nctId":2208,"briefTitle":2209,"status":207,"phases":2210,"completion":2211,"start":2212,"conditions":2213,"interventions":2214},"NCT00068289","Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy",[89],"2007-07","2003-09",[21],[475],{"nctId":823,"briefTitle":824,"status":207,"phases":2216,"primaryCompletion":826,"completion":827,"start":828,"enrollment":829,"conditions":2217,"interventions":2218},[88,89],[831,832,833],[759,250,835,836],{"nctId":838,"briefTitle":839,"status":662,"phases":2220,"primaryCompletion":841,"completion":842,"start":513,"enrollment":843,"conditions":2221,"interventions":2222},[89],[36],[475,333,364],{"nctId":569,"briefTitle":570,"status":241,"phases":2224,"primaryCompletion":408,"completion":408,"start":408,"enrollment":100,"conditions":2225,"interventions":2226},[89],[36,374],[475,506,294,333,349,399,574,363,364,575,576],{"trials":2228,"activeCount":96,"soonestReadout":753},[2229,2233],{"nctId":889,"briefTitle":890,"status":169,"phases":2230,"primaryCompletion":892,"completion":892,"start":893,"enrollment":894,"conditions":2231,"interventions":2232},[90],[374],[759,760,250,836],{"nctId":750,"briefTitle":751,"status":169,"phases":2234,"primaryCompletion":753,"completion":754,"start":56,"enrollment":755,"conditions":2235,"interventions":2236},[90],[757],[759,348,760,250,761],{"trials":2238,"activeCount":100},[],{"trials":2240,"activeCount":100},[],{"intervention":193,"totalTrials":910,"cells":2242},{"EARLY_PHASE1":2243,"PHASE1":2245,"PHASE2":2247,"PHASE3":2272,"PHASE4":2278,"NA":2280},{"trials":2244,"activeCount":100},[],{"trials":2246,"activeCount":100},[],{"trials":2248,"activeCount":117,"soonestReadout":80},[2249,2253,2257,2261],{"nctId":322,"briefTitle":323,"status":207,"phases":2250,"primaryCompletion":325,"completion":326,"start":327,"enrollment":173,"conditions":2251,"interventions":2252},[89],[18],[330,331,294,332,333,334,335,336,337],{"nctId":78,"briefTitle":79,"status":169,"phases":2254,"primaryCompletion":80,"completion":181,"start":182,"enrollment":183,"conditions":2255,"interventions":2256},[89],[185,186,187,188,189],[81,191,192,193,194,195,157],{"nctId":578,"briefTitle":579,"status":207,"phases":2258,"primaryCompletion":342,"completion":552,"start":581,"enrollment":582,"conditions":2259,"interventions":2260},[89],[24],[330,294,332,585,333,334,335,401,336,586,587,317,402,337,588,589],{"nctId":2262,"briefTitle":2263,"status":207,"phases":2264,"primaryCompletion":2265,"completion":2266,"start":2267,"enrollment":2268,"conditions":2269,"interventions":2270},"NCT01959139","S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer",[88,89],"2019-04","2023-11-09","2014-01-23",126,[2110],[2271,2015,193,191,1129],"PEGPH20",{"trials":2273,"activeCount":117,"soonestReadout":2105},[2274],{"nctId":2102,"briefTitle":2103,"status":169,"phases":2275,"primaryCompletion":2105,"completion":2106,"start":2107,"enrollment":183,"conditions":2276,"interventions":2277},[90],[2109,2110,2111,2112,2113],[81,218,191,2115,193,2116,2117],{"trials":2279,"activeCount":100},[],{"trials":2281,"activeCount":100},[],{"intervention":731,"totalTrials":910,"cells":2283},{"EARLY_PHASE1":2284,"PHASE1":2286,"PHASE2":2288,"PHASE3":2296,"PHASE4":2325,"NA":2327},{"trials":2285,"activeCount":100},[],{"trials":2287,"activeCount":100},[],{"trials":2289,"activeCount":100},[2290],{"nctId":2291,"briefTitle":2292,"status":241,"phases":2293,"primaryCompletion":995,"completion":995,"start":2160,"enrollment":100,"conditions":2294,"interventions":2295},"NCT00217659","S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer",[89],[15],[52,731],{"trials":2297,"activeCount":96,"soonestReadout":51},[2298,2306,2317,2321],{"nctId":2299,"briefTitle":2300,"status":207,"phases":2301,"primaryCompletion":2302,"completion":2302,"start":409,"enrollment":2303,"conditions":2304,"interventions":2305},"NCT00002651","SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer",[90],"2013-06",3040,[27],[1285,731],{"nctId":49,"briefTitle":50,"status":106,"phases":2307,"primaryCompletion":51,"completion":2308,"start":2309,"enrollment":2310,"conditions":2311,"interventions":2312},[90],"2030-01","2013-09-12",1939,[15],[52,2313,2314,731,2315,2316,623],"everolimus","exemestane","letrozole","leuprolide acetate",{"nctId":1182,"briefTitle":1183,"status":169,"phases":2318,"primaryCompletion":1185,"completion":1186,"start":1187,"enrollment":1188,"conditions":2319,"interventions":2320},[90],[1190,1191,1192,1193,1194],[1196,1197,1198,217,1199,1200,1201,1202,1203,694,1204],{"nctId":721,"briefTitle":722,"status":207,"phases":2322,"primaryCompletion":724,"completion":725,"start":628,"enrollment":726,"conditions":2323,"interventions":2324},[90],[15,728,729],[294,731],{"trials":2326,"activeCount":100},[],{"trials":2328,"activeCount":100},[],{"intervention":191,"totalTrials":762,"cells":2330},{"EARLY_PHASE1":2331,"PHASE1":2333,"PHASE2":2335,"PHASE3":2352,"PHASE4":2358,"NA":2360},{"trials":2332,"activeCount":100},[],{"trials":2334,"activeCount":100},[],{"trials":2336,"activeCount":117,"soonestReadout":80},[2337,2341,2348],{"nctId":78,"briefTitle":79,"status":169,"phases":2338,"primaryCompletion":80,"completion":181,"start":182,"enrollment":183,"conditions":2339,"interventions":2340},[89],[185,186,187,188,189],[81,191,192,193,194,195,157],{"nctId":2342,"briefTitle":2343,"status":662,"phases":2344,"primaryCompletion":1010,"completion":1010,"start":1003,"enrollment":96,"conditions":2345,"interventions":2346},"NCT00053833","S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",[89],[1032,1033,1034],[2347],"irinotecan",{"nctId":2262,"briefTitle":2263,"status":207,"phases":2349,"primaryCompletion":2265,"completion":2266,"start":2267,"enrollment":2268,"conditions":2350,"interventions":2351},[88,89],[2110],[2271,2015,193,191,1129],{"trials":2353,"activeCount":117,"soonestReadout":2105},[2354],{"nctId":2102,"briefTitle":2103,"status":169,"phases":2355,"primaryCompletion":2105,"completion":2106,"start":2107,"enrollment":183,"conditions":2356,"interventions":2357},[90],[2109,2110,2111,2112,2113],[81,218,191,2115,193,2116,2117],{"trials":2359,"activeCount":100},[],{"trials":2361,"activeCount":100},[],{"intervention":2316,"totalTrials":96,"cells":2363},{"EARLY_PHASE1":2364,"PHASE1":2366,"PHASE2":2368,"PHASE3":2370,"PHASE4":2380,"NA":2382},{"trials":2365,"activeCount":100},[],{"trials":2367,"activeCount":100},[],{"trials":2369,"activeCount":100},[],{"trials":2371,"activeCount":96,"soonestReadout":51},[2372,2376],{"nctId":49,"briefTitle":50,"status":106,"phases":2373,"primaryCompletion":51,"completion":2308,"start":2309,"enrollment":2310,"conditions":2374,"interventions":2375},[90],[15],[52,2313,2314,731,2315,2316,623],{"nctId":1182,"briefTitle":1183,"status":169,"phases":2377,"primaryCompletion":1185,"completion":1186,"start":1187,"enrollment":1188,"conditions":2378,"interventions":2379},[90],[1190,1191,1192,1193,1194],[1196,1197,1198,217,1199,1200,1201,1202,1203,694,1204],{"trials":2381,"activeCount":100},[],{"trials":2383,"activeCount":100},[],{"intervention":760,"totalTrials":96,"cells":2385},{"EARLY_PHASE1":2386,"PHASE1":2388,"PHASE2":2390,"PHASE3":2392,"PHASE4":2402,"NA":2404},{"trials":2387,"activeCount":100},[],{"trials":2389,"activeCount":100},[],{"trials":2391,"activeCount":100},[],{"trials":2393,"activeCount":96,"soonestReadout":753},[2394,2398],{"nctId":889,"briefTitle":890,"status":169,"phases":2395,"primaryCompletion":892,"completion":892,"start":893,"enrollment":894,"conditions":2396,"interventions":2397},[90],[374],[759,760,250,836],{"nctId":750,"briefTitle":751,"status":169,"phases":2399,"primaryCompletion":753,"completion":754,"start":56,"enrollment":755,"conditions":2400,"interventions":2401},[90],[757],[759,348,760,250,761],{"trials":2403,"activeCount":100},[],{"trials":2405,"activeCount":100},[],{"intervention":62,"totalTrials":252,"cells":2407},{"EARLY_PHASE1":2408,"PHASE1":2410,"PHASE2":2412,"PHASE3":2414,"PHASE4":2430,"NA":2432},{"trials":2409,"activeCount":100},[],{"trials":2411,"activeCount":100},[],{"trials":2413,"activeCount":100},[],{"trials":2415,"activeCount":117,"soonestReadout":66},[2416,2426],{"nctId":2417,"briefTitle":2418,"status":207,"phases":2419,"primaryCompletion":480,"completion":2420,"start":2421,"enrollment":2422,"conditions":2423,"interventions":2424},"NCT00382018","S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo",[90],"2017-07-11","2006-10",624,[15],[2425],"chemotherapy",{"nctId":64,"briefTitle":65,"status":106,"phases":2427,"primaryCompletion":66,"completion":284,"start":285,"enrollment":286,"conditions":2428,"interventions":2429},[90],[175,176],[62,220,157],{"trials":2431,"activeCount":100},[],{"trials":2433,"activeCount":117,"soonestReadout":61},[2434],{"nctId":59,"briefTitle":60,"status":106,"phases":2435,"primaryCompletion":61,"completion":2436,"start":2437,"enrollment":2438,"conditions":2439,"interventions":2477},[],"2026-09-01","2019-05-14",1336,[643,2440,2441,644,2442,2443,2444,645,646,2445,1650,2446,2447,2448,2449,2450,2451,2452,2453,2454,2455,2456,2457,2458,2459,2460,2461,2462,2463,2464,2465,2466,2467,2468,2469,2470,265,2471,266,2472,2473,2474,267,2475,268,2476],"Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage IB Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","Stage I Lung Cancer AJCC v8","Stage I Ovarian Cancer AJCC v8","Stage IA Ovarian Cancer AJCC v8","Stage IA1 Lung Cancer AJCC v8","Stage IA2 Lung Cancer AJCC v8","Stage IA3 Lung Cancer AJCC v8","Stage IB Lung Cancer AJCC v8","Stage IB Ovarian Cancer AJCC v8","Stage IC Ovarian Cancer AJCC v8","Stage II Lung Cancer AJCC v8","Stage II Ovarian Cancer AJCC v8","Stage IIA Lung Cancer AJCC v8","Stage IIA Ovarian Cancer AJCC v8","Stage IIB Lung Cancer AJCC v8","Stage IIB Ovarian Cancer AJCC v8","Stage III Ovarian Cancer AJCC v8","Stage IIIA Ovarian Cancer AJCC v8","Stage IIIA1 Ovarian Cancer AJCC v8","Stage IIIA2 Ovarian Cancer AJCC v8","Stage IIIB Ovarian Cancer AJCC v8","Stage IIIC Ovarian Cancer AJCC v8",[62],{"intervention":331,"totalTrials":31,"cells":2479},{"EARLY_PHASE1":2480,"PHASE1":2482,"PHASE2":2484,"PHASE3":2529,"PHASE4":2547,"NA":2549},{"trials":2481,"activeCount":100},[],{"trials":2483,"activeCount":100},[],{"trials":2485,"activeCount":100},[2486,2490,2494,2498,2502,2506,2510,2514,2518,2525],{"nctId":322,"briefTitle":323,"status":207,"phases":2487,"primaryCompletion":325,"completion":326,"start":327,"enrollment":173,"conditions":2488,"interventions":2489},[89],[18],[330,331,294,332,333,334,335,336,337],{"nctId":339,"briefTitle":340,"status":207,"phases":2491,"primaryCompletion":342,"completion":343,"start":344,"enrollment":345,"conditions":2492,"interventions":2493},[89],[18],[331,348,349,317,316,350,351],{"nctId":377,"briefTitle":378,"status":207,"phases":2495,"primaryCompletion":380,"completion":381,"start":382,"enrollment":383,"conditions":2496,"interventions":2497},[89],[18],[331,294,349,317,316],{"nctId":417,"briefTitle":418,"status":207,"phases":2499,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":2500,"interventions":2501},[89],[18],[331,426,294,332,333,349,400,336,316],{"nctId":466,"briefTitle":467,"status":207,"phases":2503,"primaryCompletion":469,"completion":470,"start":471,"enrollment":472,"conditions":2504,"interventions":2505},[89],[18],[331,475,294,349,317,316],{"nctId":488,"briefTitle":489,"status":207,"phases":2507,"primaryCompletion":491,"completion":492,"start":493,"enrollment":494,"conditions":2508,"interventions":2509},[89],[18],[331,294,349,317,316],{"nctId":498,"briefTitle":499,"status":241,"phases":2511,"primaryCompletion":501,"start":502,"enrollment":100,"conditions":2512,"interventions":2513},[89],[18],[331,475,505,506,294,332,333,349,399,363,364],{"nctId":519,"briefTitle":520,"status":207,"phases":2515,"primaryCompletion":522,"completion":480,"start":523,"enrollment":524,"conditions":2516,"interventions":2517},[89],[18],[331,294,349,317,316],{"nctId":2519,"briefTitle":2520,"status":241,"phases":2521,"primaryCompletion":2522,"completion":2522,"start":982,"enrollment":100,"conditions":2523,"interventions":2524},"NCT00939328","S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment",[89],"2010-09",[24],[331,426],{"nctId":538,"briefTitle":539,"status":207,"phases":2526,"primaryCompletion":541,"completion":542,"start":543,"enrollment":544,"conditions":2527,"interventions":2528},[89],[18],[331,547,294,334,317,337],{"trials":2530,"activeCount":117,"soonestReadout":684},[2531,2535,2539,2543],{"nctId":651,"briefTitle":652,"status":207,"phases":2532,"primaryCompletion":382,"completion":654,"start":655,"enrollment":656,"conditions":2533,"interventions":2534},[90],[18],[331,294,334,317,337],{"nctId":671,"briefTitle":672,"status":207,"phases":2536,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":2537,"interventions":2538},[90],[18],[331,536,505,294,349,399,317,316],{"nctId":681,"briefTitle":682,"status":125,"phases":2540,"primaryCompletion":684,"completion":685,"start":686,"enrollment":533,"conditions":2541,"interventions":2542},[90],[688,689,690],[348,692,693,694,695,696,697],{"nctId":1722,"briefTitle":1723,"status":662,"phases":2544,"primaryCompletion":1333,"completion":629,"start":1725,"enrollment":843,"conditions":2545,"interventions":2546},[90],[18],[330,331,668,399,1728],{"trials":2548,"activeCount":100},[],{"trials":2550,"activeCount":100},[],{"intervention":363,"totalTrials":158,"cells":2552},{"EARLY_PHASE1":2553,"PHASE1":2555,"PHASE2":2557,"PHASE3":2591,"PHASE4":2601,"NA":2603},{"trials":2554,"activeCount":100},[],{"trials":2556,"activeCount":100},[],{"trials":2558,"activeCount":100},[2559,2563,2567,2571,2579,2583,2587],{"nctId":353,"briefTitle":354,"status":207,"phases":2560,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":2561,"interventions":2562},[89],[36],[330,362,294,333,363,317,364],{"nctId":366,"briefTitle":367,"status":207,"phases":2564,"primaryCompletion":369,"completion":370,"start":371,"enrollment":372,"conditions":2565,"interventions":2566},[89],[36,374],[330,294,333,363,364],{"nctId":498,"briefTitle":499,"status":241,"phases":2568,"primaryCompletion":501,"start":502,"enrollment":100,"conditions":2569,"interventions":2570},[89],[18],[331,475,505,506,294,332,333,349,399,363,364],{"nctId":2572,"briefTitle":2573,"status":662,"phases":2574,"primaryCompletion":1067,"completion":1312,"start":1060,"enrollment":117,"conditions":2575,"interventions":2576},"NCT00121186","S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma",[89],[18],[2577,363,336,2578],"fludarabine phosphate","tacrolimus",{"nctId":549,"briefTitle":550,"status":207,"phases":2580,"primaryCompletion":552,"completion":553,"start":554,"enrollment":555,"conditions":2581,"interventions":2582},[89],[18],[505,294,399,363],{"nctId":569,"briefTitle":570,"status":241,"phases":2584,"primaryCompletion":408,"completion":408,"start":408,"enrollment":100,"conditions":2585,"interventions":2586},[89],[36,374],[475,506,294,333,349,399,574,363,364,575,576],{"nctId":859,"briefTitle":860,"status":207,"phases":2588,"primaryCompletion":862,"completion":371,"start":863,"enrollment":158,"conditions":2589,"interventions":2590},[89],[18],[330,415,333,363],{"trials":2592,"activeCount":117,"soonestReadout":753},[2593,2597],{"nctId":625,"briefTitle":626,"status":207,"phases":2594,"primaryCompletion":628,"completion":629,"start":630,"enrollment":631,"conditions":2595,"interventions":2596},[90],[36],[415,505,294,333,349,363,317,316],{"nctId":750,"briefTitle":751,"status":169,"phases":2598,"primaryCompletion":753,"completion":754,"start":56,"enrollment":755,"conditions":2599,"interventions":2600},[90],[757],[759,348,760,250,761],{"trials":2602,"activeCount":100},[],{"trials":2604,"activeCount":100},[],{"intervention":334,"totalTrials":843,"cells":2606},{"EARLY_PHASE1":2607,"PHASE1":2609,"PHASE2":2611,"PHASE3":2629,"PHASE4":2643,"NA":2645},{"trials":2608,"activeCount":100},[],{"trials":2610,"activeCount":100},[],{"trials":2612,"activeCount":100},[2613,2617,2621,2625],{"nctId":322,"briefTitle":323,"status":207,"phases":2614,"primaryCompletion":325,"completion":326,"start":327,"enrollment":173,"conditions":2615,"interventions":2616},[89],[18],[330,331,294,332,333,334,335,336,337],{"nctId":538,"briefTitle":539,"status":207,"phases":2618,"primaryCompletion":541,"completion":542,"start":543,"enrollment":544,"conditions":2619,"interventions":2620},[89],[18],[331,547,294,334,317,337],{"nctId":2165,"briefTitle":2166,"status":207,"phases":2622,"primaryCompletion":2168,"completion":51,"start":2169,"enrollment":2170,"conditions":2623,"interventions":2624},[89],[1315],[218,2173,2174,2175,649,2176],{"nctId":578,"briefTitle":579,"status":207,"phases":2626,"primaryCompletion":342,"completion":552,"start":581,"enrollment":582,"conditions":2627,"interventions":2628},[89],[24],[330,294,332,585,333,334,335,401,336,586,587,317,402,337,588,589],{"trials":2630,"activeCount":117,"soonestReadout":638},[2631,2635,2639],{"nctId":635,"briefTitle":636,"status":169,"phases":2632,"primaryCompletion":638,"completion":639,"start":640,"enrollment":641,"conditions":2633,"interventions":2634},[90],[643,644,645,646,647],[237,348,217,649,195,220],{"nctId":651,"briefTitle":652,"status":207,"phases":2636,"primaryCompletion":382,"completion":654,"start":655,"enrollment":656,"conditions":2637,"interventions":2638},[90],[18],[331,294,334,317,337],{"nctId":733,"briefTitle":734,"status":207,"phases":2640,"primaryCompletion":736,"completion":737,"start":738,"enrollment":739,"conditions":2641,"interventions":2642},[90],[15],[330,294,334,611],{"trials":2644,"activeCount":100},[],{"trials":2646,"activeCount":100},[],{"intervention":337,"totalTrials":910,"cells":2648},{"EARLY_PHASE1":2649,"PHASE1":2651,"PHASE2":2653,"PHASE3":2667,"PHASE4":2677,"NA":2679},{"trials":2650,"activeCount":100},[],{"trials":2652,"activeCount":100},[],{"trials":2654,"activeCount":100},[2655,2659,2663],{"nctId":322,"briefTitle":323,"status":207,"phases":2656,"primaryCompletion":325,"completion":326,"start":327,"enrollment":173,"conditions":2657,"interventions":2658},[89],[18],[330,331,294,332,333,334,335,336,337],{"nctId":538,"briefTitle":539,"status":207,"phases":2660,"primaryCompletion":541,"completion":542,"start":543,"enrollment":544,"conditions":2661,"interventions":2662},[89],[18],[331,547,294,334,317,337],{"nctId":578,"briefTitle":579,"status":207,"phases":2664,"primaryCompletion":342,"completion":552,"start":581,"enrollment":582,"conditions":2665,"interventions":2666},[89],[24],[330,294,332,585,333,334,335,401,336,586,587,317,402,337,588,589],{"trials":2668,"activeCount":117,"soonestReadout":684},[2669,2673],{"nctId":651,"briefTitle":652,"status":207,"phases":2670,"primaryCompletion":382,"completion":654,"start":655,"enrollment":656,"conditions":2671,"interventions":2672},[90],[18],[331,294,334,317,337],{"nctId":681,"briefTitle":682,"status":125,"phases":2674,"primaryCompletion":684,"completion":685,"start":686,"enrollment":533,"conditions":2675,"interventions":2676},[90],[688,689,690],[348,692,693,694,695,696,697],{"trials":2678,"activeCount":100},[],{"trials":2680,"activeCount":100},[],{"intervention":1072,"totalTrials":910,"cells":2682},{"EARLY_PHASE1":2683,"PHASE1":2685,"PHASE2":2687,"PHASE3":2731,"PHASE4":2760,"NA":2762},{"trials":2684,"activeCount":100},[],{"trials":2686,"activeCount":100},[],{"trials":2688,"activeCount":100},[2689,2719,2723],{"nctId":2690,"briefTitle":2691,"status":207,"phases":2692,"primaryCompletion":2693,"completion":2694,"start":2695,"enrollment":714,"conditions":2696,"interventions":2716},"NCT03365882","S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2\u002FNeu Amplified Colorectal Cancer That Cannot Be Removed by Surgery",[89],"2022-11-01","2025-07-01","2017-11-27",[2697,2698,2699,2700,2701,2702,2703,2704,2705,2706,2707,2708,2709,2710,2711,2712,2713,2714,2715],"Colon Adenocarcinoma","ERBB2 Gene Amplification","Rectal Adenocarcinoma","Recurrent Colon Carcinoma","Recurrent Rectal Carcinoma","Stage III Colon Cancer AJCC v7","Stage III Rectal Cancer AJCC v7","Stage IIIA Colon Cancer AJCC v7","Stage IIIA Rectal Cancer AJCC v7","Stage IIIB Colon Cancer AJCC v7","Stage IIIB Rectal Cancer AJCC v7","Stage IIIC Colon Cancer AJCC v7","Stage IIIC Rectal Cancer AJCC v7","Stage IV Colon Cancer AJCC v7","Stage IV Rectal Cancer AJCC v7","Stage IVA Colon Cancer AJCC v7","Stage IVA Rectal Cancer AJCC v7","Stage IVB Colon Cancer AJCC v7","Stage IVB Rectal Cancer AJCC v7",[1436,192,2717,2718],"Pertuzumab","Trastuzumab",{"nctId":1064,"briefTitle":1065,"status":207,"phases":2720,"primaryCompletion":1067,"completion":1068,"start":327,"enrollment":1069,"conditions":2721,"interventions":2722},[89],[15],[330,1072,961,1073],{"nctId":2724,"briefTitle":2725,"status":207,"phases":2726,"completion":1373,"start":1060,"enrollment":2727,"conditions":2728,"interventions":2730},"NCT00104949","Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma",[89],40,[2729],"Sarcoma",[1072],{"trials":2732,"activeCount":117,"soonestReadout":2744},[2733,2740],{"nctId":2734,"briefTitle":2735,"status":207,"phases":2736,"completion":973,"start":2737,"conditions":2738,"interventions":2739},"NCT00103233","Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer",[90],"2004-12",[15],[1072,1016],{"nctId":2741,"briefTitle":2742,"status":125,"phases":2743,"primaryCompletion":2744,"completion":2745,"start":2746,"enrollment":2747,"conditions":2748,"interventions":2752},"NCT07578116","Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis",[90],"2032-05-31","2033-05-31","2027-03-09",562,[2749,2750,2751],"Anatomic Stage IV Breast Cancer AJCC v8","Metastatic HER2-Positive Breast Carcinoma","Oligometastatic Breast Carcinoma",[2753,2754,2755,2756,2717,2757,2718,2758,2759],"Cyclin-Dependent Kinase 4 Inhibitor","Cyclin-Dependent Kinase 6 Inhibitor","HER2-targeted Therapy","Hormone Therapy","Taxane Compound","Trastuzumab Deruxtecan","Trastuzumab Emtansine",{"trials":2761,"activeCount":100},[],{"trials":2763,"activeCount":100},[],{"intervention":1285,"totalTrials":910,"cells":2765},{"EARLY_PHASE1":2766,"PHASE1":2768,"PHASE2":2770,"PHASE3":2776,"PHASE4":2801,"NA":2803},{"trials":2767,"activeCount":100},[],{"trials":2769,"activeCount":100},[],{"trials":2771,"activeCount":100},[2772],{"nctId":1280,"briefTitle":1281,"status":207,"phases":2773,"primaryCompletion":842,"completion":408,"start":390,"enrollment":16,"conditions":2774,"interventions":2775},[89],[27],[1285,1214,399,1286,1287,1288,1289,611],{"trials":2777,"activeCount":117,"soonestReadout":1185},[2778,2782,2786,2797],{"nctId":2299,"briefTitle":2300,"status":207,"phases":2779,"primaryCompletion":2302,"completion":2302,"start":409,"enrollment":2303,"conditions":2780,"interventions":2781},[90],[27],[1285,731],{"nctId":1546,"briefTitle":1547,"status":207,"phases":2783,"primaryCompletion":1549,"completion":1550,"start":1551,"enrollment":1552,"conditions":2784,"interventions":2785},[90],[27],[1285,1287,1555,317],{"nctId":2787,"briefTitle":2788,"status":207,"phases":2789,"primaryCompletion":2790,"completion":2791,"start":2792,"enrollment":2793,"conditions":2794,"interventions":2795},"NCT01809691","S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",[90],"2022-03-08","2025-09-09","2013-03-08",1313,[27],[2796,1197],"TAK-700",{"nctId":1182,"briefTitle":1183,"status":169,"phases":2798,"primaryCompletion":1185,"completion":1186,"start":1187,"enrollment":1188,"conditions":2799,"interventions":2800},[90],[1190,1191,1192,1193,1194],[1196,1197,1198,217,1199,1200,1201,1202,1203,694,1204],{"trials":2802,"activeCount":100},[],{"trials":2804,"activeCount":100},[],{"intervention":2313,"totalTrials":910,"cells":2806},{"EARLY_PHASE1":2807,"PHASE1":2809,"PHASE2":2819,"PHASE3":2828,"PHASE4":2856,"NA":2858},{"trials":2808,"activeCount":100},[],{"trials":2810,"activeCount":100},[2811],{"nctId":2812,"briefTitle":2813,"status":207,"phases":2814,"primaryCompletion":1373,"completion":2815,"start":736,"enrollment":200,"conditions":2816,"interventions":2817},"NCT00352443","S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma",[88],"2013-09",[18,984],[2313,2818],"lapatinib ditosylate",{"trials":2820,"activeCount":100},[2821],{"nctId":2822,"briefTitle":2823,"status":207,"phases":2824,"primaryCompletion":492,"completion":492,"start":1382,"enrollment":1709,"conditions":2825,"interventions":2827},"NCT00770120","S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery",[89],[2826],"Malignant Mesothelioma",[2313],{"trials":2829,"activeCount":117,"soonestReadout":51},[2830,2841,2845],{"nctId":2831,"briefTitle":2832,"status":207,"phases":2833,"primaryCompletion":2834,"completion":2835,"start":2836,"enrollment":2837,"conditions":2838,"interventions":2840},"NCT01120249","S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",[90],"2023-07-01","2025-09-01","2011-04-01",1545,[2839],"Kidney Cancer",[2313],{"nctId":49,"briefTitle":50,"status":106,"phases":2842,"primaryCompletion":51,"completion":2308,"start":2309,"enrollment":2310,"conditions":2843,"interventions":2844},[90],[15],[52,2313,2314,731,2315,2316,623],{"nctId":2846,"briefTitle":2847,"status":662,"phases":2848,"primaryCompletion":2849,"completion":2849,"start":1029,"enrollment":2850,"conditions":2851,"interventions":2852},"NCT02137837","S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",[90],"2019-12-31",37,[15],[2853,2854,2855],"Fulvestrant","Anastrozole","Everolimus",{"trials":2857,"activeCount":100},[],{"trials":2859,"activeCount":100},[],{"intervention":623,"totalTrials":762,"cells":2861},{"EARLY_PHASE1":2862,"PHASE1":2864,"PHASE2":2866,"PHASE3":2868,"PHASE4":2893,"NA":2895},{"trials":2863,"activeCount":100},[],{"trials":2865,"activeCount":100},[],{"trials":2867,"activeCount":100},[],{"trials":2869,"activeCount":117,"soonestReadout":51},[2870,2874,2878,2882],{"nctId":613,"briefTitle":614,"status":207,"phases":2871,"primaryCompletion":513,"completion":616,"start":617,"enrollment":618,"conditions":2872,"interventions":2873},[90],[15],[294,349,621,622,601,623],{"nctId":49,"briefTitle":50,"status":106,"phases":2875,"primaryCompletion":51,"completion":2308,"start":2309,"enrollment":2310,"conditions":2876,"interventions":2877},[90],[15],[52,2313,2314,731,2315,2316,623],{"nctId":660,"briefTitle":661,"status":662,"phases":2879,"primaryCompletion":344,"completion":344,"start":664,"enrollment":665,"conditions":2880,"interventions":2881},[90],[15],[330,668,505,506,294,349,611,623,669],{"nctId":2883,"briefTitle":2884,"status":207,"phases":2885,"primaryCompletion":2886,"completion":2887,"start":2888,"enrollment":2889,"conditions":2890,"interventions":2891},"NCT00002920","S9630, Medroxyprogesterone in Treating Women With Breast Cancer",[90],"2006-12","2009-12","1997-03",313,[15,1325],[2892,623],"medroxyprogesterone",{"trials":2894,"activeCount":100},[],{"trials":2896,"activeCount":100},[],{"intervention":221,"totalTrials":762,"cells":2898},{"EARLY_PHASE1":2899,"PHASE1":2901,"PHASE2":2903,"PHASE3":2920,"PHASE4":2926,"NA":2928},{"trials":2900,"activeCount":100},[],{"trials":2902,"activeCount":100},[],{"trials":2904,"activeCount":100},[2905,2909,2913],{"nctId":1643,"briefTitle":1644,"status":241,"phases":2906,"primaryCompletion":1646,"completion":1647,"start":1648,"enrollment":100,"conditions":2907,"interventions":2908},[89],[1650,175,176,214,215],[237,221,1652],{"nctId":205,"briefTitle":206,"status":207,"phases":2910,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":2911,"interventions":2912},[89],[175,176,214,215],[217,218,219,220,221,222,157],{"nctId":2914,"briefTitle":2915,"status":662,"phases":2916,"primaryCompletion":408,"completion":408,"start":1209,"enrollment":25,"conditions":2917,"interventions":2918},"NCT00265785","S0526: Pemetrexed Disodium in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer",[89],[21],[2919],"pemetrexed",{"trials":2921,"activeCount":117,"soonestReadout":259},[2922],{"nctId":256,"briefTitle":257,"status":106,"phases":2923,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":2924,"interventions":2925},[89,90],[264,175,265,266,267,268,176,214,215],[250,217,218,270,220,221,157],{"trials":2927,"activeCount":100},[],{"trials":2929,"activeCount":100},[],{"intervention":52,"totalTrials":762,"cells":2931},{"EARLY_PHASE1":2932,"PHASE1":2934,"PHASE2":2936,"PHASE3":2942,"PHASE4":2961,"NA":2963},{"trials":2933,"activeCount":100},[],{"trials":2935,"activeCount":100},[],{"trials":2937,"activeCount":100},[2938],{"nctId":2291,"briefTitle":2292,"status":241,"phases":2939,"primaryCompletion":995,"completion":995,"start":2160,"enrollment":100,"conditions":2940,"interventions":2941},[89],[15],[52,731],{"trials":2943,"activeCount":117,"soonestReadout":51},[2944,2948,2957],{"nctId":49,"briefTitle":50,"status":106,"phases":2945,"primaryCompletion":51,"completion":2308,"start":2309,"enrollment":2310,"conditions":2946,"interventions":2947},[90],[15],[52,2313,2314,731,2315,2316,623],{"nctId":2949,"briefTitle":2950,"status":207,"phases":2951,"primaryCompletion":469,"completion":2952,"start":2045,"enrollment":2953,"conditions":2954,"interventions":2955},"NCT00075764","S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer",[90],"2018-10-01",695,[15],[52,2956],"fulvestrant",{"nctId":2846,"briefTitle":2847,"status":662,"phases":2958,"primaryCompletion":2849,"completion":2849,"start":1029,"enrollment":2850,"conditions":2959,"interventions":2960},[90],[15],[2853,2854,2855],{"trials":2962,"activeCount":100},[],{"trials":2964,"activeCount":100},[],{"intervention":42,"totalTrials":96,"cells":2966},{"EARLY_PHASE1":2967,"PHASE1":2969,"PHASE2":2971,"PHASE3":2977,"PHASE4":2983,"NA":2985},{"trials":2968,"activeCount":100},[],{"trials":2970,"activeCount":100},[],{"trials":2972,"activeCount":100},[2973],{"nctId":477,"briefTitle":478,"status":207,"phases":2974,"primaryCompletion":357,"completion":480,"start":481,"enrollment":482,"conditions":2975,"interventions":2976},[89],[15],[485,42,294,349,486],{"trials":2978,"activeCount":117,"soonestReadout":41},[2979],{"nctId":39,"briefTitle":40,"status":106,"phases":2980,"primaryCompletion":41,"completion":606,"start":407,"enrollment":607,"conditions":2981,"interventions":2982},[90],[15],[42,610,294,349,611],{"trials":2984,"activeCount":100},[],{"trials":2986,"activeCount":100},[],{"intervention":1286,"totalTrials":96,"cells":2988},{"EARLY_PHASE1":2989,"PHASE1":2991,"PHASE2":2993,"PHASE3":2999,"PHASE4":3005,"NA":3007},{"trials":2990,"activeCount":100},[],{"trials":2992,"activeCount":100},[],{"trials":2994,"activeCount":100},[2995],{"nctId":1280,"briefTitle":1281,"status":207,"phases":2996,"primaryCompletion":842,"completion":408,"start":390,"enrollment":16,"conditions":2997,"interventions":2998},[89],[27],[1285,1214,399,1286,1287,1288,1289,611],{"trials":3000,"activeCount":117,"soonestReadout":1185},[3001],{"nctId":1182,"briefTitle":1183,"status":169,"phases":3002,"primaryCompletion":1185,"completion":1186,"start":1187,"enrollment":1188,"conditions":3003,"interventions":3004},[90],[1190,1191,1192,1193,1194],[1196,1197,1198,217,1199,1200,1201,1202,1203,694,1204],{"trials":3006,"activeCount":100},[],{"trials":3008,"activeCount":100},[],{"intervention":1289,"totalTrials":96,"cells":3010},{"EARLY_PHASE1":3011,"PHASE1":3013,"PHASE2":3015,"PHASE3":3021,"PHASE4":3027,"NA":3029},{"trials":3012,"activeCount":100},[],{"trials":3014,"activeCount":100},[],{"trials":3016,"activeCount":100},[3017],{"nctId":1280,"briefTitle":1281,"status":207,"phases":3018,"primaryCompletion":842,"completion":408,"start":390,"enrollment":16,"conditions":3019,"interventions":3020},[89],[27],[1285,1214,399,1286,1287,1288,1289,611],{"trials":3022,"activeCount":117,"soonestReadout":1185},[3023],{"nctId":1182,"briefTitle":1183,"status":169,"phases":3024,"primaryCompletion":1185,"completion":1186,"start":1187,"enrollment":1188,"conditions":3025,"interventions":3026},[90],[1190,1191,1192,1193,1194],[1196,1197,1198,217,1199,1200,1201,1202,1203,694,1204],{"trials":3028,"activeCount":100},[],{"trials":3030,"activeCount":100},[],{"intervention":2717,"totalTrials":96,"cells":3032},{"EARLY_PHASE1":3033,"PHASE1":3035,"PHASE2":3037,"PHASE3":3043,"PHASE4":3049,"NA":3051},{"trials":3034,"activeCount":100},[],{"trials":3036,"activeCount":100},[],{"trials":3038,"activeCount":100},[3039],{"nctId":2690,"briefTitle":2691,"status":207,"phases":3040,"primaryCompletion":2693,"completion":2694,"start":2695,"enrollment":714,"conditions":3041,"interventions":3042},[89],[2697,2698,2699,2700,2701,2702,2703,2704,2705,2706,2707,2708,2709,2710,2711,2712,2713,2714,2715],[1436,192,2717,2718],{"trials":3044,"activeCount":117,"soonestReadout":2744},[3045],{"nctId":2741,"briefTitle":2742,"status":125,"phases":3046,"primaryCompletion":2744,"completion":2745,"start":2746,"enrollment":2747,"conditions":3047,"interventions":3048},[90],[2749,2750,2751],[2753,2754,2755,2756,2717,2757,2718,2758,2759],{"trials":3050,"activeCount":100},[],{"trials":3052,"activeCount":100},[],{"intervention":2116,"totalTrials":96,"cells":3054},{"EARLY_PHASE1":3055,"PHASE1":3057,"PHASE2":3059,"PHASE3":3061,"PHASE4":3094,"NA":3096},{"trials":3056,"activeCount":100},[],{"trials":3058,"activeCount":100},[],{"trials":3060,"activeCount":100},[],{"trials":3062,"activeCount":117,"soonestReadout":2105},[3063,3067],{"nctId":2102,"briefTitle":2103,"status":169,"phases":3064,"primaryCompletion":2105,"completion":2106,"start":2107,"enrollment":183,"conditions":3065,"interventions":3066},[90],[2109,2110,2111,2112,2113],[81,218,191,2115,193,2116,2117],{"nctId":3068,"briefTitle":3069,"status":207,"phases":3070,"primaryCompletion":3071,"completion":3072,"start":3073,"enrollment":3074,"conditions":3075,"interventions":3093},"NCT03768414","Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers",[90],"2023-10-04","2024-10-28","2019-02-07",452,[3076,3077,3078,3079,3080,3081,3082,3083,3084,3085,3086,3087,3088,3089,3090,3091,3092],"Stage III Distal Bile Duct Cancer AJCC v8","Stage III Gallbladder Cancer AJCC v8","Stage III Intrahepatic Cholangiocarcinoma AJCC v8","Stage IIIA Distal Bile Duct Cancer AJCC v8","Stage IIIA Gallbladder Cancer AJCC v8","Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8","Stage IIIB Distal Bile Duct Cancer AJCC v8","Stage IIIB Gallbladder Cancer AJCC v8","Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8","Stage IV Distal Bile Duct Cancer AJCC v8","Stage IV Gallbladder Cancer AJCC v8","Stage IV Intrahepatic Cholangiocarcinoma AJCC v8","Stage IVA Gallbladder Cancer AJCC v8","Stage IVB Gallbladder Cancer AJCC v8","Unresectable Extrahepatic Bile Duct Carcinoma","Unresectable Gallbladder Carcinoma","Unresectable Intrahepatic Cholangiocarcinoma",[2173,219,2116],{"trials":3095,"activeCount":100},[],{"trials":3097,"activeCount":100},[],{"intervention":610,"totalTrials":117,"cells":3099},{"EARLY_PHASE1":3100,"PHASE1":3102,"PHASE2":3104,"PHASE3":3106,"PHASE4":3112,"NA":3114},{"trials":3101,"activeCount":100},[],{"trials":3103,"activeCount":100},[],{"trials":3105,"activeCount":100},[],{"trials":3107,"activeCount":117,"soonestReadout":41},[3108],{"nctId":39,"briefTitle":40,"status":106,"phases":3109,"primaryCompletion":41,"completion":606,"start":407,"enrollment":607,"conditions":3110,"interventions":3111},[90],[15],[42,610,294,349,611],{"trials":3113,"activeCount":100},[],{"trials":3115,"activeCount":100},[],{"intervention":270,"totalTrials":117,"cells":3117},{"EARLY_PHASE1":3118,"PHASE1":3120,"PHASE2":3122,"PHASE3":3124,"PHASE4":3130,"NA":3132},{"trials":3119,"activeCount":100},[],{"trials":3121,"activeCount":100},[],{"trials":3123,"activeCount":100},[],{"trials":3125,"activeCount":117,"soonestReadout":259},[3126],{"nctId":256,"briefTitle":257,"status":106,"phases":3127,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":3128,"interventions":3129},[89,90],[264,175,265,266,267,268,176,214,215],[250,217,218,270,220,221,157],{"trials":3131,"activeCount":100},[],{"trials":3133,"activeCount":100},[],{"intervention":2115,"totalTrials":117,"cells":3135},{"EARLY_PHASE1":3136,"PHASE1":3138,"PHASE2":3140,"PHASE3":3142,"PHASE4":3148,"NA":3150},{"trials":3137,"activeCount":100},[],{"trials":3139,"activeCount":100},[],{"trials":3141,"activeCount":100},[],{"trials":3143,"activeCount":117,"soonestReadout":2105},[3144],{"nctId":2102,"briefTitle":2103,"status":169,"phases":3145,"primaryCompletion":2105,"completion":2106,"start":2107,"enrollment":183,"conditions":3146,"interventions":3147},[90],[2109,2110,2111,2112,2113],[81,218,191,2115,193,2116,2117],{"trials":3149,"activeCount":100},[],{"trials":3151,"activeCount":100},[],{"intervention":2117,"totalTrials":117,"cells":3153},{"EARLY_PHASE1":3154,"PHASE1":3156,"PHASE2":3158,"PHASE3":3160,"PHASE4":3166,"NA":3168},{"trials":3155,"activeCount":100},[],{"trials":3157,"activeCount":100},[],{"trials":3159,"activeCount":100},[],{"trials":3161,"activeCount":117,"soonestReadout":2105},[3162],{"nctId":2102,"briefTitle":2103,"status":169,"phases":3163,"primaryCompletion":2105,"completion":2106,"start":2107,"enrollment":183,"conditions":3164,"interventions":3165},[90],[2109,2110,2111,2112,2113],[81,218,191,2115,193,2116,2117],{"trials":3167,"activeCount":100},[],{"trials":3169,"activeCount":100},[],{"intervention":2314,"totalTrials":117,"cells":3171},{"EARLY_PHASE1":3172,"PHASE1":3174,"PHASE2":3176,"PHASE3":3178,"PHASE4":3184,"NA":3186},{"trials":3173,"activeCount":100},[],{"trials":3175,"activeCount":100},[],{"trials":3177,"activeCount":100},[],{"trials":3179,"activeCount":117,"soonestReadout":51},[3180],{"nctId":49,"briefTitle":50,"status":106,"phases":3181,"primaryCompletion":51,"completion":2308,"start":2309,"enrollment":2310,"conditions":3182,"interventions":3183},[90],[15],[52,2313,2314,731,2315,2316,623],{"trials":3185,"activeCount":100},[],{"trials":3187,"activeCount":100},[],{"intervention":2315,"totalTrials":117,"cells":3189},{"EARLY_PHASE1":3190,"PHASE1":3192,"PHASE2":3194,"PHASE3":3196,"PHASE4":3202,"NA":3204},{"trials":3191,"activeCount":100},[],{"trials":3193,"activeCount":100},[],{"trials":3195,"activeCount":100},[],{"trials":3197,"activeCount":117,"soonestReadout":51},[3198],{"nctId":49,"briefTitle":50,"status":106,"phases":3199,"primaryCompletion":51,"completion":2308,"start":2309,"enrollment":2310,"conditions":3200,"interventions":3201},[90],[15],[52,2313,2314,731,2315,2316,623],{"trials":3203,"activeCount":100},[],{"trials":3205,"activeCount":100},[],{"intervention":3207,"totalTrials":117,"cells":3208},"Lanreotide",{"EARLY_PHASE1":3209,"PHASE1":3211,"PHASE2":3213,"PHASE3":3215,"PHASE4":3228,"NA":3230},{"trials":3210,"activeCount":100},[],{"trials":3212,"activeCount":100},[],{"trials":3214,"activeCount":100},[],{"trials":3216,"activeCount":117,"soonestReadout":3221},[3217],{"nctId":3218,"briefTitle":3219,"status":169,"phases":3220,"primaryCompletion":3221,"completion":3221,"start":3222,"enrollment":3223,"conditions":3224,"interventions":3227},"NCT06807437","Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula",[90],"2027-11-01","2025-05-09",274,[3225,3226],"Pancreatic Carcinoma","Pancreatic Neoplasm",[3207],{"trials":3229,"activeCount":100},[],{"trials":3231,"activeCount":100},[],{"intervention":71,"totalTrials":117,"cells":3233},{"EARLY_PHASE1":3234,"PHASE1":3236,"PHASE2":3238,"PHASE3":3240,"PHASE4":3254,"NA":3256},{"trials":3235,"activeCount":100},[],{"trials":3237,"activeCount":100},[],{"trials":3239,"activeCount":100},[],{"trials":3241,"activeCount":117,"soonestReadout":70},[3242],{"nctId":68,"briefTitle":69,"status":106,"phases":3243,"primaryCompletion":70,"completion":3244,"start":3245,"enrollment":3246,"conditions":3247,"interventions":3251},[90],"2026-06-15","2017-02-24",1000,[3248,3249,3250],"Stage 0 Bladder Urothelial Carcinoma","Stage 0is Bladder Urothelial Carcinoma","Stage I Bladder Urothelial Carcinoma",[71,3252,3253],"BCG Tokyo-172 Strain Solution","BCG Tokyo-172 Strain Vaccine",{"trials":3255,"activeCount":100},[],{"trials":3257,"activeCount":100},[],{"intervention":3252,"totalTrials":117,"cells":3259},{"EARLY_PHASE1":3260,"PHASE1":3262,"PHASE2":3264,"PHASE3":3266,"PHASE4":3272,"NA":3274},{"trials":3261,"activeCount":100},[],{"trials":3263,"activeCount":100},[],{"trials":3265,"activeCount":100},[],{"trials":3267,"activeCount":117,"soonestReadout":70},[3268],{"nctId":68,"briefTitle":69,"status":106,"phases":3269,"primaryCompletion":70,"completion":3244,"start":3245,"enrollment":3246,"conditions":3270,"interventions":3271},[90],[3248,3249,3250],[71,3252,3253],{"trials":3273,"activeCount":100},[],{"trials":3275,"activeCount":100},[],{"intervention":3253,"totalTrials":117,"cells":3277},{"EARLY_PHASE1":3278,"PHASE1":3280,"PHASE2":3282,"PHASE3":3284,"PHASE4":3290,"NA":3292},{"trials":3279,"activeCount":100},[],{"trials":3281,"activeCount":100},[],{"trials":3283,"activeCount":100},[],{"trials":3285,"activeCount":117,"soonestReadout":70},[3286],{"nctId":68,"briefTitle":69,"status":106,"phases":3287,"primaryCompletion":70,"completion":3244,"start":3245,"enrollment":3246,"conditions":3288,"interventions":3289},[90],[3248,3249,3250],[71,3252,3253],{"trials":3291,"activeCount":100},[],{"trials":3293,"activeCount":100},[],{"intervention":3295,"totalTrials":117,"cells":3296},"Active Comparator",{"EARLY_PHASE1":3297,"PHASE1":3299,"PHASE2":3301,"PHASE3":3303,"PHASE4":3315,"NA":3317},{"trials":3298,"activeCount":100},[],{"trials":3300,"activeCount":100},[],{"trials":3302,"activeCount":100},[],{"trials":3304,"activeCount":117,"soonestReadout":3309},[3305],{"nctId":3306,"briefTitle":3307,"status":169,"phases":3308,"primaryCompletion":3309,"completion":3309,"start":3310,"enrollment":3311,"conditions":3312,"interventions":3314},"NCT04510597","Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial",[90],"2033-07","2021-03-08",364,[942,3313,944],"Metastatic Renal Cell Carcinoma",[3295],{"trials":3316,"activeCount":100},[],{"trials":3318,"activeCount":100},[],{"intervention":3320,"totalTrials":117,"cells":3321},"Carvedilol",{"EARLY_PHASE1":3322,"PHASE1":3324,"PHASE2":3326,"PHASE3":3328,"PHASE4":3343,"NA":3345},{"trials":3323,"activeCount":100},[],{"trials":3325,"activeCount":100},[],{"trials":3327,"activeCount":100},[],{"trials":3329,"activeCount":117,"soonestReadout":3334},[3330],{"nctId":3331,"briefTitle":3332,"status":169,"phases":3333,"primaryCompletion":3334,"completion":3334,"start":3335,"enrollment":3336,"conditions":3337,"interventions":3342},"NCT03418961","S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity",[90],"2027-09-15","2017-11-01",491,[3338,3339,1807,3340,3341],"Cardiotoxicity","HER2\u002FNeu Positive","Recurrent Breast Carcinoma","Stage IV Breast Cancer AJCC v6 and v7",[3320],{"trials":3344,"activeCount":100},[],{"trials":3346,"activeCount":100},[],{"intervention":3348,"totalTrials":117,"cells":3349},"Screening Platform",{"EARLY_PHASE1":3350,"PHASE1":3352,"PHASE2":3354,"PHASE3":3356,"PHASE4":3368,"NA":3370},{"trials":3351,"activeCount":100},[],{"trials":3353,"activeCount":100},[],{"trials":3355,"activeCount":100},[],{"trials":3357,"activeCount":117,"soonestReadout":3362},[3358],{"nctId":3359,"briefTitle":3360,"status":169,"phases":3361,"primaryCompletion":3362,"completion":3362,"start":3363,"enrollment":3364,"conditions":3365,"interventions":3367},"NCT03851445","Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer",[89,90],"2029-01-28","2019-02-06",10000,[3366],"Previously Treated Non-Small Cell Lung Cancer",[3348],{"trials":3369,"activeCount":100},[],{"trials":3371,"activeCount":100},[],{"intervention":281,"totalTrials":117,"cells":3373},{"EARLY_PHASE1":3374,"PHASE1":3376,"PHASE2":3378,"PHASE3":3380,"PHASE4":3386,"NA":3388},{"trials":3375,"activeCount":100},[],{"trials":3377,"activeCount":100},[],{"trials":3379,"activeCount":100},[],{"trials":3381,"activeCount":117,"soonestReadout":275},[3382],{"nctId":272,"briefTitle":273,"status":169,"phases":3383,"primaryCompletion":275,"completion":276,"start":277,"enrollment":278,"conditions":3384,"interventions":3385},[89,90],[175,176],[281,250,217,157],{"trials":3387,"activeCount":100},[],{"trials":3389,"activeCount":100},[],{"intervention":1781,"totalTrials":117,"cells":3391},{"EARLY_PHASE1":3392,"PHASE1":3394,"PHASE2":3396,"PHASE3":3398,"PHASE4":3404,"NA":3406},{"trials":3393,"activeCount":100},[],{"trials":3395,"activeCount":100},[],{"trials":3397,"activeCount":100},[],{"trials":3399,"activeCount":117,"soonestReadout":1775},[3400],{"nctId":1772,"briefTitle":1773,"status":106,"phases":3401,"primaryCompletion":1775,"completion":1776,"start":1777,"enrollment":1778,"conditions":3402,"interventions":3403},[90],[36],[836,1781],{"trials":3405,"activeCount":100},[],{"trials":3407,"activeCount":100},[],{"intervention":3409,"totalTrials":117,"cells":3410},"Eflornithine placebo & sulindac placebo",{"EARLY_PHASE1":3411,"PHASE1":3413,"PHASE2":3415,"PHASE3":3417,"PHASE4":3431,"NA":3433},{"trials":3412,"activeCount":100},[],{"trials":3414,"activeCount":100},[],{"trials":3416,"activeCount":100},[],{"trials":3418,"activeCount":117,"soonestReadout":3334},[3419],{"nctId":3420,"briefTitle":3421,"status":106,"phases":3422,"primaryCompletion":3334,"completion":3423,"start":3424,"enrollment":1454,"conditions":3425,"interventions":3427},"NCT01349881","S0820, Adenoma and Second Primary Prevention Trial",[90],"2032-02-01","2013-08-23",[3426],"Colorectal Neoplasms",[3409,3428,3429,3430],"eflornithine & sulindac placebo","Eflornithine placebo & sulindac","Eflornithine plus sulindac",{"trials":3432,"activeCount":100},[],{"trials":3434,"activeCount":100},[],{"intervention":3428,"totalTrials":117,"cells":3436},{"EARLY_PHASE1":3437,"PHASE1":3439,"PHASE2":3441,"PHASE3":3443,"PHASE4":3449,"NA":3451},{"trials":3438,"activeCount":100},[],{"trials":3440,"activeCount":100},[],{"trials":3442,"activeCount":100},[],{"trials":3444,"activeCount":117,"soonestReadout":3334},[3445],{"nctId":3420,"briefTitle":3421,"status":106,"phases":3446,"primaryCompletion":3334,"completion":3423,"start":3424,"enrollment":1454,"conditions":3447,"interventions":3448},[90],[3426],[3409,3428,3429,3430],{"trials":3450,"activeCount":100},[],{"trials":3452,"activeCount":100},[],{"intervention":3429,"totalTrials":117,"cells":3454},{"EARLY_PHASE1":3455,"PHASE1":3457,"PHASE2":3459,"PHASE3":3461,"PHASE4":3467,"NA":3469},{"trials":3456,"activeCount":100},[],{"trials":3458,"activeCount":100},[],{"trials":3460,"activeCount":100},[],{"trials":3462,"activeCount":117,"soonestReadout":3334},[3463],{"nctId":3420,"briefTitle":3421,"status":106,"phases":3464,"primaryCompletion":3334,"completion":3423,"start":3424,"enrollment":1454,"conditions":3465,"interventions":3466},[90],[3426],[3409,3428,3429,3430],{"trials":3468,"activeCount":100},[],{"trials":3470,"activeCount":100},[],{"intervention":3430,"totalTrials":117,"cells":3472},{"EARLY_PHASE1":3473,"PHASE1":3475,"PHASE2":3477,"PHASE3":3479,"PHASE4":3485,"NA":3487},{"trials":3474,"activeCount":100},[],{"trials":3476,"activeCount":100},[],{"trials":3478,"activeCount":100},[],{"trials":3480,"activeCount":117,"soonestReadout":3334},[3481],{"nctId":3420,"briefTitle":3421,"status":106,"phases":3482,"primaryCompletion":3334,"completion":3423,"start":3424,"enrollment":1454,"conditions":3483,"interventions":3484},[90],[3426],[3409,3428,3429,3430],{"trials":3486,"activeCount":100},[],{"trials":3488,"activeCount":100},[],{"intervention":1196,"totalTrials":117,"cells":3490},{"EARLY_PHASE1":3491,"PHASE1":3493,"PHASE2":3495,"PHASE3":3497,"PHASE4":3503,"NA":3505},{"trials":3492,"activeCount":100},[],{"trials":3494,"activeCount":100},[],{"trials":3496,"activeCount":100},[],{"trials":3498,"activeCount":117,"soonestReadout":1185},[3499],{"nctId":1182,"briefTitle":1183,"status":169,"phases":3500,"primaryCompletion":1185,"completion":1186,"start":1187,"enrollment":1188,"conditions":3501,"interventions":3502},[90],[1190,1191,1192,1193,1194],[1196,1197,1198,217,1199,1200,1201,1202,1203,694,1204],{"trials":3504,"activeCount":100},[],{"trials":3506,"activeCount":100},[],{"intervention":1198,"totalTrials":117,"cells":3508},{"EARLY_PHASE1":3509,"PHASE1":3511,"PHASE2":3513,"PHASE3":3515,"PHASE4":3521,"NA":3523},{"trials":3510,"activeCount":100},[],{"trials":3512,"activeCount":100},[],{"trials":3514,"activeCount":100},[],{"trials":3516,"activeCount":117,"soonestReadout":1185},[3517],{"nctId":1182,"briefTitle":1183,"status":169,"phases":3518,"primaryCompletion":1185,"completion":1186,"start":1187,"enrollment":1188,"conditions":3519,"interventions":3520},[90],[1190,1191,1192,1193,1194],[1196,1197,1198,217,1199,1200,1201,1202,1203,694,1204],{"trials":3522,"activeCount":100},[],{"trials":3524,"activeCount":100},[],{"intervention":1201,"totalTrials":117,"cells":3526},{"EARLY_PHASE1":3527,"PHASE1":3529,"PHASE2":3531,"PHASE3":3533,"PHASE4":3539,"NA":3541},{"trials":3528,"activeCount":100},[],{"trials":3530,"activeCount":100},[],{"trials":3532,"activeCount":100},[],{"trials":3534,"activeCount":117,"soonestReadout":1185},[3535],{"nctId":1182,"briefTitle":1183,"status":169,"phases":3536,"primaryCompletion":1185,"completion":1186,"start":1187,"enrollment":1188,"conditions":3537,"interventions":3538},[90],[1190,1191,1192,1193,1194],[1196,1197,1198,217,1199,1200,1201,1202,1203,694,1204],{"trials":3540,"activeCount":100},[],{"trials":3542,"activeCount":100},[],{"intervention":1204,"totalTrials":117,"cells":3544},{"EARLY_PHASE1":3545,"PHASE1":3547,"PHASE2":3549,"PHASE3":3551,"PHASE4":3557,"NA":3559},{"trials":3546,"activeCount":100},[],{"trials":3548,"activeCount":100},[],{"trials":3550,"activeCount":100},[],{"trials":3552,"activeCount":117,"soonestReadout":1185},[3553],{"nctId":1182,"briefTitle":1183,"status":169,"phases":3554,"primaryCompletion":1185,"completion":1186,"start":1187,"enrollment":1188,"conditions":3555,"interventions":3556},[90],[1190,1191,1192,1193,1194],[1196,1197,1198,217,1199,1200,1201,1202,1203,694,1204],{"trials":3558,"activeCount":100},[],{"trials":3560,"activeCount":100},[],{"intervention":1583,"totalTrials":117,"cells":3562},{"EARLY_PHASE1":3563,"PHASE1":3565,"PHASE2":3567,"PHASE3":3569,"PHASE4":3575,"NA":3577},{"trials":3564,"activeCount":100},[],{"trials":3566,"activeCount":100},[],{"trials":3568,"activeCount":100},[],{"trials":3570,"activeCount":117,"soonestReadout":1576},[3571],{"nctId":1573,"briefTitle":1574,"status":169,"phases":3572,"primaryCompletion":1576,"completion":1577,"start":1578,"enrollment":1579,"conditions":3573,"interventions":3574},[90],[1581,1194],[1583,237,694],{"trials":3576,"activeCount":100},[],{"trials":3578,"activeCount":100},[],{"intervention":693,"totalTrials":117,"cells":3580},{"EARLY_PHASE1":3581,"PHASE1":3583,"PHASE2":3585,"PHASE3":3587,"PHASE4":3593,"NA":3595},{"trials":3582,"activeCount":100},[],{"trials":3584,"activeCount":100},[],{"trials":3586,"activeCount":100},[],{"trials":3588,"activeCount":117,"soonestReadout":684},[3589],{"nctId":681,"briefTitle":682,"status":125,"phases":3590,"primaryCompletion":684,"completion":685,"start":686,"enrollment":533,"conditions":3591,"interventions":3592},[90],[688,689,690],[348,692,693,694,695,696,697],{"trials":3594,"activeCount":100},[],{"trials":3596,"activeCount":100},[],{"intervention":696,"totalTrials":117,"cells":3598},{"EARLY_PHASE1":3599,"PHASE1":3601,"PHASE2":3603,"PHASE3":3605,"PHASE4":3611,"NA":3613},{"trials":3600,"activeCount":100},[],{"trials":3602,"activeCount":100},[],{"trials":3604,"activeCount":100},[],{"trials":3606,"activeCount":117,"soonestReadout":684},[3607],{"nctId":681,"briefTitle":682,"status":125,"phases":3608,"primaryCompletion":684,"completion":685,"start":686,"enrollment":533,"conditions":3609,"interventions":3610},[90],[688,689,690],[348,692,693,694,695,696,697],{"trials":3612,"activeCount":100},[],{"trials":3614,"activeCount":100},[],{"intervention":2753,"totalTrials":117,"cells":3616},{"EARLY_PHASE1":3617,"PHASE1":3619,"PHASE2":3621,"PHASE3":3623,"PHASE4":3629,"NA":3631},{"trials":3618,"activeCount":100},[],{"trials":3620,"activeCount":100},[],{"trials":3622,"activeCount":100},[],{"trials":3624,"activeCount":117,"soonestReadout":2744},[3625],{"nctId":2741,"briefTitle":2742,"status":125,"phases":3626,"primaryCompletion":2744,"completion":2745,"start":2746,"enrollment":2747,"conditions":3627,"interventions":3628},[90],[2749,2750,2751],[2753,2754,2755,2756,2717,2757,2718,2758,2759],{"trials":3630,"activeCount":100},[],{"trials":3632,"activeCount":100},[],{"intervention":2754,"totalTrials":117,"cells":3634},{"EARLY_PHASE1":3635,"PHASE1":3637,"PHASE2":3639,"PHASE3":3641,"PHASE4":3647,"NA":3649},{"trials":3636,"activeCount":100},[],{"trials":3638,"activeCount":100},[],{"trials":3640,"activeCount":100},[],{"trials":3642,"activeCount":117,"soonestReadout":2744},[3643],{"nctId":2741,"briefTitle":2742,"status":125,"phases":3644,"primaryCompletion":2744,"completion":2745,"start":2746,"enrollment":2747,"conditions":3645,"interventions":3646},[90],[2749,2750,2751],[2753,2754,2755,2756,2717,2757,2718,2758,2759],{"trials":3648,"activeCount":100},[],{"trials":3650,"activeCount":100},[],{"intervention":2755,"totalTrials":117,"cells":3652},{"EARLY_PHASE1":3653,"PHASE1":3655,"PHASE2":3657,"PHASE3":3659,"PHASE4":3665,"NA":3667},{"trials":3654,"activeCount":100},[],{"trials":3656,"activeCount":100},[],{"trials":3658,"activeCount":100},[],{"trials":3660,"activeCount":117,"soonestReadout":2744},[3661],{"nctId":2741,"briefTitle":2742,"status":125,"phases":3662,"primaryCompletion":2744,"completion":2745,"start":2746,"enrollment":2747,"conditions":3663,"interventions":3664},[90],[2749,2750,2751],[2753,2754,2755,2756,2717,2757,2718,2758,2759],{"trials":3666,"activeCount":100},[],{"trials":3668,"activeCount":100},[],{"intervention":2756,"totalTrials":117,"cells":3670},{"EARLY_PHASE1":3671,"PHASE1":3673,"PHASE2":3675,"PHASE3":3677,"PHASE4":3683,"NA":3685},{"trials":3672,"activeCount":100},[],{"trials":3674,"activeCount":100},[],{"trials":3676,"activeCount":100},[],{"trials":3678,"activeCount":117,"soonestReadout":2744},[3679],{"nctId":2741,"briefTitle":2742,"status":125,"phases":3680,"primaryCompletion":2744,"completion":2745,"start":2746,"enrollment":2747,"conditions":3681,"interventions":3682},[90],[2749,2750,2751],[2753,2754,2755,2756,2717,2757,2718,2758,2759],{"trials":3684,"activeCount":100},[],{"trials":3686,"activeCount":100},[],{"intervention":2757,"totalTrials":117,"cells":3688},{"EARLY_PHASE1":3689,"PHASE1":3691,"PHASE2":3693,"PHASE3":3695,"PHASE4":3701,"NA":3703},{"trials":3690,"activeCount":100},[],{"trials":3692,"activeCount":100},[],{"trials":3694,"activeCount":100},[],{"trials":3696,"activeCount":117,"soonestReadout":2744},[3697],{"nctId":2741,"briefTitle":2742,"status":125,"phases":3698,"primaryCompletion":2744,"completion":2745,"start":2746,"enrollment":2747,"conditions":3699,"interventions":3700},[90],[2749,2750,2751],[2753,2754,2755,2756,2717,2757,2718,2758,2759],{"trials":3702,"activeCount":100},[],{"trials":3704,"activeCount":100},[],{"intervention":2758,"totalTrials":117,"cells":3706},{"EARLY_PHASE1":3707,"PHASE1":3709,"PHASE2":3711,"PHASE3":3713,"PHASE4":3719,"NA":3721},{"trials":3708,"activeCount":100},[],{"trials":3710,"activeCount":100},[],{"trials":3712,"activeCount":100},[],{"trials":3714,"activeCount":117,"soonestReadout":2744},[3715],{"nctId":2741,"briefTitle":2742,"status":125,"phases":3716,"primaryCompletion":2744,"completion":2745,"start":2746,"enrollment":2747,"conditions":3717,"interventions":3718},[90],[2749,2750,2751],[2753,2754,2755,2756,2717,2757,2718,2758,2759],{"trials":3720,"activeCount":100},[],{"trials":3722,"activeCount":100},[],{"intervention":2759,"totalTrials":117,"cells":3724},{"EARLY_PHASE1":3725,"PHASE1":3727,"PHASE2":3729,"PHASE3":3731,"PHASE4":3737,"NA":3739},{"trials":3726,"activeCount":100},[],{"trials":3728,"activeCount":100},[],{"trials":3730,"activeCount":100},[],{"trials":3732,"activeCount":117,"soonestReadout":2744},[3733],{"nctId":2741,"briefTitle":2742,"status":125,"phases":3734,"primaryCompletion":2744,"completion":2745,"start":2746,"enrollment":2747,"conditions":3735,"interventions":3736},[90],[2749,2750,2751],[2753,2754,2755,2756,2717,2757,2718,2758,2759],{"trials":3738,"activeCount":100},[],{"trials":3740,"activeCount":100},[],{"intervention":946,"totalTrials":117,"cells":3742},{"EARLY_PHASE1":3743,"PHASE1":3745,"PHASE2":3747,"PHASE3":3749,"PHASE4":3755,"NA":3757},{"trials":3744,"activeCount":100},[],{"trials":3746,"activeCount":100},[],{"trials":3748,"activeCount":100},[],{"trials":3750,"activeCount":117,"soonestReadout":936},[3751],{"nctId":933,"briefTitle":934,"status":125,"phases":3752,"primaryCompletion":936,"completion":937,"start":938,"enrollment":939,"conditions":3753,"interventions":3754},[90],[941,942,943,944],[946,947,948,47,949,950,951,220],{"trials":3756,"activeCount":100},[],{"trials":3758,"activeCount":100},[],{"intervention":947,"totalTrials":117,"cells":3760},{"EARLY_PHASE1":3761,"PHASE1":3763,"PHASE2":3765,"PHASE3":3767,"PHASE4":3773,"NA":3775},{"trials":3762,"activeCount":100},[],{"trials":3764,"activeCount":100},[],{"trials":3766,"activeCount":100},[],{"trials":3768,"activeCount":117,"soonestReadout":936},[3769],{"nctId":933,"briefTitle":934,"status":125,"phases":3770,"primaryCompletion":936,"completion":937,"start":938,"enrollment":939,"conditions":3771,"interventions":3772},[90],[941,942,943,944],[946,947,948,47,949,950,951,220],{"trials":3774,"activeCount":100},[],{"trials":3776,"activeCount":100},[],{"intervention":948,"totalTrials":117,"cells":3778},{"EARLY_PHASE1":3779,"PHASE1":3781,"PHASE2":3783,"PHASE3":3785,"PHASE4":3791,"NA":3793},{"trials":3780,"activeCount":100},[],{"trials":3782,"activeCount":100},[],{"trials":3784,"activeCount":100},[],{"trials":3786,"activeCount":117,"soonestReadout":936},[3787],{"nctId":933,"briefTitle":934,"status":125,"phases":3788,"primaryCompletion":936,"completion":937,"start":938,"enrollment":939,"conditions":3789,"interventions":3790},[90],[941,942,943,944],[946,947,948,47,949,950,951,220],{"trials":3792,"activeCount":100},[],{"trials":3794,"activeCount":100},[],{"intervention":949,"totalTrials":117,"cells":3796},{"EARLY_PHASE1":3797,"PHASE1":3799,"PHASE2":3801,"PHASE3":3803,"PHASE4":3809,"NA":3811},{"trials":3798,"activeCount":100},[],{"trials":3800,"activeCount":100},[],{"trials":3802,"activeCount":100},[],{"trials":3804,"activeCount":117,"soonestReadout":936},[3805],{"nctId":933,"briefTitle":934,"status":125,"phases":3806,"primaryCompletion":936,"completion":937,"start":938,"enrollment":939,"conditions":3807,"interventions":3808},[90],[941,942,943,944],[946,947,948,47,949,950,951,220],{"trials":3810,"activeCount":100},[],{"trials":3812,"activeCount":100},[],{"intervention":951,"totalTrials":117,"cells":3814},{"EARLY_PHASE1":3815,"PHASE1":3817,"PHASE2":3819,"PHASE3":3821,"PHASE4":3827,"NA":3829},{"trials":3816,"activeCount":100},[],{"trials":3818,"activeCount":100},[],{"trials":3820,"activeCount":100},[],{"trials":3822,"activeCount":117,"soonestReadout":936},[3823],{"nctId":933,"briefTitle":934,"status":125,"phases":3824,"primaryCompletion":936,"completion":937,"start":938,"enrollment":939,"conditions":3825,"interventions":3826},[90],[941,942,943,944],[946,947,948,47,949,950,951,220],{"trials":3828,"activeCount":100},[],{"trials":3830,"activeCount":100},[],{"intervention":3832,"totalTrials":96,"cells":3833},"Sacituzumab Govitecan",{"EARLY_PHASE1":3834,"PHASE1":3836,"PHASE2":3838,"PHASE3":3862,"PHASE4":3864,"NA":3866},{"trials":3835,"activeCount":100},[],{"trials":3837,"activeCount":100},[],{"trials":3839,"activeCount":96,"soonestReadout":275},[3840,3851],{"nctId":3841,"briefTitle":3842,"status":106,"phases":3843,"primaryCompletion":275,"completion":3844,"start":3845,"enrollment":1636,"conditions":3846,"interventions":3850},"NCT04647916","Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases",[89],"2028-12","2021-06-08",[2749,3847,3848,1807,3849],"Invasive Breast Carcinoma","Metastatic HER2 Negative Breast Carcinoma","Prognostic Stage IV Breast Cancer AJCC v8",[3832],{"nctId":3852,"briefTitle":3853,"status":125,"phases":3854,"primaryCompletion":3855,"completion":3856,"start":3857,"enrollment":3858,"conditions":3859,"interventions":3860},"NCT07393555","Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)",[89],"2028-11-30","2029-11","2026-08-07",117,[175,176],[3861,3832],"Ivonescimab",{"trials":3863,"activeCount":100},[],{"trials":3865,"activeCount":100},[],{"trials":3867,"activeCount":100},[],{"intervention":399,"totalTrials":410,"cells":3869},{"EARLY_PHASE1":3870,"PHASE1":3872,"PHASE2":3880,"PHASE3":3960,"PHASE4":3985,"NA":3987},{"trials":3871,"activeCount":100},[],{"trials":3873,"activeCount":100},[3874],{"nctId":3875,"briefTitle":3876,"status":207,"phases":3877,"primaryCompletion":1010,"completion":1010,"start":1725,"enrollment":22,"conditions":3878,"interventions":3879},"NCT00006487","S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer",[88],[21],[506,399,1408],{"trials":3881,"activeCount":117,"soonestReadout":276},[3882,3900,3904,3908,3912,3916,3920,3924,3933,3937,3944,3948,3952,3956],{"nctId":3883,"briefTitle":3884,"status":169,"phases":3885,"primaryCompletion":276,"completion":2105,"start":3886,"enrollment":3887,"conditions":3888,"interventions":3894},"NCT06769126","Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study",[89],"2025-11-06",900,[3889,3890,3891,3892,3893],"Extensive Stage Lung Small Cell Carcinoma","Lung Small Cell Carcinoma, A Subtype","Lung Small Cell Carcinoma, I Subtype","Lung Small Cell Carcinoma, N Subtype","Lung Small Cell Carcinoma, P Subtype",[3895,1150,3896,3897,3898,3899],"Ceralasertib","Etoposide","Monalizumab","Platinum Compound","Saruparib",{"nctId":387,"briefTitle":388,"status":207,"phases":3901,"primaryCompletion":390,"completion":391,"start":392,"enrollment":308,"conditions":3902,"interventions":3903},[89],[24,394,395],[397,294,332,398,333,349,399,400,401,336,317,402,316],{"nctId":1280,"briefTitle":1281,"status":207,"phases":3905,"primaryCompletion":842,"completion":408,"start":390,"enrollment":16,"conditions":3906,"interventions":3907},[89],[27],[1285,1214,399,1286,1287,1288,1289,611],{"nctId":1291,"briefTitle":1292,"status":207,"phases":3909,"primaryCompletion":1294,"completion":1124,"start":1295,"enrollment":1296,"conditions":3910,"interventions":3911},[89],[21],[668,399,611],{"nctId":404,"briefTitle":405,"status":207,"phases":3913,"primaryCompletion":407,"completion":408,"start":409,"enrollment":410,"conditions":3914,"interventions":3915},[89],[18,412],[414,415,294,332,349,399,336,317,316],{"nctId":428,"briefTitle":429,"status":207,"phases":3917,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":3918,"interventions":3919},[89],[18,436],[414,330,438,439,294,440,349,399,317,441,442,316],{"nctId":1037,"briefTitle":1038,"status":207,"phases":3921,"primaryCompletion":1040,"completion":1040,"start":1041,"enrollment":345,"conditions":3922,"interventions":3923},[89],[21],[506,961,399],{"nctId":3925,"briefTitle":3926,"status":662,"phases":3927,"primaryCompletion":3928,"completion":3928,"start":531,"enrollment":158,"conditions":3929,"interventions":3930},"NCT00045617","S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer",[89],"2003-05",[21],[3931,3932,506,399],"monoclonal antibody 11D10 anti-idiotype vaccine","monoclonal antibody GD2 anti-idiotype vaccine",{"nctId":498,"briefTitle":499,"status":241,"phases":3934,"primaryCompletion":501,"start":502,"enrollment":100,"conditions":3935,"interventions":3936},[89],[18],[331,475,505,506,294,332,333,349,399,363,364],{"nctId":3938,"briefTitle":3939,"status":207,"phases":3940,"primaryCompletion":1078,"completion":1010,"start":3941,"enrollment":1145,"conditions":3942,"interventions":3943},"NCT00002642","SWOG-9416: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage III Non-small Cell Lung Cancer",[89],"1995-04",[21],[506,399],{"nctId":549,"briefTitle":550,"status":207,"phases":3945,"primaryCompletion":552,"completion":553,"start":554,"enrollment":555,"conditions":3946,"interventions":3947},[89],[18],[505,294,399,363],{"nctId":2156,"briefTitle":2157,"status":207,"phases":3949,"primaryCompletion":2159,"completion":492,"start":2160,"enrollment":19,"conditions":3950,"interventions":3951},[89],[18],[506,399,1082,2163],{"nctId":559,"briefTitle":560,"status":207,"phases":3953,"primaryCompletion":407,"completion":408,"start":562,"enrollment":563,"conditions":3954,"interventions":3955},[89],[18],[414,330,294,332,349,399,400,336,317,566,316,567],{"nctId":569,"briefTitle":570,"status":241,"phases":3957,"primaryCompletion":408,"completion":408,"start":408,"enrollment":100,"conditions":3958,"interventions":3959},[89],[36,374],[475,506,294,333,349,399,574,363,364,575,576],{"trials":3961,"activeCount":100},[3962,3969,3973,3977,3981],{"nctId":3963,"briefTitle":3964,"status":207,"phases":3965,"primaryCompletion":511,"completion":2887,"start":1333,"enrollment":3966,"conditions":3967,"interventions":3968},"NCT00045162","S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer",[90],671,[21],[506,399,1116],{"nctId":671,"briefTitle":672,"status":207,"phases":3970,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":3971,"interventions":3972},[90],[18],[331,536,505,294,349,399,317,316],{"nctId":1722,"briefTitle":1723,"status":662,"phases":3974,"primaryCompletion":1333,"completion":629,"start":1725,"enrollment":843,"conditions":3975,"interventions":3976},[90],[18],[330,331,668,399,1728],{"nctId":699,"briefTitle":700,"status":662,"phases":3978,"primaryCompletion":702,"completion":702,"start":493,"enrollment":703,"conditions":3979,"interventions":3980},[90],[18],[414,505,294,440,349,399,706],{"nctId":743,"briefTitle":744,"status":662,"phases":3982,"primaryCompletion":407,"completion":325,"start":493,"enrollment":746,"conditions":3983,"interventions":3984},[90],[36],[330,506,294,333,399,364],{"trials":3986,"activeCount":100},[],{"trials":3988,"activeCount":100},[],{"intervention":1116,"totalTrials":703,"cells":3990},{"EARLY_PHASE1":3991,"PHASE1":3993,"PHASE2":3995,"PHASE3":4055,"PHASE4":4061,"NA":4063},{"trials":3992,"activeCount":100},[],{"trials":3994,"activeCount":100},[],{"trials":3996,"activeCount":117,"soonestReadout":80},[3997,4004,4008,4012,4016,4023,4029,4033,4041,4045],{"nctId":3998,"briefTitle":3999,"status":207,"phases":4000,"primaryCompletion":1373,"completion":501,"start":1041,"enrollment":4001,"conditions":4002,"interventions":4003},"NCT00066612","S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy",[89],45,[1315,1316,1317],[1116],{"nctId":78,"briefTitle":79,"status":169,"phases":4005,"primaryCompletion":80,"completion":181,"start":182,"enrollment":183,"conditions":4006,"interventions":4007},[89],[185,186,187,188,189],[81,191,192,193,194,195,157],{"nctId":2005,"briefTitle":2006,"status":207,"phases":4009,"primaryCompletion":2008,"completion":2009,"start":2010,"enrollment":359,"conditions":4010,"interventions":4011},[89],[2012,2013],[81,219,192,2015,2016],{"nctId":2690,"briefTitle":2691,"status":207,"phases":4013,"primaryCompletion":2693,"completion":2694,"start":2695,"enrollment":714,"conditions":4014,"interventions":4015},[89],[2697,2698,2699,2700,2701,2702,2703,2704,2705,2706,2707,2708,2709,2710,2711,2712,2713,2714,2715],[1436,192,2717,2718],{"nctId":4017,"briefTitle":4018,"status":207,"phases":4019,"primaryCompletion":973,"completion":973,"start":4020,"enrollment":1709,"conditions":4021,"interventions":4022},"NCT00012363","S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus",[89],"2001-04",[1112,1113],[1336,1116],{"nctId":4024,"briefTitle":4025,"status":662,"phases":4026,"primaryCompletion":982,"completion":369,"start":702,"enrollment":1597,"conditions":4027,"interventions":4028},"NCT00109850","S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer",[89],[1112],[977,506,1116],{"nctId":2051,"briefTitle":2052,"status":241,"phases":4030,"primaryCompletion":2054,"start":2055,"enrollment":100,"conditions":4031,"interventions":4032},[89],[30],[517,601,1116,400,1117,2058],{"nctId":4034,"briefTitle":4035,"status":207,"phases":4036,"primaryCompletion":4037,"completion":1011,"start":2033,"enrollment":4038,"conditions":4039,"interventions":4040},"NCT00030433","S0119: Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer",[89],"2007-02",85,[21],[1336,1116],{"nctId":1104,"briefTitle":1105,"status":207,"phases":4042,"primaryCompletion":1107,"completion":1108,"start":737,"enrollment":1109,"conditions":4043,"interventions":4044},[89],[1111,1112,1113],[1115,961,601,1116,400,1117],{"nctId":4046,"briefTitle":4047,"status":207,"phases":4048,"primaryCompletion":4049,"completion":4050,"start":552,"enrollment":4051,"conditions":4052,"interventions":4053},"NCT02164916","S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer",[89],"2017-11-13","2020-11-19",106,[30],[977,1116,4054],"vemurafenib",{"trials":4056,"activeCount":100},[4057],{"nctId":3963,"briefTitle":3964,"status":207,"phases":4058,"primaryCompletion":511,"completion":2887,"start":1333,"enrollment":3966,"conditions":4059,"interventions":4060},[90],[21],[506,399,1116],{"trials":4062,"activeCount":100},[],{"trials":4064,"activeCount":100},[],{"intervention":400,"totalTrials":4066,"cells":4067},10,{"EARLY_PHASE1":4068,"PHASE1":4070,"PHASE2":4072,"PHASE3":4106,"PHASE4":4116,"NA":4118},{"trials":4069,"activeCount":100},[],{"trials":4071,"activeCount":100},[],{"trials":4073,"activeCount":117,"soonestReadout":80},[4074,4078,4082,4086,4090,4094,4098,4102],{"nctId":78,"briefTitle":79,"status":169,"phases":4075,"primaryCompletion":80,"completion":181,"start":182,"enrollment":183,"conditions":4076,"interventions":4077},[89],[185,186,187,188,189],[81,191,192,193,194,195,157],{"nctId":387,"briefTitle":388,"status":207,"phases":4079,"primaryCompletion":390,"completion":391,"start":392,"enrollment":308,"conditions":4080,"interventions":4081},[89],[24,394,395],[397,294,332,398,333,349,399,400,401,336,317,402,316],{"nctId":417,"briefTitle":418,"status":207,"phases":4083,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":4084,"interventions":4085},[89],[18],[331,426,294,332,333,349,400,336,316],{"nctId":2030,"briefTitle":2031,"status":207,"phases":4087,"primaryCompletion":2033,"completion":995,"start":2034,"enrollment":2035,"conditions":4088,"interventions":4089},[89],[2037],[2039,601,400,2040],{"nctId":2051,"briefTitle":2052,"status":241,"phases":4091,"primaryCompletion":2054,"start":2055,"enrollment":100,"conditions":4092,"interventions":4093},[89],[30],[517,601,1116,400,1117,2058],{"nctId":559,"briefTitle":560,"status":207,"phases":4095,"primaryCompletion":407,"completion":408,"start":562,"enrollment":563,"conditions":4096,"interventions":4097},[89],[18],[414,330,294,332,349,399,400,336,317,566,316,567],{"nctId":2060,"briefTitle":2061,"status":207,"phases":4099,"primaryCompletion":995,"completion":995,"start":2063,"enrollment":1366,"conditions":4100,"interventions":4101},[89],[1112,1113],[601,400,2066],{"nctId":1104,"briefTitle":1105,"status":207,"phases":4103,"primaryCompletion":1107,"completion":1108,"start":737,"enrollment":1109,"conditions":4104,"interventions":4105},[89],[1111,1112,1113],[1115,961,601,1116,400,1117],{"trials":4107,"activeCount":100},[4108,4112],{"nctId":2092,"briefTitle":2093,"status":207,"phases":4109,"primaryCompletion":2095,"completion":1048,"start":2096,"enrollment":2097,"conditions":4110,"interventions":4111},[90],[30],[601,400,2100],{"nctId":2119,"briefTitle":2120,"status":207,"phases":4113,"primaryCompletion":471,"completion":356,"start":2122,"enrollment":2123,"conditions":4114,"interventions":4115},[90],[30],[601,400,2100],{"trials":4117,"activeCount":100},[],{"trials":4119,"activeCount":100},[],{"intervention":517,"totalTrials":703,"cells":4121},{"EARLY_PHASE1":4122,"PHASE1":4124,"PHASE2":4126,"PHASE3":4217,"PHASE4":4219,"NA":4221},{"trials":4123,"activeCount":100},[],{"trials":4125,"activeCount":100},[],{"trials":4127,"activeCount":117,"soonestReadout":4143},[4128,4139,4155,4164,4171,4178,4187,4191,4198,4202,4209],{"nctId":4129,"briefTitle":4130,"status":241,"phases":4131,"enrollment":100,"conditions":4132,"interventions":4138},"NCT00095641","S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer",[89],[4133,4134,4135,4136,4137],"Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Oropharynx",[517],{"nctId":4140,"briefTitle":4141,"status":169,"phases":4142,"primaryCompletion":4143,"completion":4143,"start":4144,"enrollment":4145,"conditions":4146,"interventions":4152},"NCT05040360","Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors",[89],"2027-03-31","2022-05-05",141,[4147,4148,4149,4150,4151],"Metastatic Malignant Neoplasm in the Liver","Pancreatic Neuroendocrine Tumor","Stage I Pancreatic Neuroendocrine Tumor AJCC v8","Stage II Pancreatic Neuroendocrine Tumor AJCC v8","Stage III Pancreatic Neuroendocrine Tumor AJCC v8",[4153,4154],"Capecitabine","Temozolomide",{"nctId":4156,"briefTitle":4157,"status":207,"phases":4158,"primaryCompletion":4159,"completion":408,"start":2212,"enrollment":1323,"conditions":4160,"interventions":4163},"NCT00033540","S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma",[89],"2008-04",[4161,4162],"Extrahepatic Bile Duct Cancer","Gallbladder Cancer",[517,1336],{"nctId":4165,"briefTitle":4166,"status":662,"phases":4167,"primaryCompletion":543,"start":4168,"enrollment":843,"conditions":4169,"interventions":4170},"NCT00335959","S0425 Oxaliplatin, Capecitabine, and RT in Treating Patients W\u002FStomach Cancer That Can Be Removed By Surgery",[89],"2006-05",[1113],[517,1117],{"nctId":4172,"briefTitle":4173,"status":207,"phases":4174,"primaryCompletion":4175,"completion":1011,"start":2737,"enrollment":1171,"conditions":4176,"interventions":4177},"NCT00058318","S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer",[89],"2007-05",[2839],[517,1336],{"nctId":4179,"briefTitle":4180,"status":207,"phases":4181,"primaryCompletion":4182,"completion":1107,"start":4183,"enrollment":4184,"conditions":4185,"interventions":4186},"NCT00686166","S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W\u002FStage II or III Rectal Cancer",[89],"2014-07","2009-02",83,[30],[977,517,1117],{"nctId":508,"briefTitle":509,"status":207,"phases":4188,"primaryCompletion":511,"completion":512,"start":513,"enrollment":514,"conditions":4189,"interventions":4190},[89],[15],[517,294],{"nctId":4192,"briefTitle":4193,"status":207,"phases":4194,"primaryCompletion":1965,"completion":553,"start":1382,"enrollment":4195,"conditions":4196,"interventions":4197},"NCT00789958","S0809: Capecitabine, Gemcitabine, and RT in Patients w\u002FCholangiocarcinoma of the Gallbladder or Bile Duct",[89],105,[4161,4162],[517,1336],{"nctId":2051,"briefTitle":2052,"status":241,"phases":4199,"primaryCompletion":2054,"start":2055,"enrollment":100,"conditions":4200,"interventions":4201},[89],[30],[517,601,1116,400,1117,2058],{"nctId":4203,"briefTitle":4204,"status":241,"phases":4205,"primaryCompletion":4206,"completion":4206,"start":629,"enrollment":100,"conditions":4207,"interventions":4208},"NCT00118105","S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer",[89],"2007-04",[30,1157],[485,517,1117],{"nctId":4210,"briefTitle":4211,"status":207,"phases":4212,"primaryCompletion":1087,"completion":1087,"start":4213,"enrollment":4214,"conditions":4215,"interventions":4216},"NCT00049335","S0030: Capecitabine in Treating Older Patients W\u002FMetastatic or Recurrent Colorectal Cancer That Cannot Be Surgically Removed",[89],"2003-02",29,[30],[517],{"trials":4218,"activeCount":100},[],{"trials":4220,"activeCount":100},[],{"trials":4222,"activeCount":100},[],{"intervention":4224,"totalTrials":252,"cells":4225},"temozolomide",{"EARLY_PHASE1":4226,"PHASE1":4228,"PHASE2":4230,"PHASE3":4252,"PHASE4":4254,"NA":4256},{"trials":4227,"activeCount":100},[],{"trials":4229,"activeCount":100},[],{"trials":4231,"activeCount":117,"soonestReadout":4143},[4232,4236,4244],{"nctId":4140,"briefTitle":4141,"status":169,"phases":4233,"primaryCompletion":4143,"completion":4143,"start":4144,"enrollment":4145,"conditions":4234,"interventions":4235},[89],[4147,4148,4149,4150,4151],[4153,4154],{"nctId":4237,"briefTitle":4238,"status":207,"phases":4239,"primaryCompletion":2211,"completion":512,"start":1391,"enrollment":4240,"conditions":4241,"interventions":4243},"NCT00104988","S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery",[89],64,[4242],"Melanoma (Skin)",[4224,364],{"nctId":4245,"briefTitle":4246,"status":207,"phases":4247,"primaryCompletion":554,"completion":554,"start":493,"enrollment":4248,"conditions":4249,"interventions":4251},"NCT00005597","S9926 Temozolomide in Patients With Unresectable\u002FMetastatic Gastrointestinal Stromal Tumors",[89],25,[4250],"Gastrointestinal Stromal Tumor",[4224],{"trials":4253,"activeCount":100},[],{"trials":4255,"activeCount":100},[],{"trials":4257,"activeCount":100},[],{"intervention":4259,"totalTrials":96,"cells":4260},"fludarabine",{"EARLY_PHASE1":4261,"PHASE1":4263,"PHASE2":4265,"PHASE3":4279,"PHASE4":4281,"NA":4283},{"trials":4262,"activeCount":100},[],{"trials":4264,"activeCount":100},[],{"trials":4266,"activeCount":117,"soonestReadout":447},[4267,4275],{"nctId":4268,"briefTitle":4269,"status":662,"phases":4270,"primaryCompletion":1391,"completion":1332,"start":1003,"enrollment":910,"conditions":4271,"interventions":4272},"NCT00053014","S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia",[89],[24],[4273,719,4259,4274],"therapeutic allogeneic lymphocytes","mycophenolate mofetil",{"nctId":444,"briefTitle":445,"status":169,"phases":4276,"primaryCompletion":447,"completion":447,"start":448,"enrollment":449,"conditions":4277,"interventions":4278},[89],[451,452,453,454,455,456,457],[459,348,460,461,462,463,464],{"trials":4280,"activeCount":100},[],{"trials":4282,"activeCount":100},[],{"trials":4284,"activeCount":100},[],{"intervention":114,"totalTrials":96,"cells":4286},{"EARLY_PHASE1":4287,"PHASE1":4289,"PHASE2":4291,"PHASE3":4306,"PHASE4":4308,"NA":4310},{"trials":4288,"activeCount":100},[],{"trials":4290,"activeCount":100},[],{"trials":4292,"activeCount":117,"soonestReadout":56},[4293,4297],{"nctId":54,"briefTitle":55,"status":106,"phases":4294,"primaryCompletion":56,"completion":108,"start":109,"enrollment":110,"conditions":4295,"interventions":4296},[89],[112],[57,114,115,95,116],{"nctId":4298,"briefTitle":4299,"status":207,"phases":4300,"primaryCompletion":4301,"completion":724,"start":4302,"enrollment":4038,"conditions":4303,"interventions":4304},"NCT00410813","S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone",[89],"2013-01","2007-03",[15,1157],[4305],"dasatinib",{"trials":4307,"activeCount":100},[],{"trials":4309,"activeCount":100},[],{"trials":4311,"activeCount":100},[],{"intervention":1652,"totalTrials":96,"cells":4313},{"EARLY_PHASE1":4314,"PHASE1":4316,"PHASE2":4318,"PHASE3":4333,"PHASE4":4335,"NA":4337},{"trials":4315,"activeCount":100},[],{"trials":4317,"activeCount":100},[],{"trials":4319,"activeCount":117,"soonestReadout":4328},[4320,4324],{"nctId":1643,"briefTitle":1644,"status":241,"phases":4321,"primaryCompletion":1646,"completion":1647,"start":1648,"enrollment":100,"conditions":4322,"interventions":4323},[89],[1650,175,176,214,215],[237,221,1652],{"nctId":4325,"briefTitle":4326,"status":106,"phases":4327,"primaryCompletion":4328,"completion":4328,"start":4329,"enrollment":4330,"conditions":4331,"interventions":4332},"NCT04268550","Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)",[89],"2026-12-01","2020-04-08",124,[175,176,214,215],[1652],{"trials":4334,"activeCount":100},[],{"trials":4336,"activeCount":100},[],{"trials":4338,"activeCount":100},[],{"intervention":178,"totalTrials":117,"cells":4340},{"EARLY_PHASE1":4341,"PHASE1":4343,"PHASE2":4345,"PHASE3":4351,"PHASE4":4353,"NA":4355},{"trials":4342,"activeCount":100},[],{"trials":4344,"activeCount":100},[],{"trials":4346,"activeCount":117,"soonestReadout":171},[4347],{"nctId":167,"briefTitle":168,"status":169,"phases":4348,"primaryCompletion":171,"completion":171,"start":172,"enrollment":173,"conditions":4349,"interventions":4350},[89],[175,176],[157,178],{"trials":4352,"activeCount":100},[],{"trials":4354,"activeCount":100},[],{"trials":4356,"activeCount":100},[],{"intervention":3895,"totalTrials":117,"cells":4358},{"EARLY_PHASE1":4359,"PHASE1":4361,"PHASE2":4363,"PHASE3":4369,"PHASE4":4371,"NA":4373},{"trials":4360,"activeCount":100},[],{"trials":4362,"activeCount":100},[],{"trials":4364,"activeCount":117,"soonestReadout":276},[4365],{"nctId":3883,"briefTitle":3884,"status":169,"phases":4366,"primaryCompletion":276,"completion":2105,"start":3886,"enrollment":3887,"conditions":4367,"interventions":4368},[89],[3889,3890,3891,3892,3893],[3895,1150,3896,3897,3898,3899],{"trials":4370,"activeCount":100},[],{"trials":4372,"activeCount":100},[],{"trials":4374,"activeCount":100},[],{"intervention":3897,"totalTrials":117,"cells":4376},{"EARLY_PHASE1":4377,"PHASE1":4379,"PHASE2":4381,"PHASE3":4387,"PHASE4":4389,"NA":4391},{"trials":4378,"activeCount":100},[],{"trials":4380,"activeCount":100},[],{"trials":4382,"activeCount":117,"soonestReadout":276},[4383],{"nctId":3883,"briefTitle":3884,"status":169,"phases":4384,"primaryCompletion":276,"completion":2105,"start":3886,"enrollment":3887,"conditions":4385,"interventions":4386},[89],[3889,3890,3891,3892,3893],[3895,1150,3896,3897,3898,3899],{"trials":4388,"activeCount":100},[],{"trials":4390,"activeCount":100},[],{"trials":4392,"activeCount":100},[],{"intervention":3898,"totalTrials":117,"cells":4394},{"EARLY_PHASE1":4395,"PHASE1":4397,"PHASE2":4399,"PHASE3":4405,"PHASE4":4407,"NA":4409},{"trials":4396,"activeCount":100},[],{"trials":4398,"activeCount":100},[],{"trials":4400,"activeCount":117,"soonestReadout":276},[4401],{"nctId":3883,"briefTitle":3884,"status":169,"phases":4402,"primaryCompletion":276,"completion":2105,"start":3886,"enrollment":3887,"conditions":4403,"interventions":4404},[89],[3889,3890,3891,3892,3893],[3895,1150,3896,3897,3898,3899],{"trials":4406,"activeCount":100},[],{"trials":4408,"activeCount":100},[],{"trials":4410,"activeCount":100},[],{"intervention":3899,"totalTrials":117,"cells":4412},{"EARLY_PHASE1":4413,"PHASE1":4415,"PHASE2":4417,"PHASE3":4423,"PHASE4":4425,"NA":4427},{"trials":4414,"activeCount":100},[],{"trials":4416,"activeCount":100},[],{"trials":4418,"activeCount":117,"soonestReadout":276},[4419],{"nctId":3883,"briefTitle":3884,"status":169,"phases":4420,"primaryCompletion":276,"completion":2105,"start":3886,"enrollment":3887,"conditions":4421,"interventions":4422},[89],[3889,3890,3891,3892,3893],[3895,1150,3896,3897,3898,3899],{"trials":4424,"activeCount":100},[],{"trials":4426,"activeCount":100},[],{"trials":4428,"activeCount":100},[],{"intervention":1812,"totalTrials":117,"cells":4430},{"EARLY_PHASE1":4431,"PHASE1":4433,"PHASE2":4435,"PHASE3":4441,"PHASE4":4443,"NA":4445},{"trials":4432,"activeCount":100},[],{"trials":4434,"activeCount":100},[],{"trials":4436,"activeCount":117,"soonestReadout":259},[4437],{"nctId":1799,"briefTitle":1800,"status":169,"phases":4438,"primaryCompletion":259,"completion":259,"start":1802,"enrollment":514,"conditions":4439,"interventions":4440},[89],[1804,1805,1806,1807,1808,1809,1810],[1812,1813,47,950],{"trials":4442,"activeCount":100},[],{"trials":4444,"activeCount":100},[],{"trials":4446,"activeCount":100},[],{"intervention":1813,"totalTrials":117,"cells":4448},{"EARLY_PHASE1":4449,"PHASE1":4451,"PHASE2":4453,"PHASE3":4459,"PHASE4":4461,"NA":4463},{"trials":4450,"activeCount":100},[],{"trials":4452,"activeCount":100},[],{"trials":4454,"activeCount":117,"soonestReadout":259},[4455],{"nctId":1799,"briefTitle":1800,"status":169,"phases":4456,"primaryCompletion":259,"completion":259,"start":1802,"enrollment":514,"conditions":4457,"interventions":4458},[89],[1804,1805,1806,1807,1808,1809,1810],[1812,1813,47,950],{"trials":4460,"activeCount":100},[],{"trials":4462,"activeCount":100},[],{"trials":4464,"activeCount":100},[],{"intervention":85,"totalTrials":117,"cells":4466},{"EARLY_PHASE1":4467,"PHASE1":4469,"PHASE2":4471,"PHASE3":4483,"PHASE4":4485,"NA":4487},{"trials":4468,"activeCount":100},[],{"trials":4470,"activeCount":100},[],{"trials":4472,"activeCount":117,"soonestReadout":80},[4473],{"nctId":83,"briefTitle":84,"status":169,"phases":4474,"primaryCompletion":80,"completion":4475,"start":4476,"enrollment":1342,"conditions":4477,"interventions":4482},[88,89],"2028-08-01","2021-02-08",[4478,4479,4480,4481],"Recurrent T Acute Lymphoblastic Leukemia","Refractory T Acute Lymphoblastic Leukemia","Refractory T Lymphoblastic Lymphoma","T Lymphoblastic Lymphoma",[85],{"trials":4484,"activeCount":100},[],{"trials":4486,"activeCount":100},[],{"trials":4488,"activeCount":100},[],{"intervention":4490,"totalTrials":117,"cells":4491},"Sotorasib",{"EARLY_PHASE1":4492,"PHASE1":4494,"PHASE2":4496,"PHASE3":4507,"PHASE4":4509,"NA":4511},{"trials":4493,"activeCount":100},[],{"trials":4495,"activeCount":100},[],{"trials":4497,"activeCount":117,"soonestReadout":1745},[4498],{"nctId":4499,"briefTitle":4500,"status":106,"phases":4501,"primaryCompletion":1745,"completion":275,"start":4502,"enrollment":1145,"conditions":4503,"interventions":4506},"NCT04625647","Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)",[89],"2021-04-16",[4504,1650,4505,176,214,215],"Lung Adenocarcinoma","Recurrent Lung Non-Squamous Non-Small Cell Carcinoma",[4490],{"trials":4508,"activeCount":100},[],{"trials":4510,"activeCount":100},[],{"trials":4512,"activeCount":100},[],{"intervention":3861,"totalTrials":117,"cells":4514},{"EARLY_PHASE1":4515,"PHASE1":4517,"PHASE2":4519,"PHASE3":4525,"PHASE4":4527,"NA":4529},{"trials":4516,"activeCount":100},[],{"trials":4518,"activeCount":100},[],{"trials":4520,"activeCount":117,"soonestReadout":3855},[4521],{"nctId":3852,"briefTitle":3853,"status":125,"phases":4522,"primaryCompletion":3855,"completion":3856,"start":3857,"enrollment":3858,"conditions":4523,"interventions":4524},[89],[175,176],[3861,3832],{"trials":4526,"activeCount":100},[],{"trials":4528,"activeCount":100},[],{"trials":4530,"activeCount":100},[],{"intervention":57,"totalTrials":117,"cells":4532},{"EARLY_PHASE1":4533,"PHASE1":4535,"PHASE2":4537,"PHASE3":4543,"PHASE4":4545,"NA":4547},{"trials":4534,"activeCount":100},[],{"trials":4536,"activeCount":100},[],{"trials":4538,"activeCount":117,"soonestReadout":56},[4539],{"nctId":54,"briefTitle":55,"status":106,"phases":4540,"primaryCompletion":56,"completion":108,"start":109,"enrollment":110,"conditions":4541,"interventions":4542},[89],[112],[57,114,115,95,116],{"trials":4544,"activeCount":100},[],{"trials":4546,"activeCount":100},[],{"trials":4548,"activeCount":100},[],{"intervention":115,"totalTrials":117,"cells":4550},{"EARLY_PHASE1":4551,"PHASE1":4553,"PHASE2":4555,"PHASE3":4561,"PHASE4":4563,"NA":4565},{"trials":4552,"activeCount":100},[],{"trials":4554,"activeCount":100},[],{"trials":4556,"activeCount":117,"soonestReadout":56},[4557],{"nctId":54,"briefTitle":55,"status":106,"phases":4558,"primaryCompletion":56,"completion":108,"start":109,"enrollment":110,"conditions":4559,"interventions":4560},[89],[112],[57,114,115,95,116],{"trials":4562,"activeCount":100},[],{"trials":4564,"activeCount":100},[],{"trials":4566,"activeCount":100},[],{"intervention":116,"totalTrials":117,"cells":4568},{"EARLY_PHASE1":4569,"PHASE1":4571,"PHASE2":4573,"PHASE3":4579,"PHASE4":4581,"NA":4583},{"trials":4570,"activeCount":100},[],{"trials":4572,"activeCount":100},[],{"trials":4574,"activeCount":117,"soonestReadout":56},[4575],{"nctId":54,"briefTitle":55,"status":106,"phases":4576,"primaryCompletion":56,"completion":108,"start":109,"enrollment":110,"conditions":4577,"interventions":4578},[89],[112],[57,114,115,95,116],{"trials":4580,"activeCount":100},[],{"trials":4582,"activeCount":100},[],{"trials":4584,"activeCount":100},[],{"intervention":4586,"totalTrials":117,"cells":4587},"Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase",{"EARLY_PHASE1":4588,"PHASE1":4590,"PHASE2":4592,"PHASE3":4606,"PHASE4":4608,"NA":4610},{"trials":4589,"activeCount":100},[],{"trials":4591,"activeCount":100},[],{"trials":4593,"activeCount":117,"soonestReadout":4599},[4594],{"nctId":4595,"briefTitle":4596,"status":4597,"phases":4598,"primaryCompletion":4599,"completion":4600,"start":4601,"enrollment":308,"conditions":4602,"interventions":4605},"NCT07062354","Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer","ENROLLING_BY_INVITATION",[89],"2028-10","2029-10","2026-03-25",[4603,4604],"Head &Amp; Neck Cancer","Head &Amp; Neck Squamous Cell Carcinoma",[4586],{"trials":4607,"activeCount":100},[],{"trials":4609,"activeCount":100},[],{"trials":4611,"activeCount":100},[],{"intervention":1754,"totalTrials":117,"cells":4613},{"EARLY_PHASE1":4614,"PHASE1":4616,"PHASE2":4618,"PHASE3":4624,"PHASE4":4626,"NA":4628},{"trials":4615,"activeCount":100},[],{"trials":4617,"activeCount":100},[],{"trials":4619,"activeCount":117,"soonestReadout":1745},[4620],{"nctId":1742,"briefTitle":1743,"status":169,"phases":4621,"primaryCompletion":1745,"completion":1746,"start":1747,"enrollment":1748,"conditions":4622,"interventions":4623},[89],[452,1750,1751,454,455,1752],[836,1754,1755,1756],{"trials":4625,"activeCount":100},[],{"trials":4627,"activeCount":100},[],{"trials":4629,"activeCount":100},[],{"intervention":1755,"totalTrials":117,"cells":4631},{"EARLY_PHASE1":4632,"PHASE1":4634,"PHASE2":4636,"PHASE3":4642,"PHASE4":4644,"NA":4646},{"trials":4633,"activeCount":100},[],{"trials":4635,"activeCount":100},[],{"trials":4637,"activeCount":117,"soonestReadout":1745},[4638],{"nctId":1742,"briefTitle":1743,"status":169,"phases":4639,"primaryCompletion":1745,"completion":1746,"start":1747,"enrollment":1748,"conditions":4640,"interventions":4641},[89],[452,1750,1751,454,455,1752],[836,1754,1755,1756],{"trials":4643,"activeCount":100},[],{"trials":4645,"activeCount":100},[],{"trials":4647,"activeCount":100},[],{"intervention":1756,"totalTrials":117,"cells":4649},{"EARLY_PHASE1":4650,"PHASE1":4652,"PHASE2":4654,"PHASE3":4660,"PHASE4":4662,"NA":4664},{"trials":4651,"activeCount":100},[],{"trials":4653,"activeCount":100},[],{"trials":4655,"activeCount":117,"soonestReadout":1745},[4656],{"nctId":1742,"briefTitle":1743,"status":169,"phases":4657,"primaryCompletion":1745,"completion":1746,"start":1747,"enrollment":1748,"conditions":4658,"interventions":4659},[89],[452,1750,1751,454,455,1752],[836,1754,1755,1756],{"trials":4661,"activeCount":100},[],{"trials":4663,"activeCount":100},[],{"trials":4665,"activeCount":100},[],{"intervention":459,"totalTrials":117,"cells":4667},{"EARLY_PHASE1":4668,"PHASE1":4670,"PHASE2":4672,"PHASE3":4678,"PHASE4":4680,"NA":4682},{"trials":4669,"activeCount":100},[],{"trials":4671,"activeCount":100},[],{"trials":4673,"activeCount":117,"soonestReadout":447},[4674],{"nctId":444,"briefTitle":445,"status":169,"phases":4675,"primaryCompletion":447,"completion":447,"start":448,"enrollment":449,"conditions":4676,"interventions":4677},[89],[451,452,453,454,455,456,457],[459,348,460,461,462,463,464],{"trials":4679,"activeCount":100},[],{"trials":4681,"activeCount":100},[],{"trials":4683,"activeCount":100},[],{"intervention":461,"totalTrials":117,"cells":4685},{"EARLY_PHASE1":4686,"PHASE1":4688,"PHASE2":4690,"PHASE3":4696,"PHASE4":4698,"NA":4700},{"trials":4687,"activeCount":100},[],{"trials":4689,"activeCount":100},[],{"trials":4691,"activeCount":117,"soonestReadout":447},[4692],{"nctId":444,"briefTitle":445,"status":169,"phases":4693,"primaryCompletion":447,"completion":447,"start":448,"enrollment":449,"conditions":4694,"interventions":4695},[89],[451,452,453,454,455,456,457],[459,348,460,461,462,463,464],{"trials":4697,"activeCount":100},[],{"trials":4699,"activeCount":100},[],{"trials":4701,"activeCount":100},[],{"intervention":462,"totalTrials":117,"cells":4703},{"EARLY_PHASE1":4704,"PHASE1":4706,"PHASE2":4708,"PHASE3":4714,"PHASE4":4716,"NA":4718},{"trials":4705,"activeCount":100},[],{"trials":4707,"activeCount":100},[],{"trials":4709,"activeCount":117,"soonestReadout":447},[4710],{"nctId":444,"briefTitle":445,"status":169,"phases":4711,"primaryCompletion":447,"completion":447,"start":448,"enrollment":449,"conditions":4712,"interventions":4713},[89],[451,452,453,454,455,456,457],[459,348,460,461,462,463,464],{"trials":4715,"activeCount":100},[],{"trials":4717,"activeCount":100},[],{"trials":4719,"activeCount":100},[],{"intervention":463,"totalTrials":117,"cells":4721},{"EARLY_PHASE1":4722,"PHASE1":4724,"PHASE2":4726,"PHASE3":4732,"PHASE4":4734,"NA":4736},{"trials":4723,"activeCount":100},[],{"trials":4725,"activeCount":100},[],{"trials":4727,"activeCount":117,"soonestReadout":447},[4728],{"nctId":444,"briefTitle":445,"status":169,"phases":4729,"primaryCompletion":447,"completion":447,"start":448,"enrollment":449,"conditions":4730,"interventions":4731},[89],[451,452,453,454,455,456,457],[459,348,460,461,462,463,464],{"trials":4733,"activeCount":100},[],{"trials":4735,"activeCount":100},[],{"trials":4737,"activeCount":100},[],{"intervention":464,"totalTrials":117,"cells":4739},{"EARLY_PHASE1":4740,"PHASE1":4742,"PHASE2":4744,"PHASE3":4750,"PHASE4":4752,"NA":4754},{"trials":4741,"activeCount":100},[],{"trials":4743,"activeCount":100},[],{"trials":4745,"activeCount":117,"soonestReadout":447},[4746],{"nctId":444,"briefTitle":445,"status":169,"phases":4747,"primaryCompletion":447,"completion":447,"start":448,"enrollment":449,"conditions":4748,"interventions":4749},[89],[451,452,453,454,455,456,457],[459,348,460,461,462,463,464],{"trials":4751,"activeCount":100},[],{"trials":4753,"activeCount":100},[],{"trials":4755,"activeCount":100},[],{"intervention":76,"totalTrials":117,"cells":4757},{"EARLY_PHASE1":4758,"PHASE1":4760,"PHASE2":4762,"PHASE3":4768,"PHASE4":4770,"NA":4772},{"trials":4759,"activeCount":100},[],{"trials":4761,"activeCount":100},[],{"trials":4763,"activeCount":117,"soonestReadout":75},[4764],{"nctId":73,"briefTitle":74,"status":169,"phases":4765,"primaryCompletion":75,"completion":198,"start":199,"enrollment":200,"conditions":4766,"interventions":4767},[89],[175,176],[76,203,157],{"trials":4769,"activeCount":100},[],{"trials":4771,"activeCount":100},[],{"trials":4773,"activeCount":100},[],{"intervention":203,"totalTrials":117,"cells":4775},{"EARLY_PHASE1":4776,"PHASE1":4778,"PHASE2":4780,"PHASE3":4786,"PHASE4":4788,"NA":4790},{"trials":4777,"activeCount":100},[],{"trials":4779,"activeCount":100},[],{"trials":4781,"activeCount":117,"soonestReadout":75},[4782],{"nctId":73,"briefTitle":74,"status":169,"phases":4783,"primaryCompletion":75,"completion":198,"start":199,"enrollment":200,"conditions":4784,"interventions":4785},[89],[175,176],[76,203,157],{"trials":4787,"activeCount":100},[],{"trials":4789,"activeCount":100},[],{"trials":4791,"activeCount":100},[],{"intervention":4793,"totalTrials":117,"cells":4794},"Amivantamab",{"EARLY_PHASE1":4795,"PHASE1":4797,"PHASE2":4799,"PHASE3":4808,"PHASE4":4810,"NA":4812},{"trials":4796,"activeCount":100},[],{"trials":4798,"activeCount":100},[],{"trials":4800,"activeCount":117,"soonestReadout":171},[4801],{"nctId":4802,"briefTitle":4803,"status":169,"phases":4804,"primaryCompletion":171,"completion":171,"start":4805,"enrollment":1349,"conditions":4806,"interventions":4807},"NCT06116682","Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)",[89],"2024-11-19",[1650],[4793],{"trials":4809,"activeCount":100},[],{"trials":4811,"activeCount":100},[],{"trials":4813,"activeCount":100},[],{"intervention":4815,"totalTrials":117,"cells":4816},"Induction Phase",{"EARLY_PHASE1":4817,"PHASE1":4819,"PHASE2":4821,"PHASE3":4836,"PHASE4":4838,"NA":4840},{"trials":4818,"activeCount":100},[],{"trials":4820,"activeCount":100},[],{"trials":4822,"activeCount":117,"soonestReadout":4827},[4823],{"nctId":4824,"briefTitle":4825,"status":4597,"phases":4826,"primaryCompletion":4827,"completion":3309,"start":4828,"enrollment":8,"conditions":4829,"interventions":4832},"NCT06773936","Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia",[89],"2029-05","2026-05-15",[4830,4831],"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","CD19+ Acute Leukemia",[4815,4833,4834,4835],"Re-Induction Phase","Post-Remission","Maintenance",{"trials":4837,"activeCount":100},[],{"trials":4839,"activeCount":100},[],{"trials":4841,"activeCount":100},[],{"intervention":4833,"totalTrials":117,"cells":4843},{"EARLY_PHASE1":4844,"PHASE1":4846,"PHASE2":4848,"PHASE3":4854,"PHASE4":4856,"NA":4858},{"trials":4845,"activeCount":100},[],{"trials":4847,"activeCount":100},[],{"trials":4849,"activeCount":117,"soonestReadout":4827},[4850],{"nctId":4824,"briefTitle":4825,"status":4597,"phases":4851,"primaryCompletion":4827,"completion":3309,"start":4828,"enrollment":8,"conditions":4852,"interventions":4853},[89],[4830,4831],[4815,4833,4834,4835],{"trials":4855,"activeCount":100},[],{"trials":4857,"activeCount":100},[],{"trials":4859,"activeCount":100},[],{"intervention":4834,"totalTrials":117,"cells":4861},{"EARLY_PHASE1":4862,"PHASE1":4864,"PHASE2":4866,"PHASE3":4872,"PHASE4":4874,"NA":4876},{"trials":4863,"activeCount":100},[],{"trials":4865,"activeCount":100},[],{"trials":4867,"activeCount":117,"soonestReadout":4827},[4868],{"nctId":4824,"briefTitle":4825,"status":4597,"phases":4869,"primaryCompletion":4827,"completion":3309,"start":4828,"enrollment":8,"conditions":4870,"interventions":4871},[89],[4830,4831],[4815,4833,4834,4835],{"trials":4873,"activeCount":100},[],{"trials":4875,"activeCount":100},[],{"trials":4877,"activeCount":100},[],{"intervention":4835,"totalTrials":117,"cells":4879},{"EARLY_PHASE1":4880,"PHASE1":4882,"PHASE2":4884,"PHASE3":4890,"PHASE4":4892,"NA":4894},{"trials":4881,"activeCount":100},[],{"trials":4883,"activeCount":100},[],{"trials":4885,"activeCount":117,"soonestReadout":4827},[4886],{"nctId":4824,"briefTitle":4825,"status":4597,"phases":4887,"primaryCompletion":4827,"completion":3309,"start":4828,"enrollment":8,"conditions":4888,"interventions":4889},[89],[4830,4831],[4815,4833,4834,4835],{"trials":4891,"activeCount":100},[],{"trials":4893,"activeCount":100},[],{"trials":4895,"activeCount":100},[],{"intervention":1150,"totalTrials":762,"cells":4897},{"EARLY_PHASE1":4898,"PHASE1":4900,"PHASE2":4902,"PHASE3":4917,"PHASE4":4923,"NA":4925},{"trials":4899,"activeCount":100},[],{"trials":4901,"activeCount":100},[],{"trials":4903,"activeCount":117,"soonestReadout":276},[4904,4908],{"nctId":3883,"briefTitle":3884,"status":169,"phases":4905,"primaryCompletion":276,"completion":2105,"start":3886,"enrollment":3887,"conditions":4906,"interventions":4907},[89],[3889,3890,3891,3892,3893],[3895,1150,3896,3897,3898,3899],{"nctId":4909,"briefTitle":4910,"status":207,"phases":4911,"primaryCompletion":4912,"completion":4913,"start":4914,"enrollment":1342,"conditions":4915,"interventions":4916},"NCT03373760","Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer",[89],"2020-05-18","2022-03-29","2017-11-30",[1147,1148],[1150,1247],{"trials":4918,"activeCount":100},[4919],{"nctId":1139,"briefTitle":1140,"status":207,"phases":4920,"primaryCompletion":1142,"completion":1143,"start":1144,"enrollment":1145,"conditions":4921,"interventions":4922},[89,90],[1147,1148],[217,1150],{"trials":4924,"activeCount":100},[],{"trials":4926,"activeCount":100},[4927],{"nctId":1234,"briefTitle":1235,"status":207,"phases":4928,"primaryCompletion":1237,"completion":1238,"start":1239,"enrollment":1240,"conditions":4929,"interventions":4930},[],[1147,1148],[217,1150,1243,1180,47,950,1228,1244,1245,1246,1247],{"intervention":506,"totalTrials":4214,"cells":4932},{"EARLY_PHASE1":4933,"PHASE1":4935,"PHASE2":4941,"PHASE3":5032,"PHASE4":5072,"NA":5074},{"trials":4934,"activeCount":100},[],{"trials":4936,"activeCount":100},[4937],{"nctId":3875,"briefTitle":3876,"status":207,"phases":4938,"primaryCompletion":1010,"completion":1010,"start":1725,"enrollment":22,"conditions":4939,"interventions":4940},[88],[21],[506,399,1408],{"trials":4942,"activeCount":100},[4943,4947,4951,4958,4962,4969,4973,4977,4981,4985,4989,4993,4997,5001,5008,5012,5016,5020,5024,5028],{"nctId":1258,"briefTitle":1259,"status":207,"phases":4944,"primaryCompletion":1261,"completion":1261,"start":1262,"enrollment":472,"conditions":4945,"interventions":4946},[89],[1032,1033,1264],[506,1266,611],{"nctId":1000,"briefTitle":1001,"status":207,"phases":4948,"primaryCompletion":325,"start":1003,"conditions":4949,"interventions":4950},[89],[33],[506,961,601],{"nctId":4952,"briefTitle":4953,"status":207,"phases":4954,"primaryCompletion":4955,"completion":4955,"start":1011,"enrollment":4038,"conditions":4956,"interventions":4957},"NCT00792701","S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer",[89],"2016-04",[21],[506,1336],{"nctId":4024,"briefTitle":4025,"status":662,"phases":4959,"primaryCompletion":982,"completion":369,"start":702,"enrollment":1597,"conditions":4960,"interventions":4961},[89],[1112],[977,506,1116],{"nctId":4963,"briefTitle":4964,"status":662,"phases":4965,"primaryCompletion":4175,"completion":408,"start":4213,"enrollment":34,"conditions":4966,"interventions":4967},"NCT00017173","S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat",[89],[33],[4968,506],"Ad5CMV-p53 gene",{"nctId":1329,"briefTitle":1330,"status":207,"phases":4970,"primaryCompletion":1332,"completion":1332,"start":1333,"enrollment":843,"conditions":4971,"interventions":4972},[89],[1315,1317],[668,506,1336,611],{"nctId":1037,"briefTitle":1038,"status":207,"phases":4974,"primaryCompletion":1040,"completion":1040,"start":1041,"enrollment":345,"conditions":4975,"interventions":4976},[89],[21],[506,961,399],{"nctId":3925,"briefTitle":3926,"status":662,"phases":4978,"primaryCompletion":3928,"completion":3928,"start":531,"enrollment":158,"conditions":4979,"interventions":4980},[89],[21],[3931,3932,506,399],{"nctId":498,"briefTitle":499,"status":241,"phases":4982,"primaryCompletion":501,"start":502,"enrollment":100,"conditions":4983,"interventions":4984},[89],[18],[331,475,505,506,294,332,333,349,399,363,364],{"nctId":1045,"briefTitle":1046,"status":662,"phases":4986,"primaryCompletion":1048,"completion":1048,"start":655,"enrollment":1049,"conditions":4987,"interventions":4988},[89],[21],[506,961],{"nctId":1057,"briefTitle":1058,"status":241,"phases":4990,"primaryCompletion":995,"completion":995,"start":1060,"enrollment":100,"conditions":4991,"interventions":4992},[89],[33],[506,961],{"nctId":3938,"briefTitle":3939,"status":207,"phases":4994,"primaryCompletion":1078,"completion":1010,"start":3941,"enrollment":1145,"conditions":4995,"interventions":4996},[89],[21],[506,399],{"nctId":2042,"briefTitle":2043,"status":662,"phases":4998,"primaryCompletion":2045,"completion":1048,"start":2046,"enrollment":472,"conditions":4999,"interventions":5000},[89],[33],[2049,506,601],{"nctId":5002,"briefTitle":5003,"status":207,"phases":5004,"primaryCompletion":628,"completion":1010,"start":5005,"enrollment":173,"conditions":5006,"interventions":5007},"NCT00003369","S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer",[89],"1998-08",[1418],[506,1408],{"nctId":1075,"briefTitle":1076,"status":207,"phases":5009,"primaryCompletion":1078,"completion":995,"start":595,"enrollment":1079,"conditions":5010,"interventions":5011},[89],[21],[668,506,961,1082,611,1073],{"nctId":2156,"briefTitle":2157,"status":207,"phases":5013,"primaryCompletion":2159,"completion":492,"start":2160,"enrollment":19,"conditions":5014,"interventions":5015},[89],[18],[506,399,1082,2163],{"nctId":569,"briefTitle":570,"status":241,"phases":5017,"primaryCompletion":408,"completion":408,"start":408,"enrollment":100,"conditions":5018,"interventions":5019},[89],[36,374],[475,506,294,333,349,399,574,363,364,575,576],{"nctId":2165,"briefTitle":2166,"status":207,"phases":5021,"primaryCompletion":2168,"completion":51,"start":2169,"enrollment":2170,"conditions":5022,"interventions":5023},[89],[1315],[218,2173,2174,2175,649,2176],{"nctId":2068,"briefTitle":2069,"status":241,"phases":5025,"enrollment":100,"conditions":5026,"interventions":5027},[89],[33],[506,601],{"nctId":1388,"briefTitle":1389,"status":207,"phases":5029,"primaryCompletion":1391,"completion":1391,"start":1392,"enrollment":1393,"conditions":5030,"interventions":5031},[89],[33],[506,601,611],{"trials":5033,"activeCount":100},[5034,5044,5048,5052,5056,5060,5064,5068],{"nctId":5035,"briefTitle":5036,"status":207,"phases":5037,"primaryCompletion":5038,"completion":5038,"start":862,"enrollment":5039,"conditions":5040,"interventions":5041},"NCT00006237","S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma",[90],"2012-07",432,[4242],[5042,330,5043,506,440,706],"interleukin-2","interferon alfa",{"nctId":1121,"briefTitle":1122,"status":662,"phases":5045,"primaryCompletion":1124,"completion":1124,"start":1125,"enrollment":1126,"conditions":5046,"interventions":5047},[90],[33],[506,961,1129],{"nctId":3963,"briefTitle":3964,"status":207,"phases":5049,"primaryCompletion":511,"completion":2887,"start":1333,"enrollment":3966,"conditions":5050,"interventions":5051},[90],[21],[506,399,1116],{"nctId":1414,"briefTitle":1415,"status":241,"phases":5053,"primaryCompletion":1041,"completion":1041,"start":1003,"enrollment":100,"conditions":5054,"interventions":5055},[90],[1418],[506,1336,611],{"nctId":3068,"briefTitle":3069,"status":207,"phases":5057,"primaryCompletion":3071,"completion":3072,"start":3073,"enrollment":3074,"conditions":5058,"interventions":5059},[90],[3076,3077,3078,3079,3080,3081,3082,3083,3084,3085,3086,3087,3088,3089,3090,3091,3092],[2173,219,2116],{"nctId":660,"briefTitle":661,"status":662,"phases":5061,"primaryCompletion":344,"completion":344,"start":664,"enrollment":665,"conditions":5062,"interventions":5063},[90],[15],[330,668,505,506,294,349,611,623,669],{"nctId":1961,"briefTitle":1962,"status":662,"phases":5065,"primaryCompletion":1964,"completion":1965,"start":1966,"enrollment":1967,"conditions":5066,"interventions":5067},[90],[1315],[506,349,336,706],{"nctId":743,"briefTitle":744,"status":662,"phases":5069,"primaryCompletion":407,"completion":325,"start":493,"enrollment":746,"conditions":5070,"interventions":5071},[90],[36],[330,506,294,333,399,364],{"trials":5073,"activeCount":100},[],{"trials":5075,"activeCount":100},[],{"intervention":330,"totalTrials":746,"cells":5077},{"EARLY_PHASE1":5078,"PHASE1":5080,"PHASE2":5082,"PHASE3":5150,"PHASE4":5172,"NA":5174},{"trials":5079,"activeCount":100},[],{"trials":5081,"activeCount":100},[],{"trials":5083,"activeCount":100},[5084,5088,5096,5100,5104,5111,5115,5119,5123,5127,5131,5138,5142,5146],{"nctId":322,"briefTitle":323,"status":207,"phases":5085,"primaryCompletion":325,"completion":326,"start":327,"enrollment":173,"conditions":5086,"interventions":5087},[89],[18],[330,331,294,332,333,334,335,336,337],{"nctId":5089,"briefTitle":5090,"status":207,"phases":5091,"primaryCompletion":4037,"completion":5092,"start":1010,"enrollment":5093,"conditions":5094,"interventions":5095},"NCT00066794","S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia",[89],"2010-01",69,[24],[330,362,719,332,398],{"nctId":353,"briefTitle":354,"status":207,"phases":5097,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":5098,"interventions":5099},[89],[36],[330,362,294,333,363,317,364],{"nctId":366,"briefTitle":367,"status":207,"phases":5101,"primaryCompletion":369,"completion":370,"start":371,"enrollment":372,"conditions":5102,"interventions":5103},[89],[36,374],[330,294,333,363,364],{"nctId":5105,"briefTitle":5106,"status":207,"phases":5107,"primaryCompletion":1445,"completion":4159,"start":5108,"enrollment":494,"conditions":5109,"interventions":5110},"NCT00023777","S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia",[89],"2001-08",[24],[330,362,332,398],{"nctId":428,"briefTitle":429,"status":207,"phases":5112,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":5113,"interventions":5114},[89],[18,436],[414,330,438,439,294,440,349,399,317,441,442,316],{"nctId":1346,"briefTitle":1347,"status":207,"phases":5116,"primaryCompletion":711,"completion":1011,"start":1210,"enrollment":1349,"conditions":5117,"interventions":5118},[89],[21],[330,668,611,1352],{"nctId":1064,"briefTitle":1065,"status":207,"phases":5120,"primaryCompletion":1067,"completion":1068,"start":327,"enrollment":1069,"conditions":5121,"interventions":5122},[89],[15],[330,1072,961,1073],{"nctId":559,"briefTitle":560,"status":207,"phases":5124,"primaryCompletion":407,"completion":408,"start":562,"enrollment":563,"conditions":5125,"interventions":5126},[89],[18],[414,330,294,332,349,399,400,336,317,566,316,567],{"nctId":2165,"briefTitle":2166,"status":207,"phases":5128,"primaryCompletion":2168,"completion":51,"start":2169,"enrollment":2170,"conditions":5129,"interventions":5130},[89],[1315],[218,2173,2174,2175,649,2176],{"nctId":5132,"briefTitle":5133,"status":207,"phases":5134,"primaryCompletion":738,"completion":712,"start":713,"enrollment":8,"conditions":5135,"interventions":5136},"NCT00004217","S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia",[89],[24],[330,362,332,398,5137],"valspodar",{"nctId":1092,"briefTitle":1093,"status":207,"phases":5139,"primaryCompletion":1095,"completion":828,"start":738,"enrollment":1096,"conditions":5140,"interventions":5141},[89],[15],[330,961,1073],{"nctId":578,"briefTitle":579,"status":207,"phases":5143,"primaryCompletion":342,"completion":552,"start":581,"enrollment":582,"conditions":5144,"interventions":5145},[89],[24],[330,294,332,585,333,334,335,401,336,586,587,317,402,337,588,589],{"nctId":859,"briefTitle":860,"status":207,"phases":5147,"primaryCompletion":862,"completion":371,"start":863,"enrollment":158,"conditions":5148,"interventions":5149},[89],[18],[330,415,333,363],{"trials":5151,"activeCount":100},[5152,5156,5160,5164,5168],{"nctId":5035,"briefTitle":5036,"status":207,"phases":5153,"primaryCompletion":5038,"completion":5038,"start":862,"enrollment":5039,"conditions":5154,"interventions":5155},[90],[4242],[5042,330,5043,506,440,706],{"nctId":660,"briefTitle":661,"status":662,"phases":5157,"primaryCompletion":344,"completion":344,"start":664,"enrollment":665,"conditions":5158,"interventions":5159},[90],[15],[330,668,505,506,294,349,611,623,669],{"nctId":1722,"briefTitle":1723,"status":662,"phases":5161,"primaryCompletion":1333,"completion":629,"start":1725,"enrollment":843,"conditions":5162,"interventions":5163},[90],[18],[330,331,668,399,1728],{"nctId":733,"briefTitle":734,"status":207,"phases":5165,"primaryCompletion":736,"completion":737,"start":738,"enrollment":739,"conditions":5166,"interventions":5167},[90],[15],[330,294,334,611],{"nctId":743,"briefTitle":744,"status":662,"phases":5169,"primaryCompletion":407,"completion":325,"start":493,"enrollment":746,"conditions":5170,"interventions":5171},[90],[36],[330,506,294,333,399,364],{"trials":5173,"activeCount":100},[],{"trials":5175,"activeCount":100},[],{"intervention":1336,"totalTrials":1983,"cells":5177},{"EARLY_PHASE1":5178,"PHASE1":5180,"PHASE2":5182,"PHASE3":5243,"PHASE4":5268,"NA":5270},{"trials":5179,"activeCount":100},[],{"trials":5181,"activeCount":100},[],{"trials":5183,"activeCount":100},[5184,5188,5192,5196,5200,5208,5212,5216,5220,5224,5228,5235,5239],{"nctId":2005,"briefTitle":2006,"status":207,"phases":5185,"primaryCompletion":2008,"completion":2009,"start":2010,"enrollment":359,"conditions":5186,"interventions":5187},[89],[2012,2013],[81,219,192,2015,2016],{"nctId":4156,"briefTitle":4157,"status":207,"phases":5189,"primaryCompletion":4159,"completion":408,"start":2212,"enrollment":1323,"conditions":5190,"interventions":5191},[89],[4161,4162],[517,1336],{"nctId":4952,"briefTitle":4953,"status":207,"phases":5193,"primaryCompletion":4955,"completion":4955,"start":1011,"enrollment":4038,"conditions":5194,"interventions":5195},[89],[21],[506,1336],{"nctId":4017,"briefTitle":4018,"status":207,"phases":5197,"primaryCompletion":973,"completion":973,"start":4020,"enrollment":1709,"conditions":5198,"interventions":5199},[89],[1112,1113],[1336,1116],{"nctId":5201,"briefTitle":5202,"status":207,"phases":5203,"primaryCompletion":422,"completion":5204,"start":629,"enrollment":5205,"conditions":5206,"interventions":5207},"NCT00234039","S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin",[89],"2013-04",58,[1315],[1336],{"nctId":1329,"briefTitle":1330,"status":207,"phases":5209,"primaryCompletion":1332,"completion":1332,"start":1333,"enrollment":843,"conditions":5210,"interventions":5211},[89],[1315,1317],[668,506,1336,611],{"nctId":4172,"briefTitle":4173,"status":207,"phases":5213,"primaryCompletion":4175,"completion":1011,"start":2737,"enrollment":1171,"conditions":5214,"interventions":5215},[89],[2839],[517,1336],{"nctId":4192,"briefTitle":4193,"status":207,"phases":5217,"primaryCompletion":1965,"completion":553,"start":1382,"enrollment":4195,"conditions":5218,"interventions":5219},[89],[4161,4162],[517,1336],{"nctId":205,"briefTitle":206,"status":207,"phases":5221,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":5222,"interventions":5223},[89],[175,176,214,215],[217,218,219,220,221,222,157],{"nctId":1654,"briefTitle":1655,"status":662,"phases":5225,"primaryCompletion":1657,"completion":1658,"start":1659,"enrollment":1126,"conditions":5226,"interventions":5227},[89],[1661,1662,1663],[1665,219,237],{"nctId":5229,"briefTitle":5230,"status":207,"phases":5231,"primaryCompletion":1087,"completion":1124,"start":5232,"enrollment":1323,"conditions":5233,"interventions":5234},"NCT00003723","S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery",[89],"1999-02",[2826],[1336],{"nctId":1362,"briefTitle":1363,"status":662,"phases":5236,"primaryCompletion":841,"completion":408,"start":1365,"enrollment":1366,"conditions":5237,"interventions":5238},[89],[1315,1316,1317],[1336,611],{"nctId":4034,"briefTitle":4035,"status":207,"phases":5240,"primaryCompletion":4037,"completion":1011,"start":2033,"enrollment":4038,"conditions":5241,"interventions":5242},[89],[21],[1336,1116],{"trials":5244,"activeCount":100},[5245,5252,5256,5260],{"nctId":5246,"briefTitle":5247,"status":207,"phases":5248,"primaryCompletion":4175,"completion":543,"start":371,"enrollment":5249,"conditions":5250,"interventions":5251},"NCT00075686","S0205 Gemcitabine w\u002F or w\u002Fo Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer",[90],766,[2037],[977,1336],{"nctId":1414,"briefTitle":1415,"status":241,"phases":5253,"primaryCompletion":1041,"completion":1041,"start":1003,"enrollment":100,"conditions":5254,"interventions":5255},[90],[1418],[506,1336,611],{"nctId":3068,"briefTitle":3069,"status":207,"phases":5257,"primaryCompletion":3071,"completion":3072,"start":3073,"enrollment":3074,"conditions":5258,"interventions":5259},[90],[3076,3077,3078,3079,3080,3081,3082,3083,3084,3085,3086,3087,3088,3089,3090,3091,3092],[2173,219,2116],{"nctId":5261,"briefTitle":5262,"status":207,"phases":5263,"primaryCompletion":1219,"completion":1219,"start":5264,"enrollment":5265,"conditions":5266,"interventions":5267},"NCT00445601","S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer",[90],"2007-09",406,[1315],[1336],{"trials":5269,"activeCount":100},[],{"trials":5271,"activeCount":100},[],{"intervention":316,"totalTrials":31,"cells":5273},{"EARLY_PHASE1":5274,"PHASE1":5276,"PHASE2":5282,"PHASE3":5328,"PHASE4":5338,"NA":5340},{"trials":5275,"activeCount":100},[],{"trials":5277,"activeCount":100},[5278],{"nctId":302,"briefTitle":303,"status":207,"phases":5279,"primaryCompletion":305,"completion":306,"start":307,"enrollment":308,"conditions":5280,"interventions":5281},[88],[310,311,312,313,314],[294,316,317,318],{"trials":5283,"activeCount":100},[5284,5288,5292,5296,5300,5304,5308,5312,5316,5320,5324],{"nctId":339,"briefTitle":340,"status":207,"phases":5285,"primaryCompletion":342,"completion":343,"start":344,"enrollment":345,"conditions":5286,"interventions":5287},[89],[18],[331,348,349,317,316,350,351],{"nctId":377,"briefTitle":378,"status":207,"phases":5289,"primaryCompletion":380,"completion":381,"start":382,"enrollment":383,"conditions":5290,"interventions":5291},[89],[18],[331,294,349,317,316],{"nctId":387,"briefTitle":388,"status":207,"phases":5293,"primaryCompletion":390,"completion":391,"start":392,"enrollment":308,"conditions":5294,"interventions":5295},[89],[24,394,395],[397,294,332,398,333,349,399,400,401,336,317,402,316],{"nctId":404,"briefTitle":405,"status":207,"phases":5297,"primaryCompletion":407,"completion":408,"start":409,"enrollment":410,"conditions":5298,"interventions":5299},[89],[18,412],[414,415,294,332,349,399,336,317,316],{"nctId":417,"briefTitle":418,"status":207,"phases":5301,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":5302,"interventions":5303},[89],[18],[331,426,294,332,333,349,400,336,316],{"nctId":428,"briefTitle":429,"status":207,"phases":5305,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":5306,"interventions":5307},[89],[18,436],[414,330,438,439,294,440,349,399,317,441,442,316],{"nctId":466,"briefTitle":467,"status":207,"phases":5309,"primaryCompletion":469,"completion":470,"start":471,"enrollment":472,"conditions":5310,"interventions":5311},[89],[18],[331,475,294,349,317,316],{"nctId":488,"briefTitle":489,"status":207,"phases":5313,"primaryCompletion":491,"completion":492,"start":493,"enrollment":494,"conditions":5314,"interventions":5315},[89],[18],[331,294,349,317,316],{"nctId":519,"briefTitle":520,"status":207,"phases":5317,"primaryCompletion":522,"completion":480,"start":523,"enrollment":524,"conditions":5318,"interventions":5319},[89],[18],[331,294,349,317,316],{"nctId":528,"briefTitle":529,"status":207,"phases":5321,"primaryCompletion":531,"start":532,"enrollment":533,"conditions":5322,"interventions":5323},[89],[18],[536,294,349,317,316],{"nctId":559,"briefTitle":560,"status":207,"phases":5325,"primaryCompletion":407,"completion":408,"start":562,"enrollment":563,"conditions":5326,"interventions":5327},[89],[18],[414,330,294,332,349,399,400,336,317,566,316,567],{"trials":5329,"activeCount":100},[5330,5334],{"nctId":625,"briefTitle":626,"status":207,"phases":5331,"primaryCompletion":628,"completion":629,"start":630,"enrollment":631,"conditions":5332,"interventions":5333},[90],[36],[415,505,294,333,349,363,317,316],{"nctId":671,"briefTitle":672,"status":207,"phases":5335,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":5336,"interventions":5337},[90],[18],[331,536,505,294,349,399,317,316],{"trials":5339,"activeCount":100},[],{"trials":5341,"activeCount":100},[],{"intervention":336,"totalTrials":34,"cells":5343},{"EARLY_PHASE1":5344,"PHASE1":5346,"PHASE2":5348,"PHASE3":5398,"PHASE4":5417,"NA":5419},{"trials":5345,"activeCount":100},[],{"trials":5347,"activeCount":100},[],{"trials":5349,"activeCount":100},[5350,5354,5358,5362,5366,5370,5374,5378,5390,5394],{"nctId":322,"briefTitle":323,"status":207,"phases":5351,"primaryCompletion":325,"completion":326,"start":327,"enrollment":173,"conditions":5352,"interventions":5353},[89],[18],[330,331,294,332,333,334,335,336,337],{"nctId":387,"briefTitle":388,"status":207,"phases":5355,"primaryCompletion":390,"completion":391,"start":392,"enrollment":308,"conditions":5356,"interventions":5357},[89],[24,394,395],[397,294,332,398,333,349,399,400,401,336,317,402,316],{"nctId":404,"briefTitle":405,"status":207,"phases":5359,"primaryCompletion":407,"completion":408,"start":409,"enrollment":410,"conditions":5360,"interventions":5361},[89],[18,412],[414,415,294,332,349,399,336,317,316],{"nctId":417,"briefTitle":418,"status":207,"phases":5363,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":5364,"interventions":5365},[89],[18],[331,426,294,332,333,349,400,336,316],{"nctId":2572,"briefTitle":2573,"status":662,"phases":5367,"primaryCompletion":1067,"completion":1312,"start":1060,"enrollment":117,"conditions":5368,"interventions":5369},[89],[18],[2577,363,336,2578],{"nctId":559,"briefTitle":560,"status":207,"phases":5371,"primaryCompletion":407,"completion":408,"start":562,"enrollment":563,"conditions":5372,"interventions":5373},[89],[18],[414,330,294,332,349,399,400,336,317,566,316,567],{"nctId":2165,"briefTitle":2166,"status":207,"phases":5375,"primaryCompletion":2168,"completion":51,"start":2169,"enrollment":2170,"conditions":5376,"interventions":5377},[89],[1315],[218,2173,2174,2175,649,2176],{"nctId":5379,"briefTitle":5380,"status":207,"phases":5381,"primaryCompletion":5382,"completion":5383,"start":5384,"enrollment":1393,"conditions":5385,"interventions":5386},"NCT00551460","S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia",[89],"2017-06-01","2018-02-05","2007-11-15",[24],[5387,5388,401,336,5389],"arsenic trioxide","gemtuzumab ozogamicin","tretinoin",{"nctId":578,"briefTitle":579,"status":207,"phases":5391,"primaryCompletion":342,"completion":552,"start":581,"enrollment":582,"conditions":5392,"interventions":5393},[89],[24],[330,294,332,585,333,334,335,401,336,586,587,317,402,337,588,589],{"nctId":591,"briefTitle":592,"status":207,"phases":5395,"primaryCompletion":594,"completion":531,"start":595,"enrollment":596,"conditions":5396,"interventions":5397},[89],[598],[600,294,601,336],{"trials":5399,"activeCount":100},[5400,5409,5413],{"nctId":5401,"briefTitle":5402,"status":207,"phases":5403,"primaryCompletion":5404,"completion":5405,"start":5406,"enrollment":4195,"conditions":5407,"interventions":5408},"NCT00492856","S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia",[90],"2013-12-01","2016-05-04","2007-06-01",[24],[401,336,5389],{"nctId":1961,"briefTitle":1962,"status":662,"phases":5410,"primaryCompletion":1964,"completion":1965,"start":1966,"enrollment":1967,"conditions":5411,"interventions":5412},[90],[1315],[506,349,336,706],{"nctId":708,"briefTitle":709,"status":207,"phases":5414,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":5415,"interventions":5416},[90],[24,716],[718,294,719,336],{"trials":5418,"activeCount":100},[],{"trials":5420,"activeCount":100},[],{"intervention":977,"totalTrials":4066,"cells":5422},{"EARLY_PHASE1":5423,"PHASE1":5425,"PHASE2":5431,"PHASE3":5460,"PHASE4":5483,"NA":5485},{"trials":5424,"activeCount":100},[],{"trials":5426,"activeCount":100},[5427],{"nctId":969,"briefTitle":970,"status":662,"phases":5428,"primaryCompletion":972,"completion":972,"start":973,"enrollment":974,"conditions":5429,"interventions":5430},[88],[21],[977,961],{"trials":5432,"activeCount":100},[5433,5437,5441,5448,5452,5456],{"nctId":2690,"briefTitle":2691,"status":207,"phases":5434,"primaryCompletion":2693,"completion":2694,"start":2695,"enrollment":714,"conditions":5435,"interventions":5436},[89],[2697,2698,2699,2700,2701,2702,2703,2704,2705,2706,2707,2708,2709,2710,2711,2712,2713,2714,2715],[1436,192,2717,2718],{"nctId":4024,"briefTitle":4025,"status":662,"phases":5438,"primaryCompletion":982,"completion":369,"start":702,"enrollment":1597,"conditions":5439,"interventions":5440},[89],[1112],[977,506,1116],{"nctId":5442,"briefTitle":5443,"status":207,"phases":5444,"primaryCompletion":1067,"completion":5092,"start":1021,"enrollment":5445,"conditions":5446,"interventions":5447},"NCT00096031","S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer",[89],63,[1112],[977],{"nctId":4179,"briefTitle":4180,"status":207,"phases":5449,"primaryCompletion":4182,"completion":1107,"start":4183,"enrollment":4184,"conditions":5450,"interventions":5451},[89],[30],[977,517,1117],{"nctId":1370,"briefTitle":1371,"status":207,"phases":5453,"primaryCompletion":1373,"completion":408,"start":1010,"enrollment":1374,"conditions":5454,"interventions":5455},[89],[21],[977,668,611],{"nctId":4046,"briefTitle":4047,"status":207,"phases":5457,"primaryCompletion":4049,"completion":4050,"start":552,"enrollment":4051,"conditions":5458,"interventions":5459},[89],[30],[977,1116,4054],{"trials":5461,"activeCount":100},[5462,5475,5479],{"nctId":5463,"briefTitle":5464,"status":207,"phases":5465,"primaryCompletion":5466,"completion":5467,"start":5468,"enrollment":5469,"conditions":5470,"interventions":5473},"NCT02438722","S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",[89,90],"2018-09-25","2026-04-17","2015-05-07",174,[5471,5472],"Recurrent Non-Small Cell Lung Carcinoma","Stage IV Non-Small Cell Lung Cancer",[5474,1436],"Afatinib Dimaleate",{"nctId":5246,"briefTitle":5247,"status":207,"phases":5476,"primaryCompletion":4175,"completion":543,"start":371,"enrollment":5249,"conditions":5477,"interventions":5478},[90],[2037],[977,1336],{"nctId":1421,"briefTitle":1422,"status":662,"phases":5480,"primaryCompletion":1424,"completion":1425,"start":1426,"enrollment":1427,"conditions":5481,"interventions":5482},[90],[1429,1430,1147,1431,1432,1433],[1435,237,1436,195],{"trials":5484,"activeCount":100},[],{"trials":5486,"activeCount":100},[],{"intervention":364,"totalTrials":2131,"cells":5488},{"EARLY_PHASE1":5489,"PHASE1":5491,"PHASE2":5493,"PHASE3":5525,"PHASE4":5531,"NA":5533},{"trials":5490,"activeCount":100},[],{"trials":5492,"activeCount":100},[],{"trials":5494,"activeCount":100},[5495,5499,5503,5509,5513,5517,5521],{"nctId":353,"briefTitle":354,"status":207,"phases":5496,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":5497,"interventions":5498},[89],[36],[330,362,294,333,363,317,364],{"nctId":366,"briefTitle":367,"status":207,"phases":5500,"primaryCompletion":369,"completion":370,"start":371,"enrollment":372,"conditions":5501,"interventions":5502},[89],[36,374],[330,294,333,363,364],{"nctId":5504,"briefTitle":5505,"status":207,"phases":5506,"completion":973,"start":1012,"conditions":5507,"interventions":5508},"NCT00026520","Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma",[89],[4242],[415,364],{"nctId":4237,"briefTitle":4238,"status":207,"phases":5510,"primaryCompletion":2211,"completion":512,"start":1391,"enrollment":4240,"conditions":5511,"interventions":5512},[89],[4242],[4224,364],{"nctId":498,"briefTitle":499,"status":241,"phases":5514,"primaryCompletion":501,"start":502,"enrollment":100,"conditions":5515,"interventions":5516},[89],[18],[331,475,505,506,294,332,333,349,399,363,364],{"nctId":838,"briefTitle":839,"status":662,"phases":5518,"primaryCompletion":841,"completion":842,"start":513,"enrollment":843,"conditions":5519,"interventions":5520},[89],[36],[475,333,364],{"nctId":569,"briefTitle":570,"status":241,"phases":5522,"primaryCompletion":408,"completion":408,"start":408,"enrollment":100,"conditions":5523,"interventions":5524},[89],[36,374],[475,506,294,333,349,399,574,363,364,575,576],{"trials":5526,"activeCount":100},[5527],{"nctId":743,"briefTitle":744,"status":662,"phases":5528,"primaryCompletion":407,"completion":325,"start":493,"enrollment":746,"conditions":5529,"interventions":5530},[90],[36],[330,506,294,333,399,364],{"trials":5532,"activeCount":100},[],{"trials":5534,"activeCount":100},[],{"intervention":505,"totalTrials":843,"cells":5536},{"EARLY_PHASE1":5537,"PHASE1":5539,"PHASE2":5541,"PHASE3":5551,"PHASE4":5578,"NA":5580},{"trials":5538,"activeCount":100},[],{"trials":5540,"activeCount":100},[],{"trials":5542,"activeCount":100},[5543,5547],{"nctId":498,"briefTitle":499,"status":241,"phases":5544,"primaryCompletion":501,"start":502,"enrollment":100,"conditions":5545,"interventions":5546},[89],[18],[331,475,505,506,294,332,333,349,399,363,364],{"nctId":549,"briefTitle":550,"status":207,"phases":5548,"primaryCompletion":552,"completion":553,"start":554,"enrollment":555,"conditions":5549,"interventions":5550},[89],[18],[505,294,399,363],{"trials":5552,"activeCount":100},[5553,5557,5566,5570,5574],{"nctId":625,"briefTitle":626,"status":207,"phases":5554,"primaryCompletion":628,"completion":629,"start":630,"enrollment":631,"conditions":5555,"interventions":5556},[90],[36],[415,505,294,333,349,363,317,316],{"nctId":5558,"briefTitle":5559,"status":207,"phases":5560,"primaryCompletion":4168,"completion":828,"start":594,"enrollment":5561,"conditions":5562,"interventions":5564},"NCT00017147","S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma",[90],183,[5563],"Malignant Neoplasms of Eye, Brain and Other Parts of Central Nervous System",[505,5565],"O6-Benzylguanine",{"nctId":660,"briefTitle":661,"status":662,"phases":5567,"primaryCompletion":344,"completion":344,"start":664,"enrollment":665,"conditions":5568,"interventions":5569},[90],[15],[330,668,505,506,294,349,611,623,669],{"nctId":671,"briefTitle":672,"status":207,"phases":5571,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":5572,"interventions":5573},[90],[18],[331,536,505,294,349,399,317,316],{"nctId":699,"briefTitle":700,"status":662,"phases":5575,"primaryCompletion":702,"completion":702,"start":493,"enrollment":703,"conditions":5576,"interventions":5577},[90],[18],[414,505,294,440,349,399,706],{"trials":5579,"activeCount":100},[],{"trials":5581,"activeCount":100},[],{"intervention":706,"totalTrials":910,"cells":5583},{"EARLY_PHASE1":5584,"PHASE1":5586,"PHASE2":5588,"PHASE3":5594,"PHASE4":5612,"NA":5614},{"trials":5585,"activeCount":100},[],{"trials":5587,"activeCount":100},[],{"trials":5589,"activeCount":100},[5590],{"nctId":2165,"briefTitle":2166,"status":207,"phases":5591,"primaryCompletion":2168,"completion":51,"start":2169,"enrollment":2170,"conditions":5592,"interventions":5593},[89],[1315],[218,2173,2174,2175,649,2176],{"trials":5595,"activeCount":100},[5596,5600,5604,5608],{"nctId":5035,"briefTitle":5036,"status":207,"phases":5597,"primaryCompletion":5038,"completion":5038,"start":862,"enrollment":5039,"conditions":5598,"interventions":5599},[90],[4242],[5042,330,5043,506,440,706],{"nctId":1945,"briefTitle":1946,"status":207,"phases":5601,"primaryCompletion":1392,"completion":492,"start":1948,"enrollment":1949,"conditions":5602,"interventions":5603},[90],[18],[349,706],{"nctId":1961,"briefTitle":1962,"status":662,"phases":5605,"primaryCompletion":1964,"completion":1965,"start":1966,"enrollment":1967,"conditions":5606,"interventions":5607},[90],[1315],[506,349,336,706],{"nctId":699,"briefTitle":700,"status":662,"phases":5609,"primaryCompletion":702,"completion":702,"start":493,"enrollment":703,"conditions":5610,"interventions":5611},[90],[18],[414,505,294,440,349,399,706],{"trials":5613,"activeCount":100},[],{"trials":5615,"activeCount":100},[],{"intervention":415,"totalTrials":910,"cells":5617},{"EARLY_PHASE1":5618,"PHASE1":5620,"PHASE2":5622,"PHASE3":5640,"PHASE4":5646,"NA":5648},{"trials":5619,"activeCount":100},[],{"trials":5621,"activeCount":100},[],{"trials":5623,"activeCount":100},[5624,5628,5632,5636],{"nctId":404,"briefTitle":405,"status":207,"phases":5625,"primaryCompletion":407,"completion":408,"start":409,"enrollment":410,"conditions":5626,"interventions":5627},[89],[18,412],[414,415,294,332,349,399,336,317,316],{"nctId":805,"briefTitle":806,"status":207,"phases":5629,"primaryCompletion":808,"completion":809,"start":810,"enrollment":811,"conditions":5630,"interventions":5631},[89],[36],[415,333],{"nctId":5504,"briefTitle":5505,"status":207,"phases":5633,"completion":973,"start":1012,"conditions":5634,"interventions":5635},[89],[4242],[415,364],{"nctId":859,"briefTitle":860,"status":207,"phases":5637,"primaryCompletion":862,"completion":371,"start":863,"enrollment":158,"conditions":5638,"interventions":5639},[89],[18],[330,415,333,363],{"trials":5641,"activeCount":100},[5642],{"nctId":625,"briefTitle":626,"status":207,"phases":5643,"primaryCompletion":628,"completion":629,"start":630,"enrollment":631,"conditions":5644,"interventions":5645},[90],[36],[415,505,294,333,349,363,317,316],{"trials":5647,"activeCount":100},[],{"trials":5649,"activeCount":100},[],{"intervention":485,"totalTrials":910,"cells":5651},{"EARLY_PHASE1":5652,"PHASE1":5654,"PHASE2":5656,"PHASE3":5683,"PHASE4":5689,"NA":5691},{"trials":5653,"activeCount":100},[],{"trials":5655,"activeCount":100},[],{"trials":5657,"activeCount":100},[5658,5666,5675,5679],{"nctId":5659,"briefTitle":5660,"status":207,"phases":5661,"primaryCompletion":5662,"completion":724,"start":2211,"enrollment":5663,"conditions":5664,"interventions":5665},"NCT00445848","S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer",[89],"2013-08",89,[21],[485,1386],{"nctId":5667,"briefTitle":5668,"status":207,"phases":5669,"primaryCompletion":5670,"completion":5671,"start":2211,"enrollment":5672,"conditions":5673,"interventions":5674},"NCT00436332","S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma",[89],"2019-07-20","2019-08-20",84,[21],[485,1386],{"nctId":477,"briefTitle":478,"status":207,"phases":5676,"primaryCompletion":357,"completion":480,"start":481,"enrollment":482,"conditions":5677,"interventions":5678},[89],[15],[485,42,294,349,486],{"nctId":4203,"briefTitle":4204,"status":241,"phases":5680,"primaryCompletion":4206,"completion":4206,"start":629,"enrollment":100,"conditions":5681,"interventions":5682},[89],[30,1157],[485,517,1117],{"trials":5684,"activeCount":100},[5685],{"nctId":1421,"briefTitle":1422,"status":662,"phases":5686,"primaryCompletion":1424,"completion":1425,"start":1426,"enrollment":1427,"conditions":5687,"interventions":5688},[90],[1429,1430,1147,1431,1432,1433],[1435,237,1436,195],{"trials":5690,"activeCount":100},[],{"trials":5692,"activeCount":100},[],{"intervention":719,"totalTrials":762,"cells":5694},{"EARLY_PHASE1":5695,"PHASE1":5697,"PHASE2":5699,"PHASE3":5717,"PHASE4":5723,"NA":5725},{"trials":5696,"activeCount":100},[],{"trials":5698,"activeCount":100},[],{"trials":5700,"activeCount":100},[5701,5705,5709],{"nctId":5089,"briefTitle":5090,"status":207,"phases":5702,"primaryCompletion":4037,"completion":5092,"start":1010,"enrollment":5093,"conditions":5703,"interventions":5704},[89],[24],[330,362,719,332,398],{"nctId":4268,"briefTitle":4269,"status":662,"phases":5706,"primaryCompletion":1391,"completion":1332,"start":1003,"enrollment":910,"conditions":5707,"interventions":5708},[89],[24],[4273,719,4259,4274],{"nctId":5710,"briefTitle":5711,"status":207,"phases":5712,"primaryCompletion":1041,"completion":995,"start":5108,"enrollment":5713,"conditions":5714,"interventions":5715},"NCT00016419","S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome",[89],130,[24,716],[5716,719],"anti-thymocyte globulin",{"trials":5718,"activeCount":100},[5719],{"nctId":708,"briefTitle":709,"status":207,"phases":5720,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":5721,"interventions":5722},[90],[24,716],[718,294,719,336],{"trials":5724,"activeCount":100},[],{"trials":5726,"activeCount":100},[],{"intervention":401,"totalTrials":762,"cells":5728},{"EARLY_PHASE1":5729,"PHASE1":5731,"PHASE2":5733,"PHASE3":5747,"PHASE4":5753,"NA":5755},{"trials":5730,"activeCount":100},[],{"trials":5732,"activeCount":100},[],{"trials":5734,"activeCount":100},[5735,5739,5743],{"nctId":387,"briefTitle":388,"status":207,"phases":5736,"primaryCompletion":390,"completion":391,"start":392,"enrollment":308,"conditions":5737,"interventions":5738},[89],[24,394,395],[397,294,332,398,333,349,399,400,401,336,317,402,316],{"nctId":5379,"briefTitle":5380,"status":207,"phases":5740,"primaryCompletion":5382,"completion":5383,"start":5384,"enrollment":1393,"conditions":5741,"interventions":5742},[89],[24],[5387,5388,401,336,5389],{"nctId":578,"briefTitle":579,"status":207,"phases":5744,"primaryCompletion":342,"completion":552,"start":581,"enrollment":582,"conditions":5745,"interventions":5746},[89],[24],[330,294,332,585,333,334,335,401,336,586,587,317,402,337,588,589],{"trials":5748,"activeCount":100},[5749],{"nctId":5401,"briefTitle":5402,"status":207,"phases":5750,"primaryCompletion":5404,"completion":5405,"start":5406,"enrollment":4195,"conditions":5751,"interventions":5752},[90],[24],[401,336,5389],{"trials":5754,"activeCount":100},[],{"trials":5756,"activeCount":100},[],{"intervention":414,"totalTrials":762,"cells":5758},{"EARLY_PHASE1":5759,"PHASE1":5761,"PHASE2":5763,"PHASE3":5777,"PHASE4":5783,"NA":5785},{"trials":5760,"activeCount":100},[],{"trials":5762,"activeCount":100},[],{"trials":5764,"activeCount":100},[5765,5769,5773],{"nctId":404,"briefTitle":405,"status":207,"phases":5766,"primaryCompletion":407,"completion":408,"start":409,"enrollment":410,"conditions":5767,"interventions":5768},[89],[18,412],[414,415,294,332,349,399,336,317,316],{"nctId":428,"briefTitle":429,"status":207,"phases":5770,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":5771,"interventions":5772},[89],[18,436],[414,330,438,439,294,440,349,399,317,441,442,316],{"nctId":559,"briefTitle":560,"status":207,"phases":5774,"primaryCompletion":407,"completion":408,"start":562,"enrollment":563,"conditions":5775,"interventions":5776},[89],[18],[414,330,294,332,349,399,400,336,317,566,316,567],{"trials":5778,"activeCount":100},[5779],{"nctId":699,"briefTitle":700,"status":662,"phases":5780,"primaryCompletion":702,"completion":702,"start":493,"enrollment":703,"conditions":5781,"interventions":5782},[90],[18],[414,505,294,440,349,399,706],{"trials":5784,"activeCount":100},[],{"trials":5786,"activeCount":100},[],{"intervention":440,"totalTrials":252,"cells":5788},{"EARLY_PHASE1":5789,"PHASE1":5791,"PHASE2":5793,"PHASE3":5799,"PHASE4":5809,"NA":5811},{"trials":5790,"activeCount":100},[],{"trials":5792,"activeCount":100},[],{"trials":5794,"activeCount":100},[5795],{"nctId":428,"briefTitle":429,"status":207,"phases":5796,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":5797,"interventions":5798},[89],[18,436],[414,330,438,439,294,440,349,399,317,441,442,316],{"trials":5800,"activeCount":100},[5801,5805],{"nctId":5035,"briefTitle":5036,"status":207,"phases":5802,"primaryCompletion":5038,"completion":5038,"start":862,"enrollment":5039,"conditions":5803,"interventions":5804},[90],[4242],[5042,330,5043,506,440,706],{"nctId":699,"briefTitle":700,"status":662,"phases":5806,"primaryCompletion":702,"completion":702,"start":493,"enrollment":703,"conditions":5807,"interventions":5808},[90],[18],[414,505,294,440,349,399,706],{"trials":5810,"activeCount":100},[],{"trials":5812,"activeCount":100},[],{"intervention":1408,"totalTrials":252,"cells":5814},{"EARLY_PHASE1":5815,"PHASE1":5817,"PHASE2":5823,"PHASE3":5829,"PHASE4":5835,"NA":5837},{"trials":5816,"activeCount":100},[],{"trials":5818,"activeCount":100},[5819],{"nctId":3875,"briefTitle":3876,"status":207,"phases":5820,"primaryCompletion":1010,"completion":1010,"start":1725,"enrollment":22,"conditions":5821,"interventions":5822},[88],[21],[506,399,1408],{"trials":5824,"activeCount":100},[5825],{"nctId":5002,"briefTitle":5003,"status":207,"phases":5826,"primaryCompletion":628,"completion":1010,"start":5005,"enrollment":173,"conditions":5827,"interventions":5828},[89],[1418],[506,1408],{"trials":5830,"activeCount":100},[5831],{"nctId":1403,"briefTitle":1404,"status":207,"phases":5832,"completion":973,"start":1392,"conditions":5833,"interventions":5834},[90],[21],[668,611,1408],{"trials":5836,"activeCount":100},[],{"trials":5838,"activeCount":100},[],{"intervention":5388,"totalTrials":252,"cells":5840},{"EARLY_PHASE1":5841,"PHASE1":5843,"PHASE2":5845,"PHASE3":5858,"PHASE4":5870,"NA":5872},{"trials":5842,"activeCount":100},[],{"trials":5844,"activeCount":100},[],{"trials":5846,"activeCount":100},[5847,5854],{"nctId":5848,"briefTitle":5849,"status":207,"phases":5850,"primaryCompletion":1125,"completion":5851,"start":1003,"enrollment":1049,"conditions":5852,"interventions":5853},"NCT00049179","S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia",[89],"2010-10",[24],[332,5388],{"nctId":5379,"briefTitle":5380,"status":207,"phases":5855,"primaryCompletion":5382,"completion":5383,"start":5384,"enrollment":1393,"conditions":5856,"interventions":5857},[89],[24],[5387,5388,401,336,5389],{"trials":5859,"activeCount":100},[5860],{"nctId":5861,"briefTitle":5862,"status":207,"phases":5863,"primaryCompletion":616,"completion":5864,"start":1010,"enrollment":5865,"conditions":5866,"interventions":5867},"NCT00085709","S0106 Cytarabine and Daunorubicin w\u002F or w\u002Fo Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML",[90],"2014-08",637,[24],[5388,5868,5869],"Cytosine arabinoside","Daunomycin",{"trials":5871,"activeCount":100},[],{"trials":5873,"activeCount":100},[],{"intervention":5875,"totalTrials":252,"cells":5876},"Vitamin E",{"EARLY_PHASE1":5877,"PHASE1":5879,"PHASE2":5881,"PHASE3":5883,"PHASE4":5920,"NA":5922},{"trials":5878,"activeCount":100},[],{"trials":5880,"activeCount":100},[],{"trials":5882,"activeCount":100},[],{"trials":5884,"activeCount":100},[5885,5897,5911],{"nctId":5886,"briefTitle":5887,"status":207,"phases":5888,"primaryCompletion":357,"completion":5889,"start":841,"enrollment":5890,"conditions":5891,"interventions":5893},"NCT00706121","S0000D: Effect of Vitamin E and\u002For Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000",[90],"2018-01",8094,[30,5892],"Precancerous Condition",[5875,5894,5895,5896],"Selenium","Vitamin E placebo","selenium placebo",{"nctId":5898,"briefTitle":5899,"status":207,"phases":5900,"primaryCompletion":5901,"completion":5902,"start":1010,"enrollment":5903,"conditions":5904,"interventions":5907},"NCT00784225","S0000B: Vitamin E and\u002For Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT SWOG-S0000",[90],"2017-11","2018-05",13475,[5905,5906],"Cataract","Macular Degeneration",[5908,5909,5910,5896],"selenium","vitamin E","vitamin E placebo",{"nctId":5912,"briefTitle":5913,"status":207,"phases":5914,"primaryCompletion":5915,"completion":5916,"start":1365,"enrollment":5917,"conditions":5918,"interventions":5919},"NCT00006392","S0000 Selenium and Vitamin E in Preventing Prostate Cancer",[90],"2011-05","2012-09",35533,[27],[5875,5894],{"trials":5921,"activeCount":100},[],{"trials":5923,"activeCount":100},[],{"intervention":5894,"totalTrials":252,"cells":5925},{"EARLY_PHASE1":5926,"PHASE1":5928,"PHASE2":5930,"PHASE3":5932,"PHASE4":5946,"NA":5948},{"trials":5927,"activeCount":100},[],{"trials":5929,"activeCount":100},[],{"trials":5931,"activeCount":100},[],{"trials":5933,"activeCount":100},[5934,5938,5942],{"nctId":5886,"briefTitle":5887,"status":207,"phases":5935,"primaryCompletion":357,"completion":5889,"start":841,"enrollment":5890,"conditions":5936,"interventions":5937},[90],[30,5892],[5875,5894,5895,5896],{"nctId":5898,"briefTitle":5899,"status":207,"phases":5939,"primaryCompletion":5901,"completion":5902,"start":1010,"enrollment":5903,"conditions":5940,"interventions":5941},[90],[5905,5906],[5908,5909,5910,5896],{"nctId":5912,"briefTitle":5913,"status":207,"phases":5943,"primaryCompletion":5915,"completion":5916,"start":1365,"enrollment":5917,"conditions":5944,"interventions":5945},[90],[27],[5875,5894],{"trials":5947,"activeCount":100},[],{"trials":5949,"activeCount":100},[],{"intervention":1016,"totalTrials":96,"cells":5951},{"EARLY_PHASE1":5952,"PHASE1":5954,"PHASE2":5956,"PHASE3":5962,"PHASE4":5968,"NA":5970},{"trials":5953,"activeCount":100},[],{"trials":5955,"activeCount":100},[],{"trials":5957,"activeCount":100},[5958],{"nctId":1007,"briefTitle":1008,"status":207,"phases":5959,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":1013,"conditions":5960,"interventions":5961},[89],[21],[961,1016],{"trials":5963,"activeCount":100},[5964],{"nctId":2734,"briefTitle":2735,"status":207,"phases":5965,"completion":973,"start":2737,"conditions":5966,"interventions":5967},[90],[15],[1072,1016],{"trials":5969,"activeCount":100},[],{"trials":5971,"activeCount":100},[],{"intervention":1129,"totalTrials":96,"cells":5973},{"EARLY_PHASE1":5974,"PHASE1":5976,"PHASE2":5978,"PHASE3":5984,"PHASE4":5990,"NA":5992},{"trials":5975,"activeCount":100},[],{"trials":5977,"activeCount":100},[],{"trials":5979,"activeCount":100},[5980],{"nctId":2262,"briefTitle":2263,"status":207,"phases":5981,"primaryCompletion":2265,"completion":2266,"start":2267,"enrollment":2268,"conditions":5982,"interventions":5983},[88,89],[2110],[2271,2015,193,191,1129],{"trials":5985,"activeCount":100},[5986],{"nctId":1121,"briefTitle":1122,"status":662,"phases":5987,"primaryCompletion":1124,"completion":1124,"start":1125,"enrollment":1126,"conditions":5988,"interventions":5989},[90],[33],[506,961,1129],{"trials":5991,"activeCount":100},[],{"trials":5993,"activeCount":100},[],{"intervention":2100,"totalTrials":96,"cells":5995},{"EARLY_PHASE1":5996,"PHASE1":5998,"PHASE2":6000,"PHASE3":6002,"PHASE4":6012,"NA":6014},{"trials":5997,"activeCount":100},[],{"trials":5999,"activeCount":100},[],{"trials":6001,"activeCount":100},[],{"trials":6003,"activeCount":100},[6004,6008],{"nctId":2092,"briefTitle":2093,"status":207,"phases":6005,"primaryCompletion":2095,"completion":1048,"start":2096,"enrollment":2097,"conditions":6006,"interventions":6007},[90],[30],[601,400,2100],{"nctId":2119,"briefTitle":2120,"status":207,"phases":6009,"primaryCompletion":471,"completion":356,"start":2122,"enrollment":2123,"conditions":6010,"interventions":6011},[90],[30],[601,400,2100],{"trials":6013,"activeCount":100},[],{"trials":6015,"activeCount":100},[],{"intervention":5389,"totalTrials":96,"cells":6017},{"EARLY_PHASE1":6018,"PHASE1":6020,"PHASE2":6022,"PHASE3":6028,"PHASE4":6034,"NA":6036},{"trials":6019,"activeCount":100},[],{"trials":6021,"activeCount":100},[],{"trials":6023,"activeCount":100},[6024],{"nctId":5379,"briefTitle":5380,"status":207,"phases":6025,"primaryCompletion":5382,"completion":5383,"start":5384,"enrollment":1393,"conditions":6026,"interventions":6027},[89],[24],[5387,5388,401,336,5389],{"trials":6029,"activeCount":100},[6030],{"nctId":5401,"briefTitle":5402,"status":207,"phases":6031,"primaryCompletion":5404,"completion":5405,"start":5406,"enrollment":4195,"conditions":6032,"interventions":6033},[90],[24],[401,336,5389],{"trials":6035,"activeCount":100},[],{"trials":6037,"activeCount":100},[],{"intervention":1214,"totalTrials":96,"cells":6039},{"EARLY_PHASE1":6040,"PHASE1":6042,"PHASE2":6044,"PHASE3":6050,"PHASE4":6056,"NA":6058},{"trials":6041,"activeCount":100},[],{"trials":6043,"activeCount":100},[],{"trials":6045,"activeCount":100},[6046],{"nctId":1280,"briefTitle":1281,"status":207,"phases":6047,"primaryCompletion":842,"completion":408,"start":390,"enrollment":16,"conditions":6048,"interventions":6049},[89],[27],[1285,1214,399,1286,1287,1288,1289,611],{"trials":6051,"activeCount":100},[6052],{"nctId":1206,"briefTitle":1207,"status":207,"phases":6053,"primaryCompletion":1209,"completion":995,"start":1210,"enrollment":1211,"conditions":6054,"interventions":6055},[90],[27],[961,1214,586,317],{"trials":6057,"activeCount":100},[],{"trials":6059,"activeCount":100},[],{"intervention":1287,"totalTrials":96,"cells":6061},{"EARLY_PHASE1":6062,"PHASE1":6064,"PHASE2":6066,"PHASE3":6072,"PHASE4":6078,"NA":6080},{"trials":6063,"activeCount":100},[],{"trials":6065,"activeCount":100},[],{"trials":6067,"activeCount":100},[6068],{"nctId":1280,"briefTitle":1281,"status":207,"phases":6069,"primaryCompletion":842,"completion":408,"start":390,"enrollment":16,"conditions":6070,"interventions":6071},[89],[27],[1285,1214,399,1286,1287,1288,1289,611],{"trials":6073,"activeCount":100},[6074],{"nctId":1546,"briefTitle":1547,"status":207,"phases":6075,"primaryCompletion":1549,"completion":1550,"start":1551,"enrollment":1552,"conditions":6076,"interventions":6077},[90],[27],[1285,1287,1555,317],{"trials":6079,"activeCount":100},[],{"trials":6081,"activeCount":100},[],{"intervention":5895,"totalTrials":96,"cells":6083},{"EARLY_PHASE1":6084,"PHASE1":6086,"PHASE2":6088,"PHASE3":6090,"PHASE4":6100,"NA":6102},{"trials":6085,"activeCount":100},[],{"trials":6087,"activeCount":100},[],{"trials":6089,"activeCount":100},[],{"trials":6091,"activeCount":100},[6092,6096],{"nctId":5886,"briefTitle":5887,"status":207,"phases":6093,"primaryCompletion":357,"completion":5889,"start":841,"enrollment":5890,"conditions":6094,"interventions":6095},[90],[30,5892],[5875,5894,5895,5896],{"nctId":5898,"briefTitle":5899,"status":207,"phases":6097,"primaryCompletion":5901,"completion":5902,"start":1010,"enrollment":5903,"conditions":6098,"interventions":6099},[90],[5905,5906],[5908,5909,5910,5896],{"trials":6101,"activeCount":100},[],{"trials":6103,"activeCount":100},[],{"intervention":5896,"totalTrials":96,"cells":6105},{"EARLY_PHASE1":6106,"PHASE1":6108,"PHASE2":6110,"PHASE3":6112,"PHASE4":6122,"NA":6124},{"trials":6107,"activeCount":100},[],{"trials":6109,"activeCount":100},[],{"trials":6111,"activeCount":100},[],{"trials":6113,"activeCount":100},[6114,6118],{"nctId":5886,"briefTitle":5887,"status":207,"phases":6115,"primaryCompletion":357,"completion":5889,"start":841,"enrollment":5890,"conditions":6116,"interventions":6117},[90],[30,5892],[5875,5894,5895,5896],{"nctId":5898,"briefTitle":5899,"status":207,"phases":6119,"primaryCompletion":5901,"completion":5902,"start":1010,"enrollment":5903,"conditions":6120,"interventions":6121},[90],[5905,5906],[5908,5909,5910,5896],{"trials":6123,"activeCount":100},[],{"trials":6125,"activeCount":100},[],{"intervention":536,"totalTrials":96,"cells":6127},{"EARLY_PHASE1":6128,"PHASE1":6130,"PHASE2":6132,"PHASE3":6138,"PHASE4":6144,"NA":6146},{"trials":6129,"activeCount":100},[],{"trials":6131,"activeCount":100},[],{"trials":6133,"activeCount":100},[6134],{"nctId":528,"briefTitle":529,"status":207,"phases":6135,"primaryCompletion":531,"start":532,"enrollment":533,"conditions":6136,"interventions":6137},[89],[18],[536,294,349,317,316],{"trials":6139,"activeCount":100},[6140],{"nctId":671,"briefTitle":672,"status":207,"phases":6141,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":6142,"interventions":6143},[90],[18],[331,536,505,294,349,399,317,316],{"trials":6145,"activeCount":100},[],{"trials":6147,"activeCount":100},[],{"intervention":2956,"totalTrials":96,"cells":6149},{"EARLY_PHASE1":6150,"PHASE1":6152,"PHASE2":6154,"PHASE3":6156,"PHASE4":6166,"NA":6168},{"trials":6151,"activeCount":100},[],{"trials":6153,"activeCount":100},[],{"trials":6155,"activeCount":100},[],{"trials":6157,"activeCount":100},[6158,6162],{"nctId":2949,"briefTitle":2950,"status":207,"phases":6159,"primaryCompletion":469,"completion":2952,"start":2045,"enrollment":2953,"conditions":6160,"interventions":6161},[90],[15],[52,2956],{"nctId":2846,"briefTitle":2847,"status":662,"phases":6163,"primaryCompletion":2849,"completion":2849,"start":1029,"enrollment":2850,"conditions":6164,"interventions":6165},[90],[15],[2853,2854,2855],{"trials":6167,"activeCount":100},[],{"trials":6169,"activeCount":100},[],{"intervention":1728,"totalTrials":96,"cells":6171},{"EARLY_PHASE1":6172,"PHASE1":6174,"PHASE2":6176,"PHASE3":6191,"PHASE4":6197,"NA":6199},{"trials":6173,"activeCount":100},[],{"trials":6175,"activeCount":100},[],{"trials":6177,"activeCount":100},[6178],{"nctId":6179,"briefTitle":6180,"status":662,"phases":6181,"primaryCompletion":371,"completion":371,"start":6182,"enrollment":843,"conditions":6183,"interventions":6190},"NCT00003292","S9624 Ifosfamide in Treating Patients With Meningeal Tumors",[89],"1998-07",[6184,6185,6186,6187,6188,6189],"Chondrosarcoma","Adult Fibrosarcoma","Adult Leiomyosarcoma","Adult Rhabdomyosarcoma","Adult Malignant Meningioma","Adult Brain Malignant Hemangiopericytoma",[1728],{"trials":6192,"activeCount":100},[6193],{"nctId":1722,"briefTitle":1723,"status":662,"phases":6194,"primaryCompletion":1333,"completion":629,"start":1725,"enrollment":843,"conditions":6195,"interventions":6196},[90],[18],[330,331,668,399,1728],{"trials":6198,"activeCount":100},[],{"trials":6200,"activeCount":100},[],{"intervention":586,"totalTrials":96,"cells":6202},{"EARLY_PHASE1":6203,"PHASE1":6205,"PHASE2":6207,"PHASE3":6213,"PHASE4":6219,"NA":6221},{"trials":6204,"activeCount":100},[],{"trials":6206,"activeCount":100},[],{"trials":6208,"activeCount":100},[6209],{"nctId":578,"briefTitle":579,"status":207,"phases":6210,"primaryCompletion":342,"completion":552,"start":581,"enrollment":582,"conditions":6211,"interventions":6212},[89],[24],[330,294,332,585,333,334,335,401,336,586,587,317,402,337,588,589],{"trials":6214,"activeCount":100},[6215],{"nctId":1206,"briefTitle":1207,"status":207,"phases":6216,"primaryCompletion":1209,"completion":995,"start":1210,"enrollment":1211,"conditions":6217,"interventions":6218},[90],[27],[961,1214,586,317],{"trials":6220,"activeCount":100},[],{"trials":6222,"activeCount":100},[],{"intervention":6224,"totalTrials":117,"cells":6225},"l-glutamine placebo",{"EARLY_PHASE1":6226,"PHASE1":6228,"PHASE2":6230,"PHASE3":6232,"PHASE4":6242,"NA":6244},{"trials":6227,"activeCount":100},[],{"trials":6229,"activeCount":100},[],{"trials":6231,"activeCount":100},[],{"trials":6233,"activeCount":100},[6234],{"nctId":6235,"briefTitle":6236,"status":662,"phases":6237,"primaryCompletion":581,"completion":973,"start":1012,"enrollment":1866,"conditions":6238,"interventions":6241},"NCT00006994","S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat",[90],[6239,33,6240],"Cancer-related Problem\u002FCondition","Pain",[6224],{"trials":6243,"activeCount":100},[],{"trials":6245,"activeCount":100},[],{"intervention":5042,"totalTrials":117,"cells":6247},{"EARLY_PHASE1":6248,"PHASE1":6250,"PHASE2":6252,"PHASE3":6254,"PHASE4":6260,"NA":6262},{"trials":6249,"activeCount":100},[],{"trials":6251,"activeCount":100},[],{"trials":6253,"activeCount":100},[],{"trials":6255,"activeCount":100},[6256],{"nctId":5035,"briefTitle":5036,"status":207,"phases":6257,"primaryCompletion":5038,"completion":5038,"start":862,"enrollment":5039,"conditions":6258,"interventions":6259},[90],[4242],[5042,330,5043,506,440,706],{"trials":6261,"activeCount":100},[],{"trials":6263,"activeCount":100},[],{"intervention":5043,"totalTrials":117,"cells":6265},{"EARLY_PHASE1":6266,"PHASE1":6268,"PHASE2":6270,"PHASE3":6272,"PHASE4":6278,"NA":6280},{"trials":6267,"activeCount":100},[],{"trials":6269,"activeCount":100},[],{"trials":6271,"activeCount":100},[],{"trials":6273,"activeCount":100},[6274],{"nctId":5035,"briefTitle":5036,"status":207,"phases":6275,"primaryCompletion":5038,"completion":5038,"start":862,"enrollment":5039,"conditions":6276,"interventions":6277},[90],[4242],[5042,330,5043,506,440,706],{"trials":6279,"activeCount":100},[],{"trials":6281,"activeCount":100},[],{"intervention":6283,"totalTrials":117,"cells":6284},"duloxetine hydrochloride",{"EARLY_PHASE1":6285,"PHASE1":6287,"PHASE2":6289,"PHASE3":6291,"PHASE4":6304,"NA":6306},{"trials":6286,"activeCount":100},[],{"trials":6288,"activeCount":100},[],{"trials":6290,"activeCount":100},[],{"trials":6292,"activeCount":100},[6293],{"nctId":6294,"briefTitle":6295,"status":207,"phases":6296,"primaryCompletion":6297,"completion":6298,"start":6299,"enrollment":6300,"conditions":6301,"interventions":6303},"NCT01598298","S1202: Duloxetine Hydrochloride for Muscle\u002FJoint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy",[90],"2016-12-01","2018-12-20","2013-05-15",299,[15,6302,6240],"Musculoskeletal Complications",[6283],{"trials":6305,"activeCount":100},[],{"trials":6307,"activeCount":100},[],{"intervention":5474,"totalTrials":117,"cells":6309},{"EARLY_PHASE1":6310,"PHASE1":6312,"PHASE2":6314,"PHASE3":6316,"PHASE4":6322,"NA":6324},{"trials":6311,"activeCount":100},[],{"trials":6313,"activeCount":100},[],{"trials":6315,"activeCount":100},[],{"trials":6317,"activeCount":100},[6318],{"nctId":5463,"briefTitle":5464,"status":207,"phases":6319,"primaryCompletion":5466,"completion":5467,"start":5468,"enrollment":5469,"conditions":6320,"interventions":6321},[89,90],[5471,5472],[5474,1436],{"trials":6323,"activeCount":100},[],{"trials":6325,"activeCount":100},[],{"intervention":621,"totalTrials":117,"cells":6327},{"EARLY_PHASE1":6328,"PHASE1":6330,"PHASE2":6332,"PHASE3":6334,"PHASE4":6340,"NA":6342},{"trials":6329,"activeCount":100},[],{"trials":6331,"activeCount":100},[],{"trials":6333,"activeCount":100},[],{"trials":6335,"activeCount":100},[6336],{"nctId":613,"briefTitle":614,"status":207,"phases":6337,"primaryCompletion":513,"completion":616,"start":617,"enrollment":618,"conditions":6338,"interventions":6339},[90],[15],[294,349,621,622,601,623],{"trials":6341,"activeCount":100},[],{"trials":6343,"activeCount":100},[],{"intervention":622,"totalTrials":117,"cells":6345},{"EARLY_PHASE1":6346,"PHASE1":6348,"PHASE2":6350,"PHASE3":6352,"PHASE4":6358,"NA":6360},{"trials":6347,"activeCount":100},[],{"trials":6349,"activeCount":100},[],{"trials":6351,"activeCount":100},[],{"trials":6353,"activeCount":100},[6354],{"nctId":613,"briefTitle":614,"status":207,"phases":6355,"primaryCompletion":513,"completion":616,"start":617,"enrollment":618,"conditions":6356,"interventions":6357},[90],[15],[294,349,621,622,601,623],{"trials":6359,"activeCount":100},[],{"trials":6361,"activeCount":100},[],{"intervention":6363,"totalTrials":117,"cells":6364},"ibandronate",{"EARLY_PHASE1":6365,"PHASE1":6367,"PHASE2":6369,"PHASE3":6371,"PHASE4":6381,"NA":6383},{"trials":6366,"activeCount":100},[],{"trials":6368,"activeCount":100},[],{"trials":6370,"activeCount":100},[],{"trials":6372,"activeCount":100},[6373],{"nctId":6374,"briefTitle":6375,"status":241,"phases":6376,"primaryCompletion":4168,"completion":4168,"start":4168,"enrollment":100,"conditions":6377,"interventions":6379},"NCT00301886","S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone",[90],[15,6378,1157,6240],"Hypercalcemia of Malignancy",[6363,6380],"zoledronate",{"trials":6382,"activeCount":100},[],{"trials":6384,"activeCount":100},[],{"intervention":6380,"totalTrials":117,"cells":6386},{"EARLY_PHASE1":6387,"PHASE1":6389,"PHASE2":6391,"PHASE3":6393,"PHASE4":6399,"NA":6401},{"trials":6388,"activeCount":100},[],{"trials":6390,"activeCount":100},[],{"trials":6392,"activeCount":100},[],{"trials":6394,"activeCount":100},[6395],{"nctId":6374,"briefTitle":6375,"status":241,"phases":6396,"primaryCompletion":4168,"completion":4168,"start":4168,"enrollment":100,"conditions":6397,"interventions":6398},[90],[15,6378,1157,6240],[6363,6380],{"trials":6400,"activeCount":100},[],{"trials":6402,"activeCount":100},[],{"intervention":1555,"totalTrials":117,"cells":6404},{"EARLY_PHASE1":6405,"PHASE1":6407,"PHASE2":6409,"PHASE3":6411,"PHASE4":6417,"NA":6419},{"trials":6406,"activeCount":100},[],{"trials":6408,"activeCount":100},[],{"trials":6410,"activeCount":100},[],{"trials":6412,"activeCount":100},[6413],{"nctId":1546,"briefTitle":1547,"status":207,"phases":6414,"primaryCompletion":1549,"completion":1550,"start":1551,"enrollment":1552,"conditions":6415,"interventions":6416},[90],[27],[1285,1287,1555,317],{"trials":6418,"activeCount":100},[],{"trials":6420,"activeCount":100},[],{"intervention":6422,"totalTrials":117,"cells":6423},"PACx14",{"EARLY_PHASE1":6424,"PHASE1":6426,"PHASE2":6428,"PHASE3":6430,"PHASE4":6443,"NA":6445},{"trials":6425,"activeCount":100},[],{"trials":6427,"activeCount":100},[],{"trials":6429,"activeCount":100},[],{"trials":6431,"activeCount":100},[6432],{"nctId":6433,"briefTitle":6434,"status":207,"phases":6435,"primaryCompletion":408,"completion":408,"start":6436,"enrollment":6437,"conditions":6438,"interventions":6440},"NCT01061437","S0701, Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori (H. Pylori)",[90],"2009-06",1859,[6439],"Helicobacter Pylori Infection",[6422,6441,6442],"PACMx5","PAx5\u002FPCMx5",{"trials":6444,"activeCount":100},[],{"trials":6446,"activeCount":100},[],{"intervention":6441,"totalTrials":117,"cells":6448},{"EARLY_PHASE1":6449,"PHASE1":6451,"PHASE2":6453,"PHASE3":6455,"PHASE4":6461,"NA":6463},{"trials":6450,"activeCount":100},[],{"trials":6452,"activeCount":100},[],{"trials":6454,"activeCount":100},[],{"trials":6456,"activeCount":100},[6457],{"nctId":6433,"briefTitle":6434,"status":207,"phases":6458,"primaryCompletion":408,"completion":408,"start":6436,"enrollment":6437,"conditions":6459,"interventions":6460},[90],[6439],[6422,6441,6442],{"trials":6462,"activeCount":100},[],{"trials":6464,"activeCount":100},[],{"intervention":6442,"totalTrials":117,"cells":6466},{"EARLY_PHASE1":6467,"PHASE1":6469,"PHASE2":6471,"PHASE3":6473,"PHASE4":6479,"NA":6481},{"trials":6468,"activeCount":100},[],{"trials":6470,"activeCount":100},[],{"trials":6472,"activeCount":100},[],{"trials":6474,"activeCount":100},[6475],{"nctId":6433,"briefTitle":6434,"status":207,"phases":6476,"primaryCompletion":408,"completion":408,"start":6436,"enrollment":6437,"conditions":6477,"interventions":6478},[90],[6439],[6422,6441,6442],{"trials":6480,"activeCount":100},[],{"trials":6482,"activeCount":100},[],{"intervention":6484,"totalTrials":117,"cells":6485},"Mifepristone",{"EARLY_PHASE1":6486,"PHASE1":6488,"PHASE2":6490,"PHASE3":6492,"PHASE4":6503,"NA":6505},{"trials":6487,"activeCount":100},[],{"trials":6489,"activeCount":100},[],{"trials":6491,"activeCount":100},[],{"trials":6493,"activeCount":100},[6494],{"nctId":6495,"briefTitle":6496,"status":207,"phases":6497,"primaryCompletion":1088,"completion":828,"start":6498,"enrollment":6499,"conditions":6500,"interventions":6502},"NCT03015701","S9005 Mifepristone in Meningioma",[90],"1992-08",193,[6501],"Meningioma",[6484],{"trials":6504,"activeCount":100},[],{"trials":6506,"activeCount":100},[],{"intervention":6508,"totalTrials":117,"cells":6509},"cephalexin",{"EARLY_PHASE1":6510,"PHASE1":6512,"PHASE2":6514,"PHASE3":6516,"PHASE4":6527,"NA":6529},{"trials":6511,"activeCount":100},[],{"trials":6513,"activeCount":100},[],{"trials":6515,"activeCount":100},[],{"trials":6517,"activeCount":100},[6518],{"nctId":6519,"briefTitle":6520,"status":662,"phases":6521,"primaryCompletion":1365,"completion":995,"start":6522,"enrollment":6523,"conditions":6524,"interventions":6525},"NCT00003824","S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer",[90],"1999-04",114,[1315],[6508,6526],"Ciprofloxacin",{"trials":6528,"activeCount":100},[],{"trials":6530,"activeCount":100},[],{"intervention":6526,"totalTrials":117,"cells":6532},{"EARLY_PHASE1":6533,"PHASE1":6535,"PHASE2":6537,"PHASE3":6539,"PHASE4":6545,"NA":6547},{"trials":6534,"activeCount":100},[],{"trials":6536,"activeCount":100},[],{"trials":6538,"activeCount":100},[],{"trials":6540,"activeCount":100},[6541],{"nctId":6519,"briefTitle":6520,"status":662,"phases":6542,"primaryCompletion":1365,"completion":995,"start":6522,"enrollment":6523,"conditions":6543,"interventions":6544},[90],[1315],[6508,6526],{"trials":6546,"activeCount":100},[],{"trials":6548,"activeCount":100},[],{"intervention":2796,"totalTrials":117,"cells":6550},{"EARLY_PHASE1":6551,"PHASE1":6553,"PHASE2":6555,"PHASE3":6557,"PHASE4":6563,"NA":6565},{"trials":6552,"activeCount":100},[],{"trials":6554,"activeCount":100},[],{"trials":6556,"activeCount":100},[],{"trials":6558,"activeCount":100},[6559],{"nctId":2787,"briefTitle":2788,"status":207,"phases":6560,"primaryCompletion":2790,"completion":2791,"start":2792,"enrollment":2793,"conditions":6561,"interventions":6562},[90],[27],[2796,1197],{"trials":6564,"activeCount":100},[],{"trials":6566,"activeCount":100},[],{"intervention":1159,"totalTrials":117,"cells":6568},{"EARLY_PHASE1":6569,"PHASE1":6571,"PHASE2":6573,"PHASE3":6575,"PHASE4":6581,"NA":6583},{"trials":6570,"activeCount":100},[],{"trials":6572,"activeCount":100},[],{"trials":6574,"activeCount":100},[],{"trials":6576,"activeCount":100},[6577],{"nctId":1152,"briefTitle":1153,"status":207,"phases":6578,"primaryCompletion":420,"completion":420,"start":471,"enrollment":1155,"conditions":6579,"interventions":6580},[90],[1157,27],[1159,961,317],{"trials":6582,"activeCount":100},[],{"trials":6584,"activeCount":100},[],{"intervention":6586,"totalTrials":117,"cells":6587},"Entecavir",{"EARLY_PHASE1":6588,"PHASE1":6590,"PHASE2":6592,"PHASE3":6594,"PHASE4":6608,"NA":6610},{"trials":6589,"activeCount":100},[],{"trials":6591,"activeCount":100},[],{"trials":6593,"activeCount":100},[],{"trials":6595,"activeCount":100},[6596],{"nctId":6597,"briefTitle":6598,"status":662,"phases":6599,"primaryCompletion":6600,"completion":6600,"start":6601,"enrollment":762,"conditions":6602,"interventions":6605},"NCT03887702","Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors",[90],"2022-12-20","2020-01-17",[6603,6604],"Hepatitis B Infection","Malignant Solid Neoplasm",[6586,6606,6607],"Tenofovir Alafenamide","Tenofovir Disoproxil Fumarate",{"trials":6609,"activeCount":100},[],{"trials":6611,"activeCount":100},[],{"intervention":6606,"totalTrials":117,"cells":6613},{"EARLY_PHASE1":6614,"PHASE1":6616,"PHASE2":6618,"PHASE3":6620,"PHASE4":6626,"NA":6628},{"trials":6615,"activeCount":100},[],{"trials":6617,"activeCount":100},[],{"trials":6619,"activeCount":100},[],{"trials":6621,"activeCount":100},[6622],{"nctId":6597,"briefTitle":6598,"status":662,"phases":6623,"primaryCompletion":6600,"completion":6600,"start":6601,"enrollment":762,"conditions":6624,"interventions":6625},[90],[6603,6604],[6586,6606,6607],{"trials":6627,"activeCount":100},[],{"trials":6629,"activeCount":100},[],{"intervention":6607,"totalTrials":117,"cells":6631},{"EARLY_PHASE1":6632,"PHASE1":6634,"PHASE2":6636,"PHASE3":6638,"PHASE4":6644,"NA":6646},{"trials":6633,"activeCount":100},[],{"trials":6635,"activeCount":100},[],{"trials":6637,"activeCount":100},[],{"trials":6639,"activeCount":100},[6640],{"nctId":6597,"briefTitle":6598,"status":662,"phases":6641,"primaryCompletion":6600,"completion":6600,"start":6601,"enrollment":762,"conditions":6642,"interventions":6643},[90],[6603,6604],[6586,6606,6607],{"trials":6645,"activeCount":100},[],{"trials":6647,"activeCount":100},[],{"intervention":5565,"totalTrials":117,"cells":6649},{"EARLY_PHASE1":6650,"PHASE1":6652,"PHASE2":6654,"PHASE3":6656,"PHASE4":6662,"NA":6664},{"trials":6651,"activeCount":100},[],{"trials":6653,"activeCount":100},[],{"trials":6655,"activeCount":100},[],{"trials":6657,"activeCount":100},[6658],{"nctId":5558,"briefTitle":5559,"status":207,"phases":6659,"primaryCompletion":4168,"completion":828,"start":594,"enrollment":5561,"conditions":6660,"interventions":6661},[90],[5563],[505,5565],{"trials":6663,"activeCount":100},[],{"trials":6665,"activeCount":100},[],{"intervention":669,"totalTrials":117,"cells":6667},{"EARLY_PHASE1":6668,"PHASE1":6670,"PHASE2":6672,"PHASE3":6674,"PHASE4":6680,"NA":6682},{"trials":6669,"activeCount":100},[],{"trials":6671,"activeCount":100},[],{"trials":6673,"activeCount":100},[],{"trials":6675,"activeCount":100},[6676],{"nctId":660,"briefTitle":661,"status":662,"phases":6677,"primaryCompletion":344,"completion":344,"start":664,"enrollment":665,"conditions":6678,"interventions":6679},[90],[15],[330,668,505,506,294,349,611,623,669],{"trials":6681,"activeCount":100},[],{"trials":6683,"activeCount":100},[],{"intervention":1712,"totalTrials":117,"cells":6685},{"EARLY_PHASE1":6686,"PHASE1":6688,"PHASE2":6690,"PHASE3":6692,"PHASE4":6698,"NA":6700},{"trials":6687,"activeCount":100},[],{"trials":6689,"activeCount":100},[],{"trials":6691,"activeCount":100},[],{"trials":6693,"activeCount":100},[6694],{"nctId":1705,"briefTitle":1706,"status":207,"phases":6695,"primaryCompletion":1087,"completion":408,"start":1708,"enrollment":1709,"conditions":6696,"interventions":6697},[90],[1033,1264],[668,1712],{"trials":6699,"activeCount":100},[],{"trials":6701,"activeCount":100},[],{"intervention":2892,"totalTrials":117,"cells":6703},{"EARLY_PHASE1":6704,"PHASE1":6706,"PHASE2":6708,"PHASE3":6710,"PHASE4":6716,"NA":6718},{"trials":6705,"activeCount":100},[],{"trials":6707,"activeCount":100},[],{"trials":6709,"activeCount":100},[],{"trials":6711,"activeCount":100},[6712],{"nctId":2883,"briefTitle":2884,"status":207,"phases":6713,"primaryCompletion":2886,"completion":2887,"start":2888,"enrollment":2889,"conditions":6714,"interventions":6715},[90],[15,1325],[2892,623],{"trials":6717,"activeCount":100},[],{"trials":6719,"activeCount":100},[],{"intervention":6721,"totalTrials":117,"cells":6722},"Megestrol Acetate 20mg\u002Fday",{"EARLY_PHASE1":6723,"PHASE1":6725,"PHASE2":6727,"PHASE3":6729,"PHASE4":6743,"NA":6745},{"trials":6724,"activeCount":100},[],{"trials":6726,"activeCount":100},[],{"trials":6728,"activeCount":100},[],{"trials":6730,"activeCount":100},[6731],{"nctId":6732,"briefTitle":6733,"status":207,"phases":6734,"primaryCompletion":594,"completion":6735,"start":1995,"enrollment":6736,"conditions":6737,"interventions":6739},"NCT00005975","S9626: Megestrol in Treating Hot Flashes Following Treatment for Breast Cancer",[90],"2002-03",288,[15,6738],"Hot Flashes",[6721,6740,6741,6742],"Megestrol Acetate 40 mg\u002Fday","Megestrol Acetate Placebo 20 mg\u002Fday","Megestrol Acetate Placebo 40 mg\u002Fday",{"trials":6744,"activeCount":100},[],{"trials":6746,"activeCount":100},[],{"intervention":6740,"totalTrials":117,"cells":6748},{"EARLY_PHASE1":6749,"PHASE1":6751,"PHASE2":6753,"PHASE3":6755,"PHASE4":6761,"NA":6763},{"trials":6750,"activeCount":100},[],{"trials":6752,"activeCount":100},[],{"trials":6754,"activeCount":100},[],{"trials":6756,"activeCount":100},[6757],{"nctId":6732,"briefTitle":6733,"status":207,"phases":6758,"primaryCompletion":594,"completion":6735,"start":1995,"enrollment":6736,"conditions":6759,"interventions":6760},[90],[15,6738],[6721,6740,6741,6742],{"trials":6762,"activeCount":100},[],{"trials":6764,"activeCount":100},[],{"intervention":6741,"totalTrials":117,"cells":6766},{"EARLY_PHASE1":6767,"PHASE1":6769,"PHASE2":6771,"PHASE3":6773,"PHASE4":6779,"NA":6781},{"trials":6768,"activeCount":100},[],{"trials":6770,"activeCount":100},[],{"trials":6772,"activeCount":100},[],{"trials":6774,"activeCount":100},[6775],{"nctId":6732,"briefTitle":6733,"status":207,"phases":6776,"primaryCompletion":594,"completion":6735,"start":1995,"enrollment":6736,"conditions":6777,"interventions":6778},[90],[15,6738],[6721,6740,6741,6742],{"trials":6780,"activeCount":100},[],{"trials":6782,"activeCount":100},[],{"intervention":6742,"totalTrials":117,"cells":6784},{"EARLY_PHASE1":6785,"PHASE1":6787,"PHASE2":6789,"PHASE3":6791,"PHASE4":6797,"NA":6799},{"trials":6786,"activeCount":100},[],{"trials":6788,"activeCount":100},[],{"trials":6790,"activeCount":100},[],{"trials":6792,"activeCount":100},[6793],{"nctId":6732,"briefTitle":6733,"status":207,"phases":6794,"primaryCompletion":594,"completion":6735,"start":1995,"enrollment":6736,"conditions":6795,"interventions":6796},[90],[15,6738],[6721,6740,6741,6742],{"trials":6798,"activeCount":100},[],{"trials":6800,"activeCount":100},[],{"intervention":5868,"totalTrials":117,"cells":6802},{"EARLY_PHASE1":6803,"PHASE1":6805,"PHASE2":6807,"PHASE3":6809,"PHASE4":6815,"NA":6817},{"trials":6804,"activeCount":100},[],{"trials":6806,"activeCount":100},[],{"trials":6808,"activeCount":100},[],{"trials":6810,"activeCount":100},[6811],{"nctId":5861,"briefTitle":5862,"status":207,"phases":6812,"primaryCompletion":616,"completion":5864,"start":1010,"enrollment":5865,"conditions":6813,"interventions":6814},[90],[24],[5388,5868,5869],{"trials":6816,"activeCount":100},[],{"trials":6818,"activeCount":100},[],{"intervention":5869,"totalTrials":117,"cells":6820},{"EARLY_PHASE1":6821,"PHASE1":6823,"PHASE2":6825,"PHASE3":6827,"PHASE4":6833,"NA":6835},{"trials":6822,"activeCount":100},[],{"trials":6824,"activeCount":100},[],{"trials":6826,"activeCount":100},[],{"trials":6828,"activeCount":100},[6829],{"nctId":5861,"briefTitle":5862,"status":207,"phases":6830,"primaryCompletion":616,"completion":5864,"start":1010,"enrollment":5865,"conditions":6831,"interventions":6832},[90],[24],[5388,5868,5869],{"trials":6834,"activeCount":100},[],{"trials":6836,"activeCount":100},[],{"intervention":6838,"totalTrials":117,"cells":6839},"bupropion hydrochloride",{"EARLY_PHASE1":6840,"PHASE1":6842,"PHASE2":6844,"PHASE3":6846,"PHASE4":6855,"NA":6857},{"trials":6841,"activeCount":100},[],{"trials":6843,"activeCount":100},[],{"trials":6845,"activeCount":100},[],{"trials":6847,"activeCount":100},[6848],{"nctId":6849,"briefTitle":6850,"status":662,"phases":6851,"primaryCompletion":344,"completion":344,"start":2033,"enrollment":4066,"conditions":6852,"interventions":6853},"NCT00032084","S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery",[90],[21],[6838,6854],"nicotine",{"trials":6856,"activeCount":100},[],{"trials":6858,"activeCount":100},[],{"intervention":6854,"totalTrials":117,"cells":6860},{"EARLY_PHASE1":6861,"PHASE1":6863,"PHASE2":6865,"PHASE3":6867,"PHASE4":6873,"NA":6875},{"trials":6862,"activeCount":100},[],{"trials":6864,"activeCount":100},[],{"trials":6866,"activeCount":100},[],{"trials":6868,"activeCount":100},[6869],{"nctId":6849,"briefTitle":6850,"status":662,"phases":6870,"primaryCompletion":344,"completion":344,"start":2033,"enrollment":4066,"conditions":6871,"interventions":6872},[90],[21],[6838,6854],{"trials":6874,"activeCount":100},[],{"trials":6876,"activeCount":100},[],{"intervention":718,"totalTrials":117,"cells":6878},{"EARLY_PHASE1":6879,"PHASE1":6881,"PHASE2":6883,"PHASE3":6885,"PHASE4":6891,"NA":6893},{"trials":6880,"activeCount":100},[],{"trials":6882,"activeCount":100},[],{"trials":6884,"activeCount":100},[],{"trials":6886,"activeCount":100},[6887],{"nctId":708,"briefTitle":709,"status":207,"phases":6888,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":6889,"interventions":6890},[90],[24,716],[718,294,719,336],{"trials":6892,"activeCount":100},[],{"trials":6894,"activeCount":100},[],{"intervention":6896,"totalTrials":117,"cells":6897},"L-selenomethionine",{"EARLY_PHASE1":6898,"PHASE1":6900,"PHASE2":6902,"PHASE3":6904,"PHASE4":6915,"NA":6917},{"trials":6899,"activeCount":100},[],{"trials":6901,"activeCount":100},[],{"trials":6903,"activeCount":100},[],{"trials":6905,"activeCount":100},[6906],{"nctId":6907,"briefTitle":6908,"status":207,"phases":6909,"primaryCompletion":422,"completion":422,"start":713,"enrollment":6910,"conditions":6911,"interventions":6913},"NCT00030901","S9917, Selenium in Preventing Cancer in Patients With Neoplasia of the Prostate",[90],619,[6912,27],"Precancerous\u002FNonmalignant Condition",[6896,6914],"L-selenomethionine placebo",{"trials":6916,"activeCount":100},[],{"trials":6918,"activeCount":100},[],{"intervention":6914,"totalTrials":117,"cells":6920},{"EARLY_PHASE1":6921,"PHASE1":6923,"PHASE2":6925,"PHASE3":6927,"PHASE4":6933,"NA":6935},{"trials":6922,"activeCount":100},[],{"trials":6924,"activeCount":100},[],{"trials":6926,"activeCount":100},[],{"trials":6928,"activeCount":100},[6929],{"nctId":6907,"briefTitle":6908,"status":207,"phases":6930,"primaryCompletion":422,"completion":422,"start":713,"enrollment":6910,"conditions":6931,"interventions":6932},[90],[6912,27],[6896,6914],{"trials":6934,"activeCount":100},[],{"trials":6936,"activeCount":100},[],{"intervention":332,"totalTrials":31,"cells":6938},{"EARLY_PHASE1":6939,"PHASE1":6941,"PHASE2":6943,"PHASE3":7018,"PHASE4":7020,"NA":7022},{"trials":6940,"activeCount":100},[],{"trials":6942,"activeCount":100},[],{"trials":6944,"activeCount":100},[6945,6949,6953,6957,6961,6965,6969,6973,6984,6988,6999,7003,7007,7014],{"nctId":322,"briefTitle":323,"status":207,"phases":6946,"primaryCompletion":325,"completion":326,"start":327,"enrollment":173,"conditions":6947,"interventions":6948},[89],[18],[330,331,294,332,333,334,335,336,337],{"nctId":5089,"briefTitle":5090,"status":207,"phases":6950,"primaryCompletion":4037,"completion":5092,"start":1010,"enrollment":5093,"conditions":6951,"interventions":6952},[89],[24],[330,362,719,332,398],{"nctId":5105,"briefTitle":5106,"status":207,"phases":6954,"primaryCompletion":1445,"completion":4159,"start":5108,"enrollment":494,"conditions":6955,"interventions":6956},[89],[24],[330,362,332,398],{"nctId":387,"briefTitle":388,"status":207,"phases":6958,"primaryCompletion":390,"completion":391,"start":392,"enrollment":308,"conditions":6959,"interventions":6960},[89],[24,394,395],[397,294,332,398,333,349,399,400,401,336,317,402,316],{"nctId":5848,"briefTitle":5849,"status":207,"phases":6962,"primaryCompletion":1125,"completion":5851,"start":1003,"enrollment":1049,"conditions":6963,"interventions":6964},[89],[24],[332,5388],{"nctId":404,"briefTitle":405,"status":207,"phases":6966,"primaryCompletion":407,"completion":408,"start":409,"enrollment":410,"conditions":6967,"interventions":6968},[89],[18,412],[414,415,294,332,349,399,336,317,316],{"nctId":417,"briefTitle":418,"status":207,"phases":6970,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":6971,"interventions":6972},[89],[18],[331,426,294,332,333,349,400,336,316],{"nctId":6974,"briefTitle":6975,"status":207,"phases":6976,"primaryCompletion":6977,"completion":6978,"start":6979,"enrollment":11,"conditions":6980,"interventions":6981},"NCT00840177","S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia",[89],"2018-12","2021-10-21","2009-12-10",[24],[332,6982,6983],"idarubicin","pravastatin sodium",{"nctId":498,"briefTitle":499,"status":241,"phases":6985,"primaryCompletion":501,"start":502,"enrollment":100,"conditions":6986,"interventions":6987},[89],[18],[331,475,505,506,294,332,333,349,399,363,364],{"nctId":6989,"briefTitle":6990,"status":207,"phases":6991,"primaryCompletion":6992,"completion":6993,"start":2522,"enrollment":6994,"conditions":6995,"interventions":6996},"NCT00945815","S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia",[89],"2013-03","2017-08",35,[24],[6997,6998,332],"epratuzumab","clofarabine",{"nctId":559,"briefTitle":560,"status":207,"phases":7000,"primaryCompletion":407,"completion":408,"start":562,"enrollment":563,"conditions":7001,"interventions":7002},[89],[18],[414,330,294,332,349,399,400,336,317,566,316,567],{"nctId":5132,"briefTitle":5133,"status":207,"phases":7004,"primaryCompletion":738,"completion":712,"start":713,"enrollment":8,"conditions":7005,"interventions":7006},[89],[24],[330,362,332,398,5137],{"nctId":7008,"briefTitle":7009,"status":207,"phases":7010,"primaryCompletion":1382,"completion":4301,"start":2421,"enrollment":7011,"conditions":7012,"interventions":7013},"NCT00337168","S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia",[89],36,[24],[6998,332],{"nctId":578,"briefTitle":579,"status":207,"phases":7015,"primaryCompletion":342,"completion":552,"start":581,"enrollment":582,"conditions":7016,"interventions":7017},[89],[24],[330,294,332,585,333,334,335,401,336,586,587,317,402,337,588,589],{"trials":7019,"activeCount":100},[],{"trials":7021,"activeCount":100},[],{"trials":7023,"activeCount":100},[],{"intervention":1117,"totalTrials":2131,"cells":7025},{"EARLY_PHASE1":7026,"PHASE1":7028,"PHASE2":7030,"PHASE3":7064,"PHASE4":7066,"NA":7068},{"trials":7027,"activeCount":100},[],{"trials":7029,"activeCount":100},[],{"trials":7031,"activeCount":100},[7032,7036,7040,7044,7048,7052,7056,7060],{"nctId":2005,"briefTitle":2006,"status":207,"phases":7033,"primaryCompletion":2008,"completion":2009,"start":2010,"enrollment":359,"conditions":7034,"interventions":7035},[89],[2012,2013],[81,219,192,2015,2016],{"nctId":4165,"briefTitle":4166,"status":662,"phases":7037,"primaryCompletion":543,"start":4168,"enrollment":843,"conditions":7038,"interventions":7039},[89],[1113],[517,1117],{"nctId":2022,"briefTitle":2023,"status":207,"phases":7041,"primaryCompletion":512,"completion":2025,"start":2026,"enrollment":555,"conditions":7042,"interventions":7043},[89],[1112],[601,1117],{"nctId":4179,"briefTitle":4180,"status":207,"phases":7045,"primaryCompletion":4182,"completion":1107,"start":4183,"enrollment":4184,"conditions":7046,"interventions":7047},[89],[30],[977,517,1117],{"nctId":2051,"briefTitle":2052,"status":241,"phases":7049,"primaryCompletion":2054,"start":2055,"enrollment":100,"conditions":7050,"interventions":7051},[89],[30],[517,601,1116,400,1117,2058],{"nctId":4203,"briefTitle":4204,"status":241,"phases":7053,"primaryCompletion":4206,"completion":4206,"start":629,"enrollment":100,"conditions":7054,"interventions":7055},[89],[30,1157],[485,517,1117],{"nctId":1104,"briefTitle":1105,"status":207,"phases":7057,"primaryCompletion":1107,"completion":1108,"start":737,"enrollment":1109,"conditions":7058,"interventions":7059},[89],[1111,1112,1113],[1115,961,601,1116,400,1117],{"nctId":2262,"briefTitle":2263,"status":207,"phases":7061,"primaryCompletion":2265,"completion":2266,"start":2267,"enrollment":2268,"conditions":7062,"interventions":7063},[88,89],[2110],[2271,2015,193,191,1129],{"trials":7065,"activeCount":100},[],{"trials":7067,"activeCount":100},[],{"trials":7069,"activeCount":100},[],{"intervention":362,"totalTrials":762,"cells":7071},{"EARLY_PHASE1":7072,"PHASE1":7074,"PHASE2":7076,"PHASE3":7094,"PHASE4":7096,"NA":7098},{"trials":7073,"activeCount":100},[],{"trials":7075,"activeCount":100},[],{"trials":7077,"activeCount":100},[7078,7082,7086,7090],{"nctId":5089,"briefTitle":5090,"status":207,"phases":7079,"primaryCompletion":4037,"completion":5092,"start":1010,"enrollment":5093,"conditions":7080,"interventions":7081},[89],[24],[330,362,719,332,398],{"nctId":353,"briefTitle":354,"status":207,"phases":7083,"primaryCompletion":356,"completion":357,"start":358,"enrollment":359,"conditions":7084,"interventions":7085},[89],[36],[330,362,294,333,363,317,364],{"nctId":5105,"briefTitle":5106,"status":207,"phases":7087,"primaryCompletion":1445,"completion":4159,"start":5108,"enrollment":494,"conditions":7088,"interventions":7089},[89],[24],[330,362,332,398],{"nctId":5132,"briefTitle":5133,"status":207,"phases":7091,"primaryCompletion":738,"completion":712,"start":713,"enrollment":8,"conditions":7092,"interventions":7093},[89],[24],[330,362,332,398,5137],{"trials":7095,"activeCount":100},[],{"trials":7097,"activeCount":100},[],{"trials":7099,"activeCount":100},[],{"intervention":398,"totalTrials":762,"cells":7101},{"EARLY_PHASE1":7102,"PHASE1":7104,"PHASE2":7106,"PHASE3":7124,"PHASE4":7126,"NA":7128},{"trials":7103,"activeCount":100},[],{"trials":7105,"activeCount":100},[],{"trials":7107,"activeCount":100},[7108,7112,7116,7120],{"nctId":5089,"briefTitle":5090,"status":207,"phases":7109,"primaryCompletion":4037,"completion":5092,"start":1010,"enrollment":5093,"conditions":7110,"interventions":7111},[89],[24],[330,362,719,332,398],{"nctId":5105,"briefTitle":5106,"status":207,"phases":7113,"primaryCompletion":1445,"completion":4159,"start":5108,"enrollment":494,"conditions":7114,"interventions":7115},[89],[24],[330,362,332,398],{"nctId":387,"briefTitle":388,"status":207,"phases":7117,"primaryCompletion":390,"completion":391,"start":392,"enrollment":308,"conditions":7118,"interventions":7119},[89],[24,394,395],[397,294,332,398,333,349,399,400,401,336,317,402,316],{"nctId":5132,"briefTitle":5133,"status":207,"phases":7121,"primaryCompletion":738,"completion":712,"start":713,"enrollment":8,"conditions":7122,"interventions":7123},[89],[24],[330,362,332,398,5137],{"trials":7125,"activeCount":100},[],{"trials":7127,"activeCount":100},[],{"trials":7129,"activeCount":100},[],{"intervention":1073,"totalTrials":762,"cells":7131},{"EARLY_PHASE1":7132,"PHASE1":7134,"PHASE2":7136,"PHASE3":7156,"PHASE4":7158,"NA":7160},{"trials":7133,"activeCount":100},[],{"trials":7135,"activeCount":100},[],{"trials":7137,"activeCount":100},[7138,7142,7146,7150],{"nctId":1064,"briefTitle":1065,"status":207,"phases":7139,"primaryCompletion":1067,"completion":1068,"start":327,"enrollment":1069,"conditions":7140,"interventions":7141},[89],[15],[330,1072,961,1073],{"nctId":1075,"briefTitle":1076,"status":207,"phases":7143,"primaryCompletion":1078,"completion":995,"start":595,"enrollment":1079,"conditions":7144,"interventions":7145},[89],[21],[668,506,961,1082,611,1073],{"nctId":1092,"briefTitle":1093,"status":207,"phases":7147,"primaryCompletion":1095,"completion":828,"start":738,"enrollment":1096,"conditions":7148,"interventions":7149},[89],[15],[330,961,1073],{"nctId":7151,"briefTitle":7152,"status":207,"phases":7153,"primaryCompletion":390,"completion":711,"start":532,"enrollment":974,"conditions":7154,"interventions":7155},"NCT00003828","S9804: Vinorelbine in Treating Patients With Stage IV Melanoma",[89],[4242],[1073],{"trials":7157,"activeCount":100},[],{"trials":7159,"activeCount":100},[],{"trials":7161,"activeCount":100},[],{"intervention":7163,"totalTrials":252,"cells":7164},"pemetrexed disodium",{"EARLY_PHASE1":7165,"PHASE1":7167,"PHASE2":7169,"PHASE3":7192,"PHASE4":7194,"NA":7196},{"trials":7166,"activeCount":100},[],{"trials":7168,"activeCount":100},[],{"trials":7170,"activeCount":100},[7171,7177,7181],{"nctId":7172,"briefTitle":7173,"status":207,"phases":7174,"primaryCompletion":4175,"completion":512,"start":2160,"enrollment":1996,"conditions":7175,"interventions":7176},"NCT00107419","S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma",[89],[2729],[7163],{"nctId":205,"briefTitle":206,"status":207,"phases":7178,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":7179,"interventions":7180},[89],[175,176,214,215],[217,218,219,220,221,222,157],{"nctId":7182,"briefTitle":7183,"status":662,"phases":7184,"primaryCompletion":725,"completion":725,"start":5864,"enrollment":117,"conditions":7185,"interventions":7190},"NCT02134912","S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib",[89],[7186,7187,7188,7189],"Adenocarcinoma of the Lung","Large Cell Lung Cancer","Recurrent Non-small Cell Lung Cancer","Stage IV Non-small Cell Lung Cancer",[7191,7163],"crizotinib",{"trials":7193,"activeCount":100},[],{"trials":7195,"activeCount":100},[],{"trials":7197,"activeCount":100},[],{"intervention":2016,"totalTrials":96,"cells":7199},{"EARLY_PHASE1":7200,"PHASE1":7202,"PHASE2":7204,"PHASE3":7214,"PHASE4":7216,"NA":7218},{"trials":7201,"activeCount":100},[],{"trials":7203,"activeCount":100},[],{"trials":7205,"activeCount":100},[7206,7210],{"nctId":2005,"briefTitle":2006,"status":207,"phases":7207,"primaryCompletion":2008,"completion":2009,"start":2010,"enrollment":359,"conditions":7208,"interventions":7209},[89],[2012,2013],[81,219,192,2015,2016],{"nctId":477,"briefTitle":478,"status":207,"phases":7211,"primaryCompletion":357,"completion":480,"start":481,"enrollment":482,"conditions":7212,"interventions":7213},[89],[15],[485,42,294,349,486],{"trials":7215,"activeCount":100},[],{"trials":7217,"activeCount":100},[],{"trials":7219,"activeCount":100},[],{"intervention":1665,"totalTrials":96,"cells":7221},{"EARLY_PHASE1":7222,"PHASE1":7224,"PHASE2":7226,"PHASE3":7244,"PHASE4":7246,"NA":7248},{"trials":7223,"activeCount":100},[],{"trials":7225,"activeCount":100},[],{"trials":7227,"activeCount":100},[7228,7240],{"nctId":7229,"briefTitle":7230,"status":207,"phases":7231,"primaryCompletion":7232,"completion":7233,"start":7234,"enrollment":7235,"conditions":7236,"interventions":7238},"NCT04173507","Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)",[89],"2021-11-24","2024-05-01","2020-02-14",47,[7237,4505,176,214,215],"Advanced Lung Non-Squamous Non-Small Cell Carcinoma",[1665,1245,7239],"Talazoparib Tosylate",{"nctId":1654,"briefTitle":1655,"status":662,"phases":7241,"primaryCompletion":1657,"completion":1658,"start":1659,"enrollment":1126,"conditions":7242,"interventions":7243},[89],[1661,1662,1663],[1665,219,237],{"trials":7245,"activeCount":100},[],{"trials":7247,"activeCount":100},[],{"trials":7249,"activeCount":100},[],{"intervention":397,"totalTrials":96,"cells":7251},{"EARLY_PHASE1":7252,"PHASE1":7254,"PHASE2":7256,"PHASE3":7266,"PHASE4":7268,"NA":7270},{"trials":7253,"activeCount":100},[],{"trials":7255,"activeCount":100},[],{"trials":7257,"activeCount":100},[7258,7262],{"nctId":387,"briefTitle":388,"status":207,"phases":7259,"primaryCompletion":390,"completion":391,"start":392,"enrollment":308,"conditions":7260,"interventions":7261},[89],[24,394,395],[397,294,332,398,333,349,399,400,401,336,317,402,316],{"nctId":578,"briefTitle":579,"status":207,"phases":7263,"primaryCompletion":342,"completion":552,"start":581,"enrollment":582,"conditions":7264,"interventions":7265},[89],[24],[330,294,332,585,333,334,335,401,336,586,587,317,402,337,588,589],{"trials":7267,"activeCount":100},[],{"trials":7269,"activeCount":100},[],{"trials":7271,"activeCount":100},[],{"intervention":402,"totalTrials":96,"cells":7273},{"EARLY_PHASE1":7274,"PHASE1":7276,"PHASE2":7278,"PHASE3":7288,"PHASE4":7290,"NA":7292},{"trials":7275,"activeCount":100},[],{"trials":7277,"activeCount":100},[],{"trials":7279,"activeCount":100},[7280,7284],{"nctId":387,"briefTitle":388,"status":207,"phases":7281,"primaryCompletion":390,"completion":391,"start":392,"enrollment":308,"conditions":7282,"interventions":7283},[89],[24,394,395],[397,294,332,398,333,349,399,400,401,336,317,402,316],{"nctId":578,"briefTitle":579,"status":207,"phases":7285,"primaryCompletion":342,"completion":552,"start":581,"enrollment":582,"conditions":7286,"interventions":7287},[89],[24],[330,294,332,585,333,334,335,401,336,586,587,317,402,337,588,589],{"trials":7289,"activeCount":100},[],{"trials":7291,"activeCount":100},[],{"trials":7293,"activeCount":100},[],{"intervention":7295,"totalTrials":96,"cells":7296},"celecoxib",{"EARLY_PHASE1":7297,"PHASE1":7299,"PHASE2":7301,"PHASE3":7317,"PHASE4":7319,"NA":7321},{"trials":7298,"activeCount":100},[],{"trials":7300,"activeCount":100},[],{"trials":7302,"activeCount":100},[7303,7311],{"nctId":7304,"briefTitle":7305,"status":241,"phases":7306,"enrollment":100,"conditions":7307,"interventions":7310},"NCT00072540","S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix",[89],[7308,7309],"Stage 0 Cervical Cancer","High-grade Squamous Intraepithelial Lesion",[7295],{"nctId":7312,"briefTitle":7313,"status":662,"phases":7314,"primaryCompletion":433,"completion":433,"start":491,"enrollment":2131,"conditions":7315,"interventions":7316},"NCT00088972","S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women",[89],[15],[7295],{"trials":7318,"activeCount":100},[],{"trials":7320,"activeCount":100},[],{"trials":7322,"activeCount":100},[],{"intervention":7324,"totalTrials":96,"cells":7325},"CNTO 328",{"EARLY_PHASE1":7326,"PHASE1":7328,"PHASE2":7330,"PHASE3":7345,"PHASE4":7347,"NA":7349},{"trials":7327,"activeCount":100},[],{"trials":7329,"activeCount":100},[],{"trials":7331,"activeCount":100},[7332,7338],{"nctId":7333,"briefTitle":7334,"status":241,"phases":7335,"enrollment":100,"conditions":7336,"interventions":7337},"NCT00311545","S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer",[89],[2839],[7324],{"nctId":7339,"briefTitle":7340,"status":207,"phases":7341,"primaryCompletion":7342,"completion":408,"start":4206,"enrollment":1304,"conditions":7343,"interventions":7344},"NCT00433446","S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy",[89],"2009-05",[27],[7324],{"trials":7346,"activeCount":100},[],{"trials":7348,"activeCount":100},[],{"trials":7350,"activeCount":100},[],{"intervention":7352,"totalTrials":96,"cells":7353},"ixabepilone",{"EARLY_PHASE1":7354,"PHASE1":7356,"PHASE2":7358,"PHASE3":7373,"PHASE4":7375,"NA":7377},{"trials":7355,"activeCount":100},[],{"trials":7357,"activeCount":100},[],{"trials":7359,"activeCount":100},[7360,7366],{"nctId":7361,"briefTitle":7362,"status":207,"phases":7363,"completion":973,"start":1365,"conditions":7364,"interventions":7365},"NCT00016965","BMS-247550 in Treating Patients With Advanced Pancreatic Cancer",[89],[2037],[7352],{"nctId":7367,"briefTitle":7368,"status":207,"phases":7369,"completion":973,"start":7370,"conditions":7371,"interventions":7372},"NCT00016393","BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy",[89],"2001-06",[27],[7352],{"trials":7374,"activeCount":100},[],{"trials":7376,"activeCount":100},[],{"trials":7378,"activeCount":100},[],{"intervention":426,"totalTrials":96,"cells":7380},{"EARLY_PHASE1":7381,"PHASE1":7383,"PHASE2":7385,"PHASE3":7395,"PHASE4":7397,"NA":7399},{"trials":7382,"activeCount":100},[],{"trials":7384,"activeCount":100},[],{"trials":7386,"activeCount":100},[7387,7391],{"nctId":417,"briefTitle":418,"status":207,"phases":7388,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":7389,"interventions":7390},[89],[18],[331,426,294,332,333,349,400,336,316],{"nctId":2519,"briefTitle":2520,"status":241,"phases":7392,"primaryCompletion":2522,"completion":2522,"start":982,"enrollment":100,"conditions":7393,"interventions":7394},[89],[24],[331,426],{"trials":7396,"activeCount":100},[],{"trials":7398,"activeCount":100},[],{"trials":7400,"activeCount":100},[],{"intervention":986,"totalTrials":96,"cells":7402},{"EARLY_PHASE1":7403,"PHASE1":7405,"PHASE2":7411,"PHASE3":7417,"PHASE4":7419,"NA":7421},{"trials":7404,"activeCount":100},[],{"trials":7406,"activeCount":100},[7407],{"nctId":979,"briefTitle":980,"status":241,"phases":7408,"primaryCompletion":982,"completion":982,"start":502,"enrollment":100,"conditions":7409,"interventions":7410},[88],[15,33,21,27,984],[961,986,987],{"trials":7412,"activeCount":100},[7413],{"nctId":1026,"briefTitle":1027,"status":207,"phases":7414,"primaryCompletion":789,"completion":1029,"start":616,"enrollment":1030,"conditions":7415,"interventions":7416},[89],[1032,1033,1034],[961,986],{"trials":7418,"activeCount":100},[],{"trials":7420,"activeCount":100},[],{"trials":7422,"activeCount":100},[],{"intervention":6998,"totalTrials":96,"cells":7424},{"EARLY_PHASE1":7425,"PHASE1":7427,"PHASE2":7429,"PHASE3":7439,"PHASE4":7441,"NA":7443},{"trials":7426,"activeCount":100},[],{"trials":7428,"activeCount":100},[],{"trials":7430,"activeCount":100},[7431,7435],{"nctId":6989,"briefTitle":6990,"status":207,"phases":7432,"primaryCompletion":6992,"completion":6993,"start":2522,"enrollment":6994,"conditions":7433,"interventions":7434},[89],[24],[6997,6998,332],{"nctId":7008,"briefTitle":7009,"status":207,"phases":7436,"primaryCompletion":1382,"completion":4301,"start":2421,"enrollment":7011,"conditions":7437,"interventions":7438},[89],[24],[6998,332],{"trials":7440,"activeCount":100},[],{"trials":7442,"activeCount":100},[],{"trials":7444,"activeCount":100},[],{"intervention":7446,"totalTrials":96,"cells":7447},"R115777",{"EARLY_PHASE1":7448,"PHASE1":7450,"PHASE2":7452,"PHASE3":7467,"PHASE4":7469,"NA":7471},{"trials":7449,"activeCount":100},[],{"trials":7451,"activeCount":100},[],{"trials":7453,"activeCount":100},[7454,7461],{"nctId":7455,"briefTitle":7456,"status":207,"phases":7457,"primaryCompletion":554,"completion":554,"start":7458,"enrollment":5205,"conditions":7459,"interventions":7460},"NCT00005832","S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer",[89],"2000-06",[2037],[7446],{"nctId":7462,"briefTitle":7463,"status":207,"phases":7464,"primaryCompletion":1209,"completion":1209,"start":7458,"enrollment":1304,"conditions":7465,"interventions":7466},"NCT00005833","S9923 R115777 in Treating Patients With Advanced Colorectal Cancer",[89],[30],[7446],{"trials":7468,"activeCount":100},[],{"trials":7470,"activeCount":100},[],{"trials":7472,"activeCount":100},[],{"intervention":5387,"totalTrials":96,"cells":7474},{"EARLY_PHASE1":7475,"PHASE1":7477,"PHASE2":7479,"PHASE3":7494,"PHASE4":7496,"NA":7498},{"trials":7476,"activeCount":100},[],{"trials":7478,"activeCount":100},[],{"trials":7480,"activeCount":100},[7481,7490],{"nctId":7482,"briefTitle":7483,"status":207,"phases":7484,"completion":1087,"start":7485,"conditions":7486,"interventions":7489},"NCT00036842","Arsenic Trioxide in Treating Men With Germ Cell Cancer",[89],"2002-04",[7487,7488],"Extragonadal Germ Cell Tumor","Testicular Germ Cell Tumor",[5387],{"nctId":5379,"briefTitle":5380,"status":207,"phases":7491,"primaryCompletion":5382,"completion":5383,"start":5384,"enrollment":1393,"conditions":7492,"interventions":7493},[89],[24],[5387,5388,401,336,5389],{"trials":7495,"activeCount":100},[],{"trials":7497,"activeCount":100},[],{"trials":7499,"activeCount":100},[],{"intervention":350,"totalTrials":117,"cells":7501},{"EARLY_PHASE1":7502,"PHASE1":7504,"PHASE2":7506,"PHASE3":7512,"PHASE4":7514,"NA":7516},{"trials":7503,"activeCount":100},[],{"trials":7505,"activeCount":100},[],{"trials":7507,"activeCount":100},[7508],{"nctId":339,"briefTitle":340,"status":207,"phases":7509,"primaryCompletion":342,"completion":343,"start":344,"enrollment":345,"conditions":7510,"interventions":7511},[89],[18],[331,348,349,317,316,350,351],{"trials":7513,"activeCount":100},[],{"trials":7515,"activeCount":100},[],{"trials":7517,"activeCount":100},[],{"intervention":351,"totalTrials":117,"cells":7519},{"EARLY_PHASE1":7520,"PHASE1":7522,"PHASE2":7524,"PHASE3":7530,"PHASE4":7532,"NA":7534},{"trials":7521,"activeCount":100},[],{"trials":7523,"activeCount":100},[],{"trials":7525,"activeCount":100},[7526],{"nctId":339,"briefTitle":340,"status":207,"phases":7527,"primaryCompletion":342,"completion":343,"start":344,"enrollment":345,"conditions":7528,"interventions":7529},[89],[18],[331,348,349,317,316,350,351],{"trials":7531,"activeCount":100},[],{"trials":7533,"activeCount":100},[],{"trials":7535,"activeCount":100},[],{"intervention":7537,"totalTrials":117,"cells":7538},"nelarabine",{"EARLY_PHASE1":7539,"PHASE1":7541,"PHASE2":7543,"PHASE3":7551,"PHASE4":7553,"NA":7555},{"trials":7540,"activeCount":100},[],{"trials":7542,"activeCount":100},[],{"trials":7544,"activeCount":100},[7545],{"nctId":7546,"briefTitle":7547,"status":207,"phases":7548,"primaryCompletion":994,"completion":1010,"start":809,"enrollment":6994,"conditions":7549,"interventions":7550},"NCT00006020","S0010 506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia",[89],[24],[7537],{"trials":7552,"activeCount":100},[],{"trials":7554,"activeCount":100},[],{"trials":7556,"activeCount":100},[],{"intervention":7558,"totalTrials":117,"cells":7559},"Rucaparib",{"EARLY_PHASE1":7560,"PHASE1":7562,"PHASE2":7564,"PHASE3":7579,"PHASE4":7581,"NA":7583},{"trials":7561,"activeCount":100},[],{"trials":7563,"activeCount":100},[],{"trials":7565,"activeCount":100},[7566],{"nctId":7567,"briefTitle":7568,"status":207,"phases":7569,"primaryCompletion":305,"completion":7570,"start":7571,"enrollment":4240,"conditions":7572,"interventions":7578},"NCT03845296","Rucaparib in Treating Patients With Genomic LOH High and\u002For Deleterious BRCA1\u002F2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)",[89],"2024-09-21","2019-04-16",[7573,7574,7575,7576,1429,1430,175,7577,176,214,215],"Deleterious BRCA1 Gene Mutation","Deleterious BRCA2 Gene Mutation","Loss of Heterozygosity","Lung Non-Small Cell Squamous Carcinoma","Recurrent Non-Squamous Non-Small Cell Lung Carcinoma",[7558],{"trials":7580,"activeCount":100},[],{"trials":7582,"activeCount":100},[],{"trials":7584,"activeCount":100},[],{"intervention":1999,"totalTrials":117,"cells":7586},{"EARLY_PHASE1":7587,"PHASE1":7589,"PHASE2":7591,"PHASE3":7597,"PHASE4":7599,"NA":7601},{"trials":7588,"activeCount":100},[],{"trials":7590,"activeCount":100},[],{"trials":7592,"activeCount":100},[7593],{"nctId":1992,"briefTitle":1993,"status":207,"phases":7594,"primaryCompletion":1333,"completion":628,"start":1995,"enrollment":1996,"conditions":7595,"interventions":7596},[89],[30],[1999,601],{"trials":7598,"activeCount":100},[],{"trials":7600,"activeCount":100},[],{"trials":7602,"activeCount":100},[],{"intervention":1266,"totalTrials":117,"cells":7604},{"EARLY_PHASE1":7605,"PHASE1":7607,"PHASE2":7609,"PHASE3":7615,"PHASE4":7617,"NA":7619},{"trials":7606,"activeCount":100},[],{"trials":7608,"activeCount":100},[],{"trials":7610,"activeCount":100},[7611],{"nctId":1258,"briefTitle":1259,"status":207,"phases":7612,"primaryCompletion":1261,"completion":1261,"start":1262,"enrollment":472,"conditions":7613,"interventions":7614},[89],[1032,1033,1264],[506,1266,611],{"trials":7616,"activeCount":100},[],{"trials":7618,"activeCount":100},[],{"trials":7620,"activeCount":100},[],{"intervention":7622,"totalTrials":117,"cells":7623},"suramin",{"EARLY_PHASE1":7624,"PHASE1":7626,"PHASE2":7628,"PHASE3":7638,"PHASE4":7640,"NA":7642},{"trials":7625,"activeCount":100},[],{"trials":7627,"activeCount":100},[],{"trials":7629,"activeCount":100},[7630],{"nctId":7631,"briefTitle":7632,"status":662,"phases":7633,"primaryCompletion":371,"completion":371,"start":2888,"enrollment":34,"conditions":7634,"interventions":7636},"NCT00002921","S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery",[89],[7635],"Adrenocortical Carcinoma",[7622,7637],"therapeutic hydrocortisone",{"trials":7639,"activeCount":100},[],{"trials":7641,"activeCount":100},[],{"trials":7643,"activeCount":100},[],{"intervention":7637,"totalTrials":117,"cells":7645},{"EARLY_PHASE1":7646,"PHASE1":7648,"PHASE2":7650,"PHASE3":7656,"PHASE4":7658,"NA":7660},{"trials":7647,"activeCount":100},[],{"trials":7649,"activeCount":100},[],{"trials":7651,"activeCount":100},[7652],{"nctId":7631,"briefTitle":7632,"status":662,"phases":7653,"primaryCompletion":371,"completion":371,"start":2888,"enrollment":34,"conditions":7654,"interventions":7655},[89],[7635],[7622,7637],{"trials":7657,"activeCount":100},[],{"trials":7659,"activeCount":100},[],{"trials":7661,"activeCount":100},[],{"intervention":7663,"totalTrials":117,"cells":7664},"GVAX lung cancer vaccine",{"EARLY_PHASE1":7665,"PHASE1":7667,"PHASE2":7669,"PHASE3":7677,"PHASE4":7679,"NA":7681},{"trials":7666,"activeCount":100},[],{"trials":7668,"activeCount":100},[],{"trials":7670,"activeCount":100},[7671],{"nctId":7672,"briefTitle":7673,"status":662,"phases":7674,"primaryCompletion":1373,"completion":1373,"start":711,"enrollment":746,"conditions":7675,"interventions":7676},"NCT00074295","S0310: Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Bronchoalveolar Lung Cancer",[89],[21],[7663],{"trials":7678,"activeCount":100},[],{"trials":7680,"activeCount":100},[],{"trials":7682,"activeCount":100},[],{"intervention":795,"totalTrials":117,"cells":7684},{"EARLY_PHASE1":7685,"PHASE1":7687,"PHASE2":7689,"PHASE3":7695,"PHASE4":7697,"NA":7699},{"trials":7686,"activeCount":100},[],{"trials":7688,"activeCount":100},[],{"trials":7690,"activeCount":100},[7691],{"nctId":784,"briefTitle":785,"status":207,"phases":7692,"primaryCompletion":787,"completion":788,"start":789,"enrollment":790,"conditions":7693,"interventions":7694},[89],[792,793],[795,250],{"trials":7696,"activeCount":100},[],{"trials":7698,"activeCount":100},[],{"trials":7700,"activeCount":100},[],{"intervention":7239,"totalTrials":117,"cells":7702},{"EARLY_PHASE1":7703,"PHASE1":7705,"PHASE2":7707,"PHASE3":7713,"PHASE4":7715,"NA":7717},{"trials":7704,"activeCount":100},[],{"trials":7706,"activeCount":100},[],{"trials":7708,"activeCount":100},[7709],{"nctId":7229,"briefTitle":7230,"status":207,"phases":7710,"primaryCompletion":7232,"completion":7233,"start":7234,"enrollment":7235,"conditions":7711,"interventions":7712},[89],[7237,4505,176,214,215],[1665,1245,7239],{"trials":7714,"activeCount":100},[],{"trials":7716,"activeCount":100},[],{"trials":7718,"activeCount":100},[],{"intervention":4273,"totalTrials":117,"cells":7720},{"EARLY_PHASE1":7721,"PHASE1":7723,"PHASE2":7725,"PHASE3":7731,"PHASE4":7733,"NA":7735},{"trials":7722,"activeCount":100},[],{"trials":7724,"activeCount":100},[],{"trials":7726,"activeCount":100},[7727],{"nctId":4268,"briefTitle":4269,"status":662,"phases":7728,"primaryCompletion":1391,"completion":1332,"start":1003,"enrollment":910,"conditions":7729,"interventions":7730},[89],[24],[4273,719,4259,4274],{"trials":7732,"activeCount":100},[],{"trials":7734,"activeCount":100},[],{"trials":7736,"activeCount":100},[],{"intervention":4274,"totalTrials":117,"cells":7738},{"EARLY_PHASE1":7739,"PHASE1":7741,"PHASE2":7743,"PHASE3":7749,"PHASE4":7751,"NA":7753},{"trials":7740,"activeCount":100},[],{"trials":7742,"activeCount":100},[],{"trials":7744,"activeCount":100},[7745],{"nctId":4268,"briefTitle":4269,"status":662,"phases":7746,"primaryCompletion":1391,"completion":1332,"start":1003,"enrollment":910,"conditions":7747,"interventions":7748},[89],[24],[4273,719,4259,4274],{"trials":7750,"activeCount":100},[],{"trials":7752,"activeCount":100},[],{"trials":7754,"activeCount":100},[],{"intervention":1288,"totalTrials":117,"cells":7756},{"EARLY_PHASE1":7757,"PHASE1":7759,"PHASE2":7761,"PHASE3":7767,"PHASE4":7769,"NA":7771},{"trials":7758,"activeCount":100},[],{"trials":7760,"activeCount":100},[],{"trials":7762,"activeCount":100},[7763],{"nctId":1280,"briefTitle":1281,"status":207,"phases":7764,"primaryCompletion":842,"completion":408,"start":390,"enrollment":16,"conditions":7765,"interventions":7766},[89],[27],[1285,1214,399,1286,1287,1288,1289,611],{"trials":7768,"activeCount":100},[],{"trials":7770,"activeCount":100},[],{"trials":7772,"activeCount":100},[],{"intervention":7774,"totalTrials":117,"cells":7775},"ABBV-399",{"EARLY_PHASE1":7776,"PHASE1":7778,"PHASE2":7780,"PHASE3":7792,"PHASE4":7794,"NA":7796},{"trials":7777,"activeCount":100},[],{"trials":7779,"activeCount":100},[],{"trials":7781,"activeCount":100},[7782],{"nctId":7783,"briefTitle":7784,"status":207,"phases":7785,"primaryCompletion":7786,"completion":7787,"start":7788,"enrollment":962,"conditions":7789,"interventions":7791},"NCT03574753","Lung-MAP S1400K: c-MET Positive",[89],"2019-12-21","2021-07-30","2018-03-16",[1147,7790],"Stage IV Squamous Cell Lung Carcinoma AJCC V7",[7774],{"trials":7793,"activeCount":100},[],{"trials":7795,"activeCount":100},[],{"trials":7797,"activeCount":100},[],{"intervention":7799,"totalTrials":117,"cells":7800},"Depsipeptide",{"EARLY_PHASE1":7801,"PHASE1":7803,"PHASE2":7805,"PHASE3":7813,"PHASE4":7815,"NA":7817},{"trials":7802,"activeCount":100},[],{"trials":7804,"activeCount":100},[],{"trials":7806,"activeCount":100},[7807],{"nctId":7808,"briefTitle":7809,"status":662,"phases":7810,"primaryCompletion":973,"completion":973,"start":994,"enrollment":1126,"conditions":7811,"interventions":7812},"NCT00087295","S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium",[89],[1315,1316,1317],[7799],{"trials":7814,"activeCount":100},[],{"trials":7816,"activeCount":100},[],{"trials":7818,"activeCount":100},[],{"intervention":7820,"totalTrials":117,"cells":7821},"D1\u002F3-MAGE-3-His fusion protein",{"EARLY_PHASE1":7822,"PHASE1":7824,"PHASE2":7826,"PHASE3":7835,"PHASE4":7837,"NA":7839},{"trials":7823,"activeCount":100},[],{"trials":7825,"activeCount":100},[],{"trials":7827,"activeCount":100},[7828],{"nctId":7829,"briefTitle":7830,"status":207,"phases":7831,"completion":712,"start":327,"conditions":7832,"interventions":7833},"NCT00042783","Vaccine Therapy in Treating Patients With Stage IV Melanoma",[89],[4242],[7820,7834],"SB-AS02B adjuvant",{"trials":7836,"activeCount":100},[],{"trials":7838,"activeCount":100},[],{"trials":7840,"activeCount":100},[],{"intervention":7834,"totalTrials":117,"cells":7842},{"EARLY_PHASE1":7843,"PHASE1":7845,"PHASE2":7847,"PHASE3":7853,"PHASE4":7855,"NA":7857},{"trials":7844,"activeCount":100},[],{"trials":7846,"activeCount":100},[],{"trials":7848,"activeCount":100},[7849],{"nctId":7829,"briefTitle":7830,"status":207,"phases":7850,"completion":712,"start":327,"conditions":7851,"interventions":7852},[89],[4242],[7820,7834],{"trials":7854,"activeCount":100},[],{"trials":7856,"activeCount":100},[],{"trials":7858,"activeCount":100},[],{"intervention":4968,"totalTrials":117,"cells":7860},{"EARLY_PHASE1":7861,"PHASE1":7863,"PHASE2":7865,"PHASE3":7871,"PHASE4":7873,"NA":7875},{"trials":7862,"activeCount":100},[],{"trials":7864,"activeCount":100},[],{"trials":7866,"activeCount":100},[7867],{"nctId":4963,"briefTitle":4964,"status":662,"phases":7868,"primaryCompletion":4175,"completion":408,"start":4213,"enrollment":34,"conditions":7869,"interventions":7870},[89],[33],[4968,506],{"trials":7872,"activeCount":100},[],{"trials":7874,"activeCount":100},[],{"trials":7876,"activeCount":100},[],{"intervention":1327,"totalTrials":117,"cells":7878},{"EARLY_PHASE1":7879,"PHASE1":7881,"PHASE2":7883,"PHASE3":7889,"PHASE4":7891,"NA":7893},{"trials":7880,"activeCount":100},[],{"trials":7882,"activeCount":100},[],{"trials":7884,"activeCount":100},[7885],{"nctId":1320,"briefTitle":1321,"status":207,"phases":7886,"primaryCompletion":1003,"completion":1010,"start":1295,"enrollment":1323,"conditions":7887,"interventions":7888},[89],[1325],[1327,668,611],{"trials":7890,"activeCount":100},[],{"trials":7892,"activeCount":100},[],{"trials":7894,"activeCount":100},[],{"intervention":7896,"totalTrials":117,"cells":7897},"hydroxyurea",{"EARLY_PHASE1":7898,"PHASE1":7900,"PHASE2":7902,"PHASE3":7912,"PHASE4":7914,"NA":7916},{"trials":7899,"activeCount":100},[],{"trials":7901,"activeCount":100},[],{"trials":7903,"activeCount":100},[7904],{"nctId":7905,"briefTitle":7906,"status":207,"phases":7907,"primaryCompletion":1382,"completion":408,"start":7908,"enrollment":4214,"conditions":7909,"interventions":7911},"NCT00003590","S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma",[89],"1998-11",[7910],"Adult Meningioma",[7896],{"trials":7913,"activeCount":100},[],{"trials":7915,"activeCount":100},[],{"trials":7917,"activeCount":100},[],{"intervention":7919,"totalTrials":117,"cells":7920},"anti-CCR2 monoclonal antibody MLN1202",{"EARLY_PHASE1":7921,"PHASE1":7923,"PHASE2":7925,"PHASE3":7934,"PHASE4":7936,"NA":7938},{"trials":7922,"activeCount":100},[],{"trials":7924,"activeCount":100},[],{"trials":7926,"activeCount":100},[7927],{"nctId":7928,"briefTitle":7929,"status":207,"phases":7930,"primaryCompletion":469,"completion":469,"start":616,"enrollment":1636,"conditions":7931,"interventions":7932},"NCT01015560","S0916, MLN1202 in Treating Patients With Bone Metastases",[89],[1157,984],[7919,7933],"polymorphism analysis",{"trials":7935,"activeCount":100},[],{"trials":7937,"activeCount":100},[],{"trials":7939,"activeCount":100},[],{"intervention":2039,"totalTrials":117,"cells":7941},{"EARLY_PHASE1":7942,"PHASE1":7944,"PHASE2":7946,"PHASE3":7952,"PHASE4":7954,"NA":7956},{"trials":7943,"activeCount":100},[],{"trials":7945,"activeCount":100},[],{"trials":7947,"activeCount":100},[7948],{"nctId":2030,"briefTitle":2031,"status":207,"phases":7949,"primaryCompletion":2033,"completion":995,"start":2034,"enrollment":2035,"conditions":7950,"interventions":7951},[89],[2037],[2039,601,400,2040],{"trials":7953,"activeCount":100},[],{"trials":7955,"activeCount":100},[],{"trials":7957,"activeCount":100},[],{"intervention":2040,"totalTrials":117,"cells":7959},{"EARLY_PHASE1":7960,"PHASE1":7962,"PHASE2":7964,"PHASE3":7970,"PHASE4":7972,"NA":7974},{"trials":7961,"activeCount":100},[],{"trials":7963,"activeCount":100},[],{"trials":7965,"activeCount":100},[7966],{"nctId":2030,"briefTitle":2031,"status":207,"phases":7967,"primaryCompletion":2033,"completion":995,"start":2034,"enrollment":2035,"conditions":7968,"interventions":7969},[89],[2037],[2039,601,400,2040],{"trials":7971,"activeCount":100},[],{"trials":7973,"activeCount":100},[],{"trials":7975,"activeCount":100},[],{"intervention":438,"totalTrials":117,"cells":7977},{"EARLY_PHASE1":7978,"PHASE1":7980,"PHASE2":7982,"PHASE3":7988,"PHASE4":7990,"NA":7992},{"trials":7979,"activeCount":100},[],{"trials":7981,"activeCount":100},[],{"trials":7983,"activeCount":100},[7984],{"nctId":428,"briefTitle":429,"status":207,"phases":7985,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":7986,"interventions":7987},[89],[18,436],[414,330,438,439,294,440,349,399,317,441,442,316],{"trials":7989,"activeCount":100},[],{"trials":7991,"activeCount":100},[],{"trials":7993,"activeCount":100},[],{"intervention":439,"totalTrials":117,"cells":7995},{"EARLY_PHASE1":7996,"PHASE1":7998,"PHASE2":8000,"PHASE3":8006,"PHASE4":8008,"NA":8010},{"trials":7997,"activeCount":100},[],{"trials":7999,"activeCount":100},[],{"trials":8001,"activeCount":100},[8002],{"nctId":428,"briefTitle":429,"status":207,"phases":8003,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":8004,"interventions":8005},[89],[18,436],[414,330,438,439,294,440,349,399,317,441,442,316],{"trials":8007,"activeCount":100},[],{"trials":8009,"activeCount":100},[],{"trials":8011,"activeCount":100},[],{"intervention":441,"totalTrials":117,"cells":8013},{"EARLY_PHASE1":8014,"PHASE1":8016,"PHASE2":8018,"PHASE3":8024,"PHASE4":8026,"NA":8028},{"trials":8015,"activeCount":100},[],{"trials":8017,"activeCount":100},[],{"trials":8019,"activeCount":100},[8020],{"nctId":428,"briefTitle":429,"status":207,"phases":8021,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":8022,"interventions":8023},[89],[18,436],[414,330,438,439,294,440,349,399,317,441,442,316],{"trials":8025,"activeCount":100},[],{"trials":8027,"activeCount":100},[],{"trials":8029,"activeCount":100},[],{"intervention":442,"totalTrials":117,"cells":8031},{"EARLY_PHASE1":8032,"PHASE1":8034,"PHASE2":8036,"PHASE3":8042,"PHASE4":8044,"NA":8046},{"trials":8033,"activeCount":100},[],{"trials":8035,"activeCount":100},[],{"trials":8037,"activeCount":100},[8038],{"nctId":428,"briefTitle":429,"status":207,"phases":8039,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":8040,"interventions":8041},[89],[18,436],[414,330,438,439,294,440,349,399,317,441,442,316],{"trials":8043,"activeCount":100},[],{"trials":8045,"activeCount":100},[],{"trials":8047,"activeCount":100},[],{"intervention":6982,"totalTrials":117,"cells":8049},{"EARLY_PHASE1":8050,"PHASE1":8052,"PHASE2":8054,"PHASE3":8060,"PHASE4":8062,"NA":8064},{"trials":8051,"activeCount":100},[],{"trials":8053,"activeCount":100},[],{"trials":8055,"activeCount":100},[8056],{"nctId":6974,"briefTitle":6975,"status":207,"phases":8057,"primaryCompletion":6977,"completion":6978,"start":6979,"enrollment":11,"conditions":8058,"interventions":8059},[89],[24],[332,6982,6983],{"trials":8061,"activeCount":100},[],{"trials":8063,"activeCount":100},[],{"trials":8065,"activeCount":100},[],{"intervention":6983,"totalTrials":117,"cells":8067},{"EARLY_PHASE1":8068,"PHASE1":8070,"PHASE2":8072,"PHASE3":8078,"PHASE4":8080,"NA":8082},{"trials":8069,"activeCount":100},[],{"trials":8071,"activeCount":100},[],{"trials":8073,"activeCount":100},[8074],{"nctId":6974,"briefTitle":6975,"status":207,"phases":8075,"primaryCompletion":6977,"completion":6978,"start":6979,"enrollment":11,"conditions":8076,"interventions":8077},[89],[24],[332,6982,6983],{"trials":8079,"activeCount":100},[],{"trials":8081,"activeCount":100},[],{"trials":8083,"activeCount":100},[],{"intervention":8085,"totalTrials":117,"cells":8086},"alvocidib",{"EARLY_PHASE1":8087,"PHASE1":8089,"PHASE2":8091,"PHASE3":8099,"PHASE4":8101,"NA":8103},{"trials":8088,"activeCount":100},[],{"trials":8090,"activeCount":100},[],{"trials":8092,"activeCount":100},[8093],{"nctId":8094,"briefTitle":8095,"status":207,"phases":8096,"completion":973,"start":738,"conditions":8097,"interventions":8098},"NCT00016939","Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer",[89],[2839],[8085],{"trials":8100,"activeCount":100},[],{"trials":8102,"activeCount":100},[],{"trials":8104,"activeCount":100},[],{"intervention":8106,"totalTrials":117,"cells":8107},"recombinant modified vaccinia Ankara-5T4 vaccine",{"EARLY_PHASE1":8108,"PHASE1":8110,"PHASE2":8112,"PHASE3":8120,"PHASE4":8122,"NA":8124},{"trials":8109,"activeCount":100},[],{"trials":8111,"activeCount":100},[],{"trials":8113,"activeCount":100},[8114],{"nctId":8115,"briefTitle":8116,"status":241,"phases":8117,"enrollment":100,"conditions":8118,"interventions":8119},"NCT00227474","S0348 Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Breast Cancer in Remission",[89],[15],[8106],{"trials":8121,"activeCount":100},[],{"trials":8123,"activeCount":100},[],{"trials":8125,"activeCount":100},[],{"intervention":8127,"totalTrials":117,"cells":8128},"fenretinide",{"EARLY_PHASE1":8129,"PHASE1":8131,"PHASE2":8133,"PHASE3":8143,"PHASE4":8145,"NA":8147},{"trials":8130,"activeCount":100},[],{"trials":8132,"activeCount":100},[],{"trials":8134,"activeCount":100},[8135],{"nctId":8136,"briefTitle":8137,"status":662,"phases":8138,"primaryCompletion":8139,"completion":8139,"start":8140,"enrollment":910,"conditions":8141,"interventions":8142},"NCT00003223","SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth",[89],"2000-03","1997-12",[33],[8127],{"trials":8144,"activeCount":100},[],{"trials":8146,"activeCount":100},[],{"trials":8148,"activeCount":100},[],{"intervention":5716,"totalTrials":117,"cells":8150},{"EARLY_PHASE1":8151,"PHASE1":8153,"PHASE2":8155,"PHASE3":8161,"PHASE4":8163,"NA":8165},{"trials":8152,"activeCount":100},[],{"trials":8154,"activeCount":100},[],{"trials":8156,"activeCount":100},[8157],{"nctId":5710,"briefTitle":5711,"status":207,"phases":8158,"primaryCompletion":1041,"completion":995,"start":5108,"enrollment":5713,"conditions":8159,"interventions":8160},[89],[24,716],[5716,719],{"trials":8162,"activeCount":100},[],{"trials":8164,"activeCount":100},[],{"trials":8166,"activeCount":100},[],{"intervention":3931,"totalTrials":117,"cells":8168},{"EARLY_PHASE1":8169,"PHASE1":8171,"PHASE2":8173,"PHASE3":8179,"PHASE4":8181,"NA":8183},{"trials":8170,"activeCount":100},[],{"trials":8172,"activeCount":100},[],{"trials":8174,"activeCount":100},[8175],{"nctId":3925,"briefTitle":3926,"status":662,"phases":8176,"primaryCompletion":3928,"completion":3928,"start":531,"enrollment":158,"conditions":8177,"interventions":8178},[89],[21],[3931,3932,506,399],{"trials":8180,"activeCount":100},[],{"trials":8182,"activeCount":100},[],{"trials":8184,"activeCount":100},[],{"intervention":3932,"totalTrials":117,"cells":8186},{"EARLY_PHASE1":8187,"PHASE1":8189,"PHASE2":8191,"PHASE3":8197,"PHASE4":8199,"NA":8201},{"trials":8188,"activeCount":100},[],{"trials":8190,"activeCount":100},[],{"trials":8192,"activeCount":100},[8193],{"nctId":3925,"briefTitle":3926,"status":662,"phases":8194,"primaryCompletion":3928,"completion":3928,"start":531,"enrollment":158,"conditions":8195,"interventions":8196},[89],[21],[3931,3932,506,399],{"trials":8198,"activeCount":100},[],{"trials":8200,"activeCount":100},[],{"trials":8202,"activeCount":100},[],{"intervention":6997,"totalTrials":117,"cells":8204},{"EARLY_PHASE1":8205,"PHASE1":8207,"PHASE2":8209,"PHASE3":8215,"PHASE4":8217,"NA":8219},{"trials":8206,"activeCount":100},[],{"trials":8208,"activeCount":100},[],{"trials":8210,"activeCount":100},[8211],{"nctId":6989,"briefTitle":6990,"status":207,"phases":8212,"primaryCompletion":6992,"completion":6993,"start":2522,"enrollment":6994,"conditions":8213,"interventions":8214},[89],[24],[6997,6998,332],{"trials":8216,"activeCount":100},[],{"trials":8218,"activeCount":100},[],{"trials":8220,"activeCount":100},[],{"intervention":1352,"totalTrials":117,"cells":8222},{"EARLY_PHASE1":8223,"PHASE1":8225,"PHASE2":8227,"PHASE3":8233,"PHASE4":8235,"NA":8237},{"trials":8224,"activeCount":100},[],{"trials":8226,"activeCount":100},[],{"trials":8228,"activeCount":100},[8229],{"nctId":1346,"briefTitle":1347,"status":207,"phases":8230,"primaryCompletion":711,"completion":1011,"start":1210,"enrollment":1349,"conditions":8231,"interventions":8232},[89],[21],[330,668,611,1352],{"trials":8234,"activeCount":100},[],{"trials":8236,"activeCount":100},[],{"trials":8238,"activeCount":100},[],{"intervention":547,"totalTrials":117,"cells":8240},{"EARLY_PHASE1":8241,"PHASE1":8243,"PHASE2":8245,"PHASE3":8251,"PHASE4":8253,"NA":8255},{"trials":8242,"activeCount":100},[],{"trials":8244,"activeCount":100},[],{"trials":8246,"activeCount":100},[8247],{"nctId":538,"briefTitle":539,"status":207,"phases":8248,"primaryCompletion":541,"completion":542,"start":543,"enrollment":544,"conditions":8249,"interventions":8250},[89],[18],[331,547,294,334,317,337],{"trials":8252,"activeCount":100},[],{"trials":8254,"activeCount":100},[],{"trials":8256,"activeCount":100},[],{"intervention":2049,"totalTrials":117,"cells":8258},{"EARLY_PHASE1":8259,"PHASE1":8261,"PHASE2":8263,"PHASE3":8269,"PHASE4":8271,"NA":8273},{"trials":8260,"activeCount":100},[],{"trials":8262,"activeCount":100},[],{"trials":8264,"activeCount":100},[8265],{"nctId":2042,"briefTitle":2043,"status":662,"phases":8266,"primaryCompletion":2045,"completion":1048,"start":2046,"enrollment":472,"conditions":8267,"interventions":8268},[89],[33],[2049,506,601],{"trials":8270,"activeCount":100},[],{"trials":8272,"activeCount":100},[],{"trials":8274,"activeCount":100},[],{"intervention":8276,"totalTrials":117,"cells":8277},"Isatuximab",{"EARLY_PHASE1":8278,"PHASE1":8280,"PHASE2":8282,"PHASE3":8306,"PHASE4":8308,"NA":8310},{"trials":8279,"activeCount":100},[],{"trials":8281,"activeCount":100},[],{"trials":8283,"activeCount":100},[8284],{"nctId":8285,"briefTitle":8286,"status":207,"phases":8287,"primaryCompletion":8288,"completion":8289,"start":8290,"enrollment":1171,"conditions":8291,"interventions":8305},"NCT03499808","S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis",[89],"2023-08-30","2023-09-19","2018-06-06",[8292,8293,8294,8295,8296,8297,8298,8299,8300,8301,8302,8303,8304],"Amorphous, Eosinophilic, and Acellular Deposit","Constipation","Diarrhea","Early Satiety","Gastrointestinal Hemorrhage","Hepatomegaly","Lymphadenopathy","Macroglossia","Nausea","Primary Systemic Amyloidosis","Purpura","Recurrent Primary Amyloidosis","Refractory Primary Amyloidosis",[8276],{"trials":8307,"activeCount":100},[],{"trials":8309,"activeCount":100},[],{"trials":8311,"activeCount":100},[],{"intervention":2577,"totalTrials":117,"cells":8313},{"EARLY_PHASE1":8314,"PHASE1":8316,"PHASE2":8318,"PHASE3":8324,"PHASE4":8326,"NA":8328},{"trials":8315,"activeCount":100},[],{"trials":8317,"activeCount":100},[],{"trials":8319,"activeCount":100},[8320],{"nctId":2572,"briefTitle":2573,"status":662,"phases":8321,"primaryCompletion":1067,"completion":1312,"start":1060,"enrollment":117,"conditions":8322,"interventions":8323},[89],[18],[2577,363,336,2578],{"trials":8325,"activeCount":100},[],{"trials":8327,"activeCount":100},[],{"trials":8329,"activeCount":100},[],{"intervention":2578,"totalTrials":117,"cells":8331},{"EARLY_PHASE1":8332,"PHASE1":8334,"PHASE2":8336,"PHASE3":8342,"PHASE4":8344,"NA":8346},{"trials":8333,"activeCount":100},[],{"trials":8335,"activeCount":100},[],{"trials":8337,"activeCount":100},[8338],{"nctId":2572,"briefTitle":2573,"status":662,"phases":8339,"primaryCompletion":1067,"completion":1312,"start":1060,"enrollment":117,"conditions":8340,"interventions":8341},[89],[18],[2577,363,336,2578],{"trials":8343,"activeCount":100},[],{"trials":8345,"activeCount":100},[],{"trials":8347,"activeCount":100},[],{"intervention":835,"totalTrials":117,"cells":8349},{"EARLY_PHASE1":8350,"PHASE1":8352,"PHASE2":8354,"PHASE3":8360,"PHASE4":8362,"NA":8364},{"trials":8351,"activeCount":100},[],{"trials":8353,"activeCount":100},[],{"trials":8355,"activeCount":100},[8356],{"nctId":823,"briefTitle":824,"status":207,"phases":8357,"primaryCompletion":826,"completion":827,"start":828,"enrollment":829,"conditions":8358,"interventions":8359},[88,89],[831,832,833],[759,250,835,836],{"trials":8361,"activeCount":100},[],{"trials":8363,"activeCount":100},[],{"trials":8365,"activeCount":100},[],{"intervention":2163,"totalTrials":117,"cells":8367},{"EARLY_PHASE1":8368,"PHASE1":8370,"PHASE2":8372,"PHASE3":8378,"PHASE4":8380,"NA":8382},{"trials":8369,"activeCount":100},[],{"trials":8371,"activeCount":100},[],{"trials":8373,"activeCount":100},[8374],{"nctId":2156,"briefTitle":2157,"status":207,"phases":8375,"primaryCompletion":2159,"completion":492,"start":2160,"enrollment":19,"conditions":8376,"interventions":8377},[89],[18],[506,399,1082,2163],{"trials":8379,"activeCount":100},[],{"trials":8381,"activeCount":100},[],{"trials":8383,"activeCount":100},[],{"intervention":2058,"totalTrials":117,"cells":8385},{"EARLY_PHASE1":8386,"PHASE1":8388,"PHASE2":8390,"PHASE3":8396,"PHASE4":8398,"NA":8400},{"trials":8387,"activeCount":100},[],{"trials":8389,"activeCount":100},[],{"trials":8391,"activeCount":100},[8392],{"nctId":2051,"briefTitle":2052,"status":241,"phases":8393,"primaryCompletion":2054,"start":2055,"enrollment":100,"conditions":8394,"interventions":8395},[89],[30],[517,601,1116,400,1117,2058],{"trials":8397,"activeCount":100},[],{"trials":8399,"activeCount":100},[],{"trials":8401,"activeCount":100},[],{"intervention":566,"totalTrials":117,"cells":8403},{"EARLY_PHASE1":8404,"PHASE1":8406,"PHASE2":8408,"PHASE3":8414,"PHASE4":8416,"NA":8418},{"trials":8405,"activeCount":100},[],{"trials":8407,"activeCount":100},[],{"trials":8409,"activeCount":100},[8410],{"nctId":559,"briefTitle":560,"status":207,"phases":8411,"primaryCompletion":407,"completion":408,"start":562,"enrollment":563,"conditions":8412,"interventions":8413},[89],[18],[414,330,294,332,349,399,400,336,317,566,316,567],{"trials":8415,"activeCount":100},[],{"trials":8417,"activeCount":100},[],{"trials":8419,"activeCount":100},[],{"intervention":567,"totalTrials":117,"cells":8421},{"EARLY_PHASE1":8422,"PHASE1":8424,"PHASE2":8426,"PHASE3":8432,"PHASE4":8434,"NA":8436},{"trials":8423,"activeCount":100},[],{"trials":8425,"activeCount":100},[],{"trials":8427,"activeCount":100},[8428],{"nctId":559,"briefTitle":560,"status":207,"phases":8429,"primaryCompletion":407,"completion":408,"start":562,"enrollment":563,"conditions":8430,"interventions":8431},[89],[18],[414,330,294,332,349,399,400,336,317,566,316,567],{"trials":8433,"activeCount":100},[],{"trials":8435,"activeCount":100},[],{"trials":8437,"activeCount":100},[],{"intervention":8439,"totalTrials":117,"cells":8440},"romidepsin",{"EARLY_PHASE1":8441,"PHASE1":8443,"PHASE2":8445,"PHASE3":8453,"PHASE4":8455,"NA":8457},{"trials":8442,"activeCount":100},[],{"trials":8444,"activeCount":100},[],{"trials":8446,"activeCount":100},[8447],{"nctId":8448,"briefTitle":8449,"status":207,"phases":8450,"completion":973,"start":2045,"conditions":8451,"interventions":8452},"NCT00077337","FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer",[89],[30],[8439],{"trials":8454,"activeCount":100},[],{"trials":8456,"activeCount":100},[],{"trials":8458,"activeCount":100},[],{"intervention":2066,"totalTrials":117,"cells":8460},{"EARLY_PHASE1":8461,"PHASE1":8463,"PHASE2":8465,"PHASE3":8471,"PHASE4":8473,"NA":8475},{"trials":8462,"activeCount":100},[],{"trials":8464,"activeCount":100},[],{"trials":8466,"activeCount":100},[8467],{"nctId":2060,"briefTitle":2061,"status":207,"phases":8468,"primaryCompletion":995,"completion":995,"start":2063,"enrollment":1366,"conditions":8469,"interventions":8470},[89],[1112,1113],[601,400,2066],{"trials":8472,"activeCount":100},[],{"trials":8474,"activeCount":100},[],{"trials":8476,"activeCount":100},[],{"intervention":1534,"totalTrials":117,"cells":8478},{"EARLY_PHASE1":8479,"PHASE1":8481,"PHASE2":8483,"PHASE3":8489,"PHASE4":8491,"NA":8493},{"trials":8480,"activeCount":100},[],{"trials":8482,"activeCount":100},[],{"trials":8484,"activeCount":100},[8485],{"nctId":1526,"briefTitle":1527,"status":207,"phases":8486,"primaryCompletion":1529,"completion":1530,"start":1531,"enrollment":16,"conditions":8487,"interventions":8488},[89],[27],[1534,694],{"trials":8490,"activeCount":100},[],{"trials":8492,"activeCount":100},[],{"trials":8494,"activeCount":100},[],{"intervention":5137,"totalTrials":117,"cells":8496},{"EARLY_PHASE1":8497,"PHASE1":8499,"PHASE2":8501,"PHASE3":8507,"PHASE4":8509,"NA":8511},{"trials":8498,"activeCount":100},[],{"trials":8500,"activeCount":100},[],{"trials":8502,"activeCount":100},[8503],{"nctId":5132,"briefTitle":5133,"status":207,"phases":8504,"primaryCompletion":738,"completion":712,"start":713,"enrollment":8,"conditions":8505,"interventions":8506},[89],[24],[330,362,332,398,5137],{"trials":8508,"activeCount":100},[],{"trials":8510,"activeCount":100},[],{"trials":8512,"activeCount":100},[],{"intervention":7191,"totalTrials":117,"cells":8514},{"EARLY_PHASE1":8515,"PHASE1":8517,"PHASE2":8519,"PHASE3":8525,"PHASE4":8527,"NA":8529},{"trials":8516,"activeCount":100},[],{"trials":8518,"activeCount":100},[],{"trials":8520,"activeCount":100},[8521],{"nctId":7182,"briefTitle":7183,"status":662,"phases":8522,"primaryCompletion":725,"completion":725,"start":5864,"enrollment":117,"conditions":8523,"interventions":8524},[89],[7186,7187,7188,7189],[7191,7163],{"trials":8526,"activeCount":100},[],{"trials":8528,"activeCount":100},[],{"trials":8530,"activeCount":100},[],{"intervention":251,"totalTrials":117,"cells":8532},{"EARLY_PHASE1":8533,"PHASE1":8535,"PHASE2":8537,"PHASE3":8543,"PHASE4":8545,"NA":8547},{"trials":8534,"activeCount":100},[],{"trials":8536,"activeCount":100},[],{"trials":8538,"activeCount":100},[8539],{"nctId":239,"briefTitle":240,"status":241,"phases":8540,"primaryCompletion":243,"completion":244,"start":245,"enrollment":100,"conditions":8541,"interventions":8542},[89],[247,248,176,214,215],[250,217,157,251],{"trials":8544,"activeCount":100},[],{"trials":8546,"activeCount":100},[],{"trials":8548,"activeCount":100},[],{"intervention":1115,"totalTrials":117,"cells":8550},{"EARLY_PHASE1":8551,"PHASE1":8553,"PHASE2":8555,"PHASE3":8561,"PHASE4":8563,"NA":8565},{"trials":8552,"activeCount":100},[],{"trials":8554,"activeCount":100},[],{"trials":8556,"activeCount":100},[8557],{"nctId":1104,"briefTitle":1105,"status":207,"phases":8558,"primaryCompletion":1107,"completion":1108,"start":737,"enrollment":1109,"conditions":8559,"interventions":8560},[89],[1111,1112,1113],[1115,961,601,1116,400,1117],{"trials":8562,"activeCount":100},[],{"trials":8564,"activeCount":100},[],{"trials":8566,"activeCount":100},[],{"intervention":585,"totalTrials":117,"cells":8568},{"EARLY_PHASE1":8569,"PHASE1":8571,"PHASE2":8573,"PHASE3":8579,"PHASE4":8581,"NA":8583},{"trials":8570,"activeCount":100},[],{"trials":8572,"activeCount":100},[],{"trials":8574,"activeCount":100},[8575],{"nctId":578,"briefTitle":579,"status":207,"phases":8576,"primaryCompletion":342,"completion":552,"start":581,"enrollment":582,"conditions":8577,"interventions":8578},[89],[24],[330,294,332,585,333,334,335,401,336,586,587,317,402,337,588,589],{"trials":8580,"activeCount":100},[],{"trials":8582,"activeCount":100},[],{"trials":8584,"activeCount":100},[],{"intervention":588,"totalTrials":117,"cells":8586},{"EARLY_PHASE1":8587,"PHASE1":8589,"PHASE2":8591,"PHASE3":8597,"PHASE4":8599,"NA":8601},{"trials":8588,"activeCount":100},[],{"trials":8590,"activeCount":100},[],{"trials":8592,"activeCount":100},[8593],{"nctId":578,"briefTitle":579,"status":207,"phases":8594,"primaryCompletion":342,"completion":552,"start":581,"enrollment":582,"conditions":8595,"interventions":8596},[89],[24],[330,294,332,585,333,334,335,401,336,586,587,317,402,337,588,589],{"trials":8598,"activeCount":100},[],{"trials":8600,"activeCount":100},[],{"trials":8602,"activeCount":100},[],{"intervention":589,"totalTrials":117,"cells":8604},{"EARLY_PHASE1":8605,"PHASE1":8607,"PHASE2":8609,"PHASE3":8615,"PHASE4":8617,"NA":8619},{"trials":8606,"activeCount":100},[],{"trials":8608,"activeCount":100},[],{"trials":8610,"activeCount":100},[8611],{"nctId":578,"briefTitle":579,"status":207,"phases":8612,"primaryCompletion":342,"completion":552,"start":581,"enrollment":582,"conditions":8613,"interventions":8614},[89],[24],[330,294,332,585,333,334,335,401,336,586,587,317,402,337,588,589],{"trials":8616,"activeCount":100},[],{"trials":8618,"activeCount":100},[],{"trials":8620,"activeCount":100},[],{"intervention":4054,"totalTrials":117,"cells":8622},{"EARLY_PHASE1":8623,"PHASE1":8625,"PHASE2":8627,"PHASE3":8633,"PHASE4":8635,"NA":8637},{"trials":8624,"activeCount":100},[],{"trials":8626,"activeCount":100},[],{"trials":8628,"activeCount":100},[8629],{"nctId":4046,"briefTitle":4047,"status":207,"phases":8630,"primaryCompletion":4049,"completion":4050,"start":552,"enrollment":4051,"conditions":8631,"interventions":8632},[89],[30],[977,1116,4054],{"trials":8634,"activeCount":100},[],{"trials":8636,"activeCount":100},[],{"trials":8638,"activeCount":100},[],{"intervention":600,"totalTrials":117,"cells":8640},{"EARLY_PHASE1":8641,"PHASE1":8643,"PHASE2":8645,"PHASE3":8651,"PHASE4":8653,"NA":8655},{"trials":8642,"activeCount":100},[],{"trials":8644,"activeCount":100},[],{"trials":8646,"activeCount":100},[8647],{"nctId":591,"briefTitle":592,"status":207,"phases":8648,"primaryCompletion":594,"completion":531,"start":595,"enrollment":596,"conditions":8649,"interventions":8650},[89],[598],[600,294,601,336],{"trials":8652,"activeCount":100},[],{"trials":8654,"activeCount":100},[],{"trials":8656,"activeCount":100},[],{"intervention":8658,"totalTrials":117,"cells":8659},"gefitinib",{"EARLY_PHASE1":8660,"PHASE1":8662,"PHASE2":8664,"PHASE3":8673,"PHASE4":8675,"NA":8677},{"trials":8661,"activeCount":100},[],{"trials":8663,"activeCount":100},[],{"trials":8665,"activeCount":100},[8666],{"nctId":8667,"briefTitle":8668,"status":207,"phases":8669,"primaryCompletion":3928,"completion":1124,"start":2063,"enrollment":8670,"conditions":8671,"interventions":8672},"NCT00014144","S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract",[89],31,[1315,1316,1317],[8658],{"trials":8674,"activeCount":100},[],{"trials":8676,"activeCount":100},[],{"trials":8678,"activeCount":100},[],{"intervention":2271,"totalTrials":117,"cells":8680},{"EARLY_PHASE1":8681,"PHASE1":8683,"PHASE2":8685,"PHASE3":8691,"PHASE4":8693,"NA":8695},{"trials":8682,"activeCount":100},[],{"trials":8684,"activeCount":100},[],{"trials":8686,"activeCount":100},[8687],{"nctId":2262,"briefTitle":2263,"status":207,"phases":8688,"primaryCompletion":2265,"completion":2266,"start":2267,"enrollment":2268,"conditions":8689,"interventions":8690},[88,89],[2110],[2271,2015,193,191,1129],{"trials":8692,"activeCount":100},[],{"trials":8694,"activeCount":100},[],{"trials":8696,"activeCount":100},[],{"intervention":8698,"totalTrials":117,"cells":8699},"BMS-247550",{"EARLY_PHASE1":8700,"PHASE1":8702,"PHASE2":8711,"PHASE3":8713,"PHASE4":8715,"NA":8717},{"trials":8701,"activeCount":100},[],{"trials":8703,"activeCount":100},[8704],{"nctId":8705,"briefTitle":8706,"status":207,"phases":8707,"primaryCompletion":736,"completion":1124,"start":628,"enrollment":1393,"conditions":8708,"interventions":8710},"NCT00049400","S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction",[88],[18,8709,984],"Small Intestine Cancer",[8698],{"trials":8712,"activeCount":100},[],{"trials":8714,"activeCount":100},[],{"trials":8716,"activeCount":100},[],{"trials":8718,"activeCount":100},[],{"intervention":318,"totalTrials":117,"cells":8720},{"EARLY_PHASE1":8721,"PHASE1":8723,"PHASE2":8729,"PHASE3":8731,"PHASE4":8733,"NA":8735},{"trials":8722,"activeCount":100},[],{"trials":8724,"activeCount":100},[8725],{"nctId":302,"briefTitle":303,"status":207,"phases":8726,"primaryCompletion":305,"completion":306,"start":307,"enrollment":308,"conditions":8727,"interventions":8728},[88],[310,311,312,313,314],[294,316,317,318],{"trials":8730,"activeCount":100},[],{"trials":8732,"activeCount":100},[],{"trials":8734,"activeCount":100},[],{"trials":8736,"activeCount":100},[],{"intervention":2818,"totalTrials":117,"cells":8738},{"EARLY_PHASE1":8739,"PHASE1":8741,"PHASE2":8747,"PHASE3":8749,"PHASE4":8751,"NA":8753},{"trials":8740,"activeCount":100},[],{"trials":8742,"activeCount":100},[8743],{"nctId":2812,"briefTitle":2813,"status":207,"phases":8744,"primaryCompletion":1373,"completion":2815,"start":736,"enrollment":200,"conditions":8745,"interventions":8746},[88],[18,984],[2313,2818],{"trials":8748,"activeCount":100},[],{"trials":8750,"activeCount":100},[],{"trials":8752,"activeCount":100},[],{"trials":8754,"activeCount":100},[],{"intervention":8756,"totalTrials":117,"cells":8757},"KLH",{"EARLY_PHASE1":8758,"PHASE1":8760,"PHASE2":8770,"PHASE3":8772,"PHASE4":8774,"NA":8776},{"trials":8759,"activeCount":100},[],{"trials":8761,"activeCount":100},[8762],{"nctId":8763,"briefTitle":8764,"status":662,"phases":8765,"primaryCompletion":1011,"completion":1011,"start":7370,"enrollment":31,"conditions":8766,"interventions":8768},"NCT00023634","S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer",[88],[8767,1113,1033,27],"Brain Tumors",[8756,8769],"GMCSF",{"trials":8771,"activeCount":100},[],{"trials":8773,"activeCount":100},[],{"trials":8775,"activeCount":100},[],{"trials":8777,"activeCount":100},[],{"intervention":8769,"totalTrials":117,"cells":8779},{"EARLY_PHASE1":8780,"PHASE1":8782,"PHASE2":8788,"PHASE3":8790,"PHASE4":8792,"NA":8794},{"trials":8781,"activeCount":100},[],{"trials":8783,"activeCount":100},[8784],{"nctId":8763,"briefTitle":8764,"status":662,"phases":8785,"primaryCompletion":1011,"completion":1011,"start":7370,"enrollment":31,"conditions":8786,"interventions":8787},[88],[8767,1113,1033,27],[8756,8769],{"trials":8789,"activeCount":100},[],{"trials":8791,"activeCount":100},[],{"trials":8793,"activeCount":100},[],{"trials":8795,"activeCount":100},[],{"intervention":8797,"totalTrials":117,"cells":8798},"pazopanib hydrochloride",{"EARLY_PHASE1":8799,"PHASE1":8801,"PHASE2":8810,"PHASE3":8812,"PHASE4":8814,"NA":8816},{"trials":8800,"activeCount":100},[],{"trials":8802,"activeCount":100},[8803],{"nctId":8804,"briefTitle":8805,"status":241,"phases":8806,"enrollment":100,"conditions":8807,"interventions":8808},"NCT00788580","S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors",[88],[984],[8797,8809],"temsirolimus",{"trials":8811,"activeCount":100},[],{"trials":8813,"activeCount":100},[],{"trials":8815,"activeCount":100},[],{"trials":8817,"activeCount":100},[],{"intervention":8809,"totalTrials":117,"cells":8819},{"EARLY_PHASE1":8820,"PHASE1":8822,"PHASE2":8828,"PHASE3":8830,"PHASE4":8832,"NA":8834},{"trials":8821,"activeCount":100},[],{"trials":8823,"activeCount":100},[8824],{"nctId":8804,"briefTitle":8805,"status":241,"phases":8825,"enrollment":100,"conditions":8826,"interventions":8827},[88],[984],[8797,8809],{"trials":8829,"activeCount":100},[],{"trials":8831,"activeCount":100},[],{"trials":8833,"activeCount":100},[],{"trials":8835,"activeCount":100},[],{"intervention":575,"totalTrials":703,"cells":8837},{"EARLY_PHASE1":8838,"PHASE1":8840,"PHASE2":8842,"PHASE3":8848,"PHASE4":8850,"NA":8852},{"trials":8839,"activeCount":100},[],{"trials":8841,"activeCount":100},[],{"trials":8843,"activeCount":100},[8844],{"nctId":569,"briefTitle":570,"status":241,"phases":8845,"primaryCompletion":408,"completion":408,"start":408,"enrollment":100,"conditions":8846,"interventions":8847},[89],[36,374],[475,506,294,333,349,399,574,363,364,575,576],{"trials":8849,"activeCount":100},[],{"trials":8851,"activeCount":100},[],{"trials":8853,"activeCount":100},[8854,8860,8868,8879,8889,8898,8906,8913,8921,8930],{"nctId":8855,"briefTitle":8856,"status":207,"phases":8857,"primaryCompletion":2054,"completion":4037,"start":810,"enrollment":9,"conditions":8858,"interventions":8859},"NCT00898183","S9431: Studying Genes and Immune Response in Tumor Samples From Patients With Locally Advanced or Metastatic Melanoma",[],[4242],[575,7933],{"nctId":8861,"briefTitle":8862,"status":207,"phases":8863,"primaryCompletion":674,"completion":675,"start":8864,"enrollment":677,"conditions":8865,"interventions":8866},"NCT01563861","S9704-S0014-S0313A Studying Genes in Samples From Patients With Limited or Advanced Diffuse Large B-Cell Lymphoma",[],"1997-09-15",[18],[8867,575],"RNA analysis",{"nctId":8869,"briefTitle":8870,"status":207,"phases":8871,"primaryCompletion":8872,"completion":8873,"start":8874,"enrollment":8875,"conditions":8876,"interventions":8877},"NCT00896727","S9313A Protein Expression Analysis of Breast Cancer Tissue Microarrays From Clinical Trial SWOG-9313",[],"2009-01-02","2009-04-02","2006-07-17",2100,[15],[575,8878],"protein expression analysis",{"nctId":8880,"briefTitle":8881,"status":207,"phases":8882,"primaryCompletion":2159,"completion":2159,"start":1312,"enrollment":8883,"conditions":8884,"interventions":8885},"NCT01503541","S9031-9333-0106-0112-A Study of Biomarkers in Samples From Patients With Acute Myeloid Leukemia Treated With Standard Chemotherapy With or Without Gemtuzumab Ozogamicin",[],365,[24],[8886,8867,575,8887,8888],"DNA analysis","mutation analysis","polymerase chain reaction",{"nctId":8890,"briefTitle":8891,"status":207,"phases":8892,"primaryCompletion":5916,"completion":5916,"start":1011,"enrollment":8893,"conditions":8894,"interventions":8895},"NCT00899171","S9031-S9126-S9333-S9500-A, Studying Bone Marrow and Blood Samples From Patients With Acute Myeloid Leukemia",[],251,[24],[8886,8896,8867,575,8897],"DNA methylation analysis","reverse transcriptase-polymerase chain reaction",{"nctId":8899,"briefTitle":8900,"status":207,"phases":8901,"primaryCompletion":8902,"completion":8902,"start":1964,"enrollment":8903,"conditions":8904,"interventions":8905},"NCT01338974","S9031-S9333-S0112-S0301-A Biomarkers Associated With Response to Cytarabine in Samples From Older Patients With Acute Myeloid Leukemia",[],"2012-08",290,[24],[575,987],{"nctId":8907,"briefTitle":8908,"status":207,"phases":8909,"primaryCompletion":369,"completion":369,"start":972,"enrollment":8910,"conditions":8911,"interventions":8912},"NCT01575535","S0106B Studying Bone Marrow Samples From Women With Acute Myeloid Leukemia",[],100,[24],[575],{"nctId":8914,"briefTitle":8915,"status":207,"phases":8916,"primaryCompletion":5038,"completion":5038,"start":554,"enrollment":8917,"conditions":8918,"interventions":8919},"NCT00450281","S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7\u002F15\u002F07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer",[],981,[21],[8920,575,8887,8888,7933],"chromogenic in situ hybridization",{"nctId":8922,"briefTitle":8923,"status":207,"phases":8924,"primaryCompletion":8925,"completion":8925,"start":8926,"enrollment":8927,"conditions":8928,"interventions":8929},"NCT01120262","S9346A Blood Samples From Patients With Metastatic Prostate Cancer Previously Treated With Bicalutamide and Goserelin",[],"2010-07","2010-02",545,[27],[575,7933],{"nctId":8931,"briefTitle":8932,"status":207,"phases":8933,"primaryCompletion":480,"completion":480,"start":8934,"enrollment":8935,"conditions":8936,"interventions":8937},"NCT01434329","S8600-S9031-S9333-A, Study of DNA in Samples From Patients With Acute Myeloid Leukemia",[],"2011-10",200,[24],[8896,575,576],{"intervention":7933,"totalTrials":2131,"cells":8939},{"EARLY_PHASE1":8940,"PHASE1":8942,"PHASE2":8944,"PHASE3":8950,"PHASE4":8952,"NA":8954},{"trials":8941,"activeCount":100},[],{"trials":8943,"activeCount":100},[],{"trials":8945,"activeCount":100},[8946],{"nctId":7928,"briefTitle":7929,"status":207,"phases":8947,"primaryCompletion":469,"completion":469,"start":616,"enrollment":1636,"conditions":8948,"interventions":8949},[89],[1157,984],[7919,7933],{"trials":8951,"activeCount":100},[],{"trials":8953,"activeCount":100},[],{"trials":8955,"activeCount":100},[8956,8960,8968,8975,8982,8986,8990],{"nctId":8855,"briefTitle":8856,"status":207,"phases":8957,"primaryCompletion":2054,"completion":4037,"start":810,"enrollment":9,"conditions":8958,"interventions":8959},[],[4242],[575,7933],{"nctId":8961,"briefTitle":8962,"status":207,"phases":8963,"primaryCompletion":8964,"completion":8964,"start":543,"enrollment":8965,"conditions":8966,"interventions":8967},"NCT00985699","S8516-S8736-S9125-S9240 Research Study of Genes in Tissue Samples From Patients With B-cell Non-Hodgkin Lymphoma",[],"2014-06",337,[18],[7933],{"nctId":8969,"briefTitle":8970,"status":207,"phases":8971,"primaryCompletion":1087,"completion":1087,"start":2886,"enrollment":8972,"conditions":8973,"interventions":8974},"NCT00896623","SWOG 8897-A DNA Analysis in Predicting Treatment Outcome in Women With Breast Cancer in SWOG 8897",[],1577,[15],[8887,7933],{"nctId":8976,"briefTitle":8977,"status":207,"phases":8978,"primaryCompletion":2159,"completion":2159,"start":842,"enrollment":8979,"conditions":8980,"interventions":8981},"NCT01059734","S9031-S9126-S9333-S9500-B Biomarker Expression in Patients With Acute Myeloid Leukemia",[],357,[24],[8886,8867,8887,8888,7933],{"nctId":8914,"briefTitle":8915,"status":207,"phases":8983,"primaryCompletion":5038,"completion":5038,"start":554,"enrollment":8917,"conditions":8984,"interventions":8985},[],[21],[8920,575,8887,8888,7933],{"nctId":8922,"briefTitle":8923,"status":207,"phases":8987,"primaryCompletion":8925,"completion":8925,"start":8926,"enrollment":8927,"conditions":8988,"interventions":8989},[],[27],[575,7933],{"nctId":8991,"briefTitle":8992,"status":207,"phases":8993,"primaryCompletion":2159,"completion":2159,"start":1382,"enrollment":829,"conditions":8994,"interventions":8995},"NCT00933127","S8809-S9800-S9911-S9704-A Study of Blood and Tissue Samples From Patients With Follicular Lymphoma Treated With Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone",[],[18],[8886,8888,7933],{"intervention":1386,"totalTrials":843,"cells":8997},{"EARLY_PHASE1":8998,"PHASE1":9000,"PHASE2":9002,"PHASE3":9028,"PHASE4":9040,"NA":9042},{"trials":8999,"activeCount":100},[],{"trials":9001,"activeCount":100},[],{"trials":9003,"activeCount":100},[9004,9008,9012,9018,9024],{"nctId":5659,"briefTitle":5660,"status":207,"phases":9005,"primaryCompletion":5662,"completion":724,"start":2211,"enrollment":5663,"conditions":9006,"interventions":9007},[89],[21],[485,1386],{"nctId":5667,"briefTitle":5668,"status":207,"phases":9009,"primaryCompletion":5670,"completion":5671,"start":2211,"enrollment":5672,"conditions":9010,"interventions":9011},[89],[21],[485,1386],{"nctId":9013,"briefTitle":9014,"status":207,"phases":9015,"completion":4168,"start":358,"conditions":9016,"interventions":9017},"NCT00032123","Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer",[89],[1112,1113],[1386],{"nctId":9019,"briefTitle":9020,"status":207,"phases":9021,"primaryCompletion":2211,"completion":512,"start":391,"enrollment":974,"conditions":9022,"interventions":9023},"NCT00068367","S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor",[89],[2729],[1386],{"nctId":1378,"briefTitle":1379,"status":207,"phases":9025,"primaryCompletion":480,"completion":1381,"start":1382,"enrollment":1383,"conditions":9026,"interventions":9027},[89],[21],[668,1386,611],{"trials":9029,"activeCount":100},[9030],{"nctId":9031,"briefTitle":9032,"status":662,"phases":9033,"primaryCompletion":9034,"completion":9035,"start":9036,"enrollment":158,"conditions":9037,"interventions":9039},"NCT02926638","Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches",[89,90],"2015-01-12","2016-10-12","2014-06-16",[9038,1147,1148],"MET Positive",[1243,1244],{"trials":9041,"activeCount":100},[],{"trials":9043,"activeCount":100},[9044],{"nctId":1234,"briefTitle":1235,"status":207,"phases":9045,"primaryCompletion":1237,"completion":1238,"start":1239,"enrollment":1240,"conditions":9046,"interventions":9047},[],[1147,1148],[217,1150,1243,1180,47,950,1228,1244,1245,1246,1247],{"intervention":576,"totalTrials":910,"cells":9049},{"EARLY_PHASE1":9050,"PHASE1":9052,"PHASE2":9054,"PHASE3":9060,"PHASE4":9062,"NA":9064},{"trials":9051,"activeCount":100},[],{"trials":9053,"activeCount":100},[],{"trials":9055,"activeCount":100},[9056],{"nctId":569,"briefTitle":570,"status":241,"phases":9057,"primaryCompletion":408,"completion":408,"start":408,"enrollment":100,"conditions":9058,"interventions":9059},[89],[36,374],[475,506,294,333,349,399,574,363,364,575,576],{"trials":9061,"activeCount":100},[],{"trials":9063,"activeCount":100},[],{"trials":9065,"activeCount":100},[9066,9074,9083,9087],{"nctId":9067,"briefTitle":9068,"status":207,"phases":9069,"primaryCompletion":4955,"start":358,"enrollment":9070,"conditions":9071,"interventions":9072},"NCT00900263","S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma",[],375,[36,374,5892],[9073,576],"cytogenetic analysis",{"nctId":9075,"briefTitle":9076,"status":207,"phases":9077,"primaryCompletion":9078,"completion":9078,"start":1209,"enrollment":9079,"conditions":9080,"interventions":9081},"NCT00897091","S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil",[],"2007-10",750,[15],[9082,576,8897],"comparative genomic hybridization",{"nctId":8931,"briefTitle":8932,"status":207,"phases":9084,"primaryCompletion":480,"completion":480,"start":8934,"enrollment":8935,"conditions":9085,"interventions":9086},[],[24],[8896,575,576],{"nctId":9088,"briefTitle":9089,"status":207,"phases":9090,"primaryCompletion":9091,"completion":9091,"start":995,"enrollment":9092,"conditions":9093,"interventions":9094},"NCT00896922","S8809-S9800-S9911TM- Biological Markers in Patients With Follicular Lymphoma Treated on Clinical Trial SWOG-8809, SWOG-9800, or SWOG-9911",[],"2009-10",180,[18],[576],{"intervention":9073,"totalTrials":762,"cells":9096},{"EARLY_PHASE1":9097,"PHASE1":9099,"PHASE2":9101,"PHASE3":9103,"PHASE4":9105,"NA":9107},{"trials":9098,"activeCount":100},[],{"trials":9100,"activeCount":100},[],{"trials":9102,"activeCount":100},[],{"trials":9104,"activeCount":100},[],{"trials":9106,"activeCount":100},[],{"trials":9108,"activeCount":100},[9109,9113,9123,9133],{"nctId":9067,"briefTitle":9068,"status":207,"phases":9110,"primaryCompletion":4955,"start":358,"enrollment":9070,"conditions":9111,"interventions":9112},[],[36,374,5892],[9073,576],{"nctId":9114,"briefTitle":9115,"status":207,"phases":9116,"primaryCompletion":1294,"completion":531,"start":9117,"enrollment":19,"conditions":9118,"interventions":9119},"NCT00900042","SWOG-9023, DNA Analysis of Tumor Tissue From Patients With Metastatic Kidney Cancer",[],"1993-07",[2839],[9120,9121,9122,9073],"DNA ploidy analysis","DNA stability analysis","chromosomal translocation analysis",{"nctId":9124,"briefTitle":9125,"status":207,"phases":9126,"primaryCompletion":1068,"completion":1068,"start":9127,"enrollment":9128,"conditions":9129,"interventions":9131},"NCT00996047","S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers",[],"1991-07",3341,[24,716,9130],"Myelodysplastic\u002FMyeloproliferative Neoplasms",[9073,9132],"fluorescence in situ hybridization",{"nctId":9134,"briefTitle":9135,"status":207,"phases":9136,"primaryCompletion":1087,"completion":1087,"start":2160,"enrollment":2850,"conditions":9137,"interventions":9138},"NCT00898066","S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease",[],[18,412,6912],[9073,9132],{"intervention":8867,"totalTrials":762,"cells":9140},{"EARLY_PHASE1":9141,"PHASE1":9143,"PHASE2":9145,"PHASE3":9147,"PHASE4":9149,"NA":9151},{"trials":9142,"activeCount":100},[],{"trials":9144,"activeCount":100},[],{"trials":9146,"activeCount":100},[],{"trials":9148,"activeCount":100},[],{"trials":9150,"activeCount":100},[],{"trials":9152,"activeCount":100},[9153,9157,9161,9165],{"nctId":8861,"briefTitle":8862,"status":207,"phases":9154,"primaryCompletion":674,"completion":675,"start":8864,"enrollment":677,"conditions":9155,"interventions":9156},[],[18],[8867,575],{"nctId":8880,"briefTitle":8881,"status":207,"phases":9158,"primaryCompletion":2159,"completion":2159,"start":1312,"enrollment":8883,"conditions":9159,"interventions":9160},[],[24],[8886,8867,575,8887,8888],{"nctId":8890,"briefTitle":8891,"status":207,"phases":9162,"primaryCompletion":5916,"completion":5916,"start":1011,"enrollment":8893,"conditions":9163,"interventions":9164},[],[24],[8886,8896,8867,575,8897],{"nctId":8976,"briefTitle":8977,"status":207,"phases":9166,"primaryCompletion":2159,"completion":2159,"start":842,"enrollment":8979,"conditions":9167,"interventions":9168},[],[24],[8886,8867,8887,8888,7933],{"intervention":8886,"totalTrials":762,"cells":9170},{"EARLY_PHASE1":9171,"PHASE1":9173,"PHASE2":9175,"PHASE3":9177,"PHASE4":9179,"NA":9181},{"trials":9172,"activeCount":100},[],{"trials":9174,"activeCount":100},[],{"trials":9176,"activeCount":100},[],{"trials":9178,"activeCount":100},[],{"trials":9180,"activeCount":100},[],{"trials":9182,"activeCount":100},[9183,9187,9191,9195],{"nctId":8880,"briefTitle":8881,"status":207,"phases":9184,"primaryCompletion":2159,"completion":2159,"start":1312,"enrollment":8883,"conditions":9185,"interventions":9186},[],[24],[8886,8867,575,8887,8888],{"nctId":8890,"briefTitle":8891,"status":207,"phases":9188,"primaryCompletion":5916,"completion":5916,"start":1011,"enrollment":8893,"conditions":9189,"interventions":9190},[],[24],[8886,8896,8867,575,8897],{"nctId":8976,"briefTitle":8977,"status":207,"phases":9192,"primaryCompletion":2159,"completion":2159,"start":842,"enrollment":8979,"conditions":9193,"interventions":9194},[],[24],[8886,8867,8887,8888,7933],{"nctId":8991,"briefTitle":8992,"status":207,"phases":9196,"primaryCompletion":2159,"completion":2159,"start":1382,"enrollment":829,"conditions":9197,"interventions":9198},[],[18],[8886,8888,7933],{"intervention":8887,"totalTrials":762,"cells":9200},{"EARLY_PHASE1":9201,"PHASE1":9203,"PHASE2":9205,"PHASE3":9207,"PHASE4":9209,"NA":9211},{"trials":9202,"activeCount":100},[],{"trials":9204,"activeCount":100},[],{"trials":9206,"activeCount":100},[],{"trials":9208,"activeCount":100},[],{"trials":9210,"activeCount":100},[],{"trials":9212,"activeCount":100},[9213,9217,9221,9225],{"nctId":8880,"briefTitle":8881,"status":207,"phases":9214,"primaryCompletion":2159,"completion":2159,"start":1312,"enrollment":8883,"conditions":9215,"interventions":9216},[],[24],[8886,8867,575,8887,8888],{"nctId":8969,"briefTitle":8970,"status":207,"phases":9218,"primaryCompletion":1087,"completion":1087,"start":2886,"enrollment":8972,"conditions":9219,"interventions":9220},[],[15],[8887,7933],{"nctId":8976,"briefTitle":8977,"status":207,"phases":9222,"primaryCompletion":2159,"completion":2159,"start":842,"enrollment":8979,"conditions":9223,"interventions":9224},[],[24],[8886,8867,8887,8888,7933],{"nctId":8914,"briefTitle":8915,"status":207,"phases":9226,"primaryCompletion":5038,"completion":5038,"start":554,"enrollment":8917,"conditions":9227,"interventions":9228},[],[21],[8920,575,8887,8888,7933],{"intervention":8888,"totalTrials":762,"cells":9230},{"EARLY_PHASE1":9231,"PHASE1":9233,"PHASE2":9235,"PHASE3":9237,"PHASE4":9239,"NA":9241},{"trials":9232,"activeCount":100},[],{"trials":9234,"activeCount":100},[],{"trials":9236,"activeCount":100},[],{"trials":9238,"activeCount":100},[],{"trials":9240,"activeCount":100},[],{"trials":9242,"activeCount":100},[9243,9247,9251,9255],{"nctId":8880,"briefTitle":8881,"status":207,"phases":9244,"primaryCompletion":2159,"completion":2159,"start":1312,"enrollment":8883,"conditions":9245,"interventions":9246},[],[24],[8886,8867,575,8887,8888],{"nctId":8976,"briefTitle":8977,"status":207,"phases":9248,"primaryCompletion":2159,"completion":2159,"start":842,"enrollment":8979,"conditions":9249,"interventions":9250},[],[24],[8886,8867,8887,8888,7933],{"nctId":8914,"briefTitle":8915,"status":207,"phases":9252,"primaryCompletion":5038,"completion":5038,"start":554,"enrollment":8917,"conditions":9253,"interventions":9254},[],[21],[8920,575,8887,8888,7933],{"nctId":8991,"briefTitle":8992,"status":207,"phases":9256,"primaryCompletion":2159,"completion":2159,"start":1382,"enrollment":829,"conditions":9257,"interventions":9258},[],[18],[8886,8888,7933],{"intervention":1245,"totalTrials":252,"cells":9260},{"EARLY_PHASE1":9261,"PHASE1":9263,"PHASE2":9265,"PHASE3":9299,"PHASE4":9301,"NA":9303},{"trials":9262,"activeCount":100},[],{"trials":9264,"activeCount":100},[],{"trials":9266,"activeCount":100},[9267,9271],{"nctId":7229,"briefTitle":7230,"status":207,"phases":9268,"primaryCompletion":7232,"completion":7233,"start":7234,"enrollment":7235,"conditions":9269,"interventions":9270},[89],[7237,4505,176,214,215],[1665,1245,7239],{"nctId":9272,"briefTitle":9273,"status":207,"phases":9274,"primaryCompletion":9275,"completion":4502,"start":9276,"enrollment":9277,"conditions":9278,"interventions":9298},"NCT03377556","Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer",[89],"2021-01-10","2017-03-03",51,[9279,9280,9281,9282,9283,9284,9285,9286,9287,9288,9289,9290,9291,9292,9293,9294,9295,9296,1147,9297,1148],"ATM Gene Mutation","ATR Gene Mutation","BARD1 Gene Mutation","BRCA1 Gene Mutation","BRCA2 Gene Mutation","BRIP1 Gene Mutation","CHEK1 Gene Mutation","CHEK2 Gene Mutation","FANCA Gene Mutation","FANCC Gene Mutation","FANCD2 Gene Mutation","FANCF Gene Mutation","FANCM Gene Mutation","NBN Gene Mutation","PALB2 Gene Mutation","RAD51 Gene Mutation","RAD51B Gene Mutation","RAD54L Gene Mutation","RPA1 Gene Mutation",[1245],{"trials":9300,"activeCount":100},[],{"trials":9302,"activeCount":100},[],{"trials":9304,"activeCount":100},[9305],{"nctId":1234,"briefTitle":1235,"status":207,"phases":9306,"primaryCompletion":1237,"completion":1238,"start":1239,"enrollment":1240,"conditions":9307,"interventions":9308},[],[1147,1148],[217,1150,1243,1180,47,950,1228,1244,1245,1246,1247],{"intervention":987,"totalTrials":252,"cells":9310},{"EARLY_PHASE1":9311,"PHASE1":9313,"PHASE2":9319,"PHASE3":9321,"PHASE4":9323,"NA":9325},{"trials":9312,"activeCount":100},[],{"trials":9314,"activeCount":100},[9315],{"nctId":979,"briefTitle":980,"status":241,"phases":9316,"primaryCompletion":982,"completion":982,"start":502,"enrollment":100,"conditions":9317,"interventions":9318},[88],[15,33,21,27,984],[961,986,987],{"trials":9320,"activeCount":100},[],{"trials":9322,"activeCount":100},[],{"trials":9324,"activeCount":100},[],{"trials":9326,"activeCount":100},[9327,9334],{"nctId":9328,"briefTitle":9329,"status":207,"phases":9330,"primaryCompletion":480,"completion":480,"start":326,"enrollment":9331,"conditions":9332,"interventions":9333},"NCT01360125","S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based Chemotherapy",[],310,[24],[987],{"nctId":8899,"briefTitle":8900,"status":207,"phases":9335,"primaryCompletion":8902,"completion":8902,"start":1964,"enrollment":8903,"conditions":9336,"interventions":9337},[],[24],[575,987],{"intervention":9339,"totalTrials":96,"cells":9340},"clodronate disodium",{"EARLY_PHASE1":9341,"PHASE1":9343,"PHASE2":9345,"PHASE3":9347,"PHASE4":9359,"NA":9361},{"trials":9342,"activeCount":100},[],{"trials":9344,"activeCount":100},[],{"trials":9346,"activeCount":100},[],{"trials":9348,"activeCount":100},[9349],{"nctId":9350,"briefTitle":9351,"status":207,"phases":9352,"primaryCompletion":553,"completion":9353,"start":1060,"enrollment":9354,"conditions":9355,"interventions":9356},"NCT00127205","S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.",[90],"2021-03-29",6097,[15],[9339,9357,9358],"ibandronate sodium","zoledronic acid",{"trials":9360,"activeCount":100},[],{"trials":9362,"activeCount":100},[9363],{"nctId":9364,"briefTitle":9365,"status":241,"phases":9366,"primaryCompletion":8926,"completion":8926,"start":356,"enrollment":100,"conditions":9367,"interventions":9368},"NCT00873808","S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307",[],[15],[9339,9369,9357,9370,9358],"demeclocycline hydrochloride","tetracycline hydrochloride",{"intervention":9357,"totalTrials":96,"cells":9372},{"EARLY_PHASE1":9373,"PHASE1":9375,"PHASE2":9377,"PHASE3":9379,"PHASE4":9385,"NA":9387},{"trials":9374,"activeCount":100},[],{"trials":9376,"activeCount":100},[],{"trials":9378,"activeCount":100},[],{"trials":9380,"activeCount":100},[9381],{"nctId":9350,"briefTitle":9351,"status":207,"phases":9382,"primaryCompletion":553,"completion":9353,"start":1060,"enrollment":9354,"conditions":9383,"interventions":9384},[90],[15],[9339,9357,9358],{"trials":9386,"activeCount":100},[],{"trials":9388,"activeCount":100},[9389],{"nctId":9364,"briefTitle":9365,"status":241,"phases":9390,"primaryCompletion":8926,"completion":8926,"start":356,"enrollment":100,"conditions":9391,"interventions":9392},[],[15],[9339,9369,9357,9370,9358],{"intervention":9358,"totalTrials":96,"cells":9394},{"EARLY_PHASE1":9395,"PHASE1":9397,"PHASE2":9399,"PHASE3":9401,"PHASE4":9407,"NA":9409},{"trials":9396,"activeCount":100},[],{"trials":9398,"activeCount":100},[],{"trials":9400,"activeCount":100},[],{"trials":9402,"activeCount":100},[9403],{"nctId":9350,"briefTitle":9351,"status":207,"phases":9404,"primaryCompletion":553,"completion":9353,"start":1060,"enrollment":9354,"conditions":9405,"interventions":9406},[90],[15],[9339,9357,9358],{"trials":9408,"activeCount":100},[],{"trials":9410,"activeCount":100},[9411],{"nctId":9364,"briefTitle":9365,"status":241,"phases":9412,"primaryCompletion":8926,"completion":8926,"start":356,"enrollment":100,"conditions":9413,"interventions":9414},[],[15],[9339,9369,9357,9370,9358],{"intervention":1180,"totalTrials":96,"cells":9416},{"EARLY_PHASE1":9417,"PHASE1":9419,"PHASE2":9421,"PHASE3":9423,"PHASE4":9429,"NA":9431},{"trials":9418,"activeCount":100},[],{"trials":9420,"activeCount":100},[],{"trials":9422,"activeCount":100},[],{"trials":9424,"activeCount":100},[9425],{"nctId":1165,"briefTitle":1166,"status":207,"phases":9426,"primaryCompletion":1168,"completion":1169,"start":1170,"enrollment":1171,"conditions":9427,"interventions":9428},[89,90],[1173,1174,1175,1176,1177,1178,1147,1148],[217,1180],{"trials":9430,"activeCount":100},[],{"trials":9432,"activeCount":100},[9433],{"nctId":1234,"briefTitle":1235,"status":207,"phases":9434,"primaryCompletion":1237,"completion":1238,"start":1239,"enrollment":1240,"conditions":9435,"interventions":9436},[],[1147,1148],[217,1150,1243,1180,47,950,1228,1244,1245,1246,1247],{"intervention":1228,"totalTrials":96,"cells":9438},{"EARLY_PHASE1":9439,"PHASE1":9441,"PHASE2":9443,"PHASE3":9445,"PHASE4":9451,"NA":9453},{"trials":9440,"activeCount":100},[],{"trials":9442,"activeCount":100},[],{"trials":9444,"activeCount":100},[],{"trials":9446,"activeCount":100},[9447],{"nctId":1216,"briefTitle":1217,"status":207,"phases":9448,"primaryCompletion":1219,"completion":1220,"start":1221,"enrollment":423,"conditions":9449,"interventions":9450},[89,90],[1223,1224,1225,1226,1147,1148],[217,1228],{"trials":9452,"activeCount":100},[],{"trials":9454,"activeCount":100},[9455],{"nctId":1234,"briefTitle":1235,"status":207,"phases":9456,"primaryCompletion":1237,"completion":1238,"start":1239,"enrollment":1240,"conditions":9457,"interventions":9458},[],[1147,1148],[217,1150,1243,1180,47,950,1228,1244,1245,1246,1247],{"intervention":1244,"totalTrials":96,"cells":9460},{"EARLY_PHASE1":9461,"PHASE1":9463,"PHASE2":9465,"PHASE3":9467,"PHASE4":9473,"NA":9475},{"trials":9462,"activeCount":100},[],{"trials":9464,"activeCount":100},[],{"trials":9466,"activeCount":100},[],{"trials":9468,"activeCount":100},[9469],{"nctId":9031,"briefTitle":9032,"status":662,"phases":9470,"primaryCompletion":9034,"completion":9035,"start":9036,"enrollment":158,"conditions":9471,"interventions":9472},[89,90],[9038,1147,1148],[1243,1244],{"trials":9474,"activeCount":100},[],{"trials":9476,"activeCount":100},[9477],{"nctId":1234,"briefTitle":1235,"status":207,"phases":9478,"primaryCompletion":1237,"completion":1238,"start":1239,"enrollment":1240,"conditions":9479,"interventions":9480},[],[1147,1148],[217,1150,1243,1180,47,950,1228,1244,1245,1246,1247],{"intervention":1246,"totalTrials":96,"cells":9482},{"EARLY_PHASE1":9483,"PHASE1":9485,"PHASE2":9487,"PHASE3":9497,"PHASE4":9499,"NA":9501},{"trials":9484,"activeCount":100},[],{"trials":9486,"activeCount":100},[],{"trials":9488,"activeCount":100},[9489],{"nctId":9490,"briefTitle":9491,"status":207,"phases":9492,"primaryCompletion":9493,"completion":9494,"start":552,"enrollment":8670,"conditions":9495,"interventions":9496},"NCT02785913","Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches",[89],"2017-02","2019-11",[1147,1433],[1246],{"trials":9498,"activeCount":100},[],{"trials":9500,"activeCount":100},[],{"trials":9502,"activeCount":100},[9503],{"nctId":1234,"briefTitle":1235,"status":207,"phases":9504,"primaryCompletion":1237,"completion":1238,"start":1239,"enrollment":1240,"conditions":9505,"interventions":9506},[],[1147,1148],[217,1150,1243,1180,47,950,1228,1244,1245,1246,1247],{"intervention":1247,"totalTrials":96,"cells":9508},{"EARLY_PHASE1":9509,"PHASE1":9511,"PHASE2":9513,"PHASE3":9519,"PHASE4":9521,"NA":9523},{"trials":9510,"activeCount":100},[],{"trials":9512,"activeCount":100},[],{"trials":9514,"activeCount":100},[9515],{"nctId":4909,"briefTitle":4910,"status":207,"phases":9516,"primaryCompletion":4912,"completion":4913,"start":4914,"enrollment":1342,"conditions":9517,"interventions":9518},[89],[1147,1148],[1150,1247],{"trials":9520,"activeCount":100},[],{"trials":9522,"activeCount":100},[],{"trials":9524,"activeCount":100},[9525],{"nctId":1234,"briefTitle":1235,"status":207,"phases":9526,"primaryCompletion":1237,"completion":1238,"start":1239,"enrollment":1240,"conditions":9527,"interventions":9528},[],[1147,1148],[217,1150,1243,1180,47,950,1228,1244,1245,1246,1247],{"intervention":8896,"totalTrials":96,"cells":9530},{"EARLY_PHASE1":9531,"PHASE1":9533,"PHASE2":9535,"PHASE3":9537,"PHASE4":9539,"NA":9541},{"trials":9532,"activeCount":100},[],{"trials":9534,"activeCount":100},[],{"trials":9536,"activeCount":100},[],{"trials":9538,"activeCount":100},[],{"trials":9540,"activeCount":100},[],{"trials":9542,"activeCount":100},[9543,9547],{"nctId":8890,"briefTitle":8891,"status":207,"phases":9544,"primaryCompletion":5916,"completion":5916,"start":1011,"enrollment":8893,"conditions":9545,"interventions":9546},[],[24],[8886,8896,8867,575,8897],{"nctId":8931,"briefTitle":8932,"status":207,"phases":9548,"primaryCompletion":480,"completion":480,"start":8934,"enrollment":8935,"conditions":9549,"interventions":9550},[],[24],[8896,575,576],{"intervention":8897,"totalTrials":96,"cells":9552},{"EARLY_PHASE1":9553,"PHASE1":9555,"PHASE2":9557,"PHASE3":9559,"PHASE4":9561,"NA":9563},{"trials":9554,"activeCount":100},[],{"trials":9556,"activeCount":100},[],{"trials":9558,"activeCount":100},[],{"trials":9560,"activeCount":100},[],{"trials":9562,"activeCount":100},[],{"trials":9564,"activeCount":100},[9565,9569],{"nctId":8890,"briefTitle":8891,"status":207,"phases":9566,"primaryCompletion":5916,"completion":5916,"start":1011,"enrollment":8893,"conditions":9567,"interventions":9568},[],[24],[8886,8896,8867,575,8897],{"nctId":9075,"briefTitle":9076,"status":207,"phases":9570,"primaryCompletion":9078,"completion":9078,"start":1209,"enrollment":9079,"conditions":9571,"interventions":9572},[],[15],[9082,576,8897],{"intervention":9132,"totalTrials":96,"cells":9574},{"EARLY_PHASE1":9575,"PHASE1":9577,"PHASE2":9579,"PHASE3":9581,"PHASE4":9583,"NA":9585},{"trials":9576,"activeCount":100},[],{"trials":9578,"activeCount":100},[],{"trials":9580,"activeCount":100},[],{"trials":9582,"activeCount":100},[],{"trials":9584,"activeCount":100},[],{"trials":9586,"activeCount":100},[9587,9591],{"nctId":9124,"briefTitle":9125,"status":207,"phases":9588,"primaryCompletion":1068,"completion":1068,"start":9127,"enrollment":9128,"conditions":9589,"interventions":9590},[],[24,716,9130],[9073,9132],{"nctId":9134,"briefTitle":9135,"status":207,"phases":9592,"primaryCompletion":1087,"completion":1087,"start":2160,"enrollment":2850,"conditions":9593,"interventions":9594},[],[18,412,6912],[9073,9132],{"intervention":9120,"totalTrials":117,"cells":9596},{"EARLY_PHASE1":9597,"PHASE1":9599,"PHASE2":9601,"PHASE3":9603,"PHASE4":9605,"NA":9607},{"trials":9598,"activeCount":100},[],{"trials":9600,"activeCount":100},[],{"trials":9602,"activeCount":100},[],{"trials":9604,"activeCount":100},[],{"trials":9606,"activeCount":100},[],{"trials":9608,"activeCount":100},[9609],{"nctId":9114,"briefTitle":9115,"status":207,"phases":9610,"primaryCompletion":1294,"completion":531,"start":9117,"enrollment":19,"conditions":9611,"interventions":9612},[],[2839],[9120,9121,9122,9073],{"intervention":9121,"totalTrials":117,"cells":9614},{"EARLY_PHASE1":9615,"PHASE1":9617,"PHASE2":9619,"PHASE3":9621,"PHASE4":9623,"NA":9625},{"trials":9616,"activeCount":100},[],{"trials":9618,"activeCount":100},[],{"trials":9620,"activeCount":100},[],{"trials":9622,"activeCount":100},[],{"trials":9624,"activeCount":100},[],{"trials":9626,"activeCount":100},[9627],{"nctId":9114,"briefTitle":9115,"status":207,"phases":9628,"primaryCompletion":1294,"completion":531,"start":9117,"enrollment":19,"conditions":9629,"interventions":9630},[],[2839],[9120,9121,9122,9073],{"intervention":9122,"totalTrials":117,"cells":9632},{"EARLY_PHASE1":9633,"PHASE1":9635,"PHASE2":9637,"PHASE3":9639,"PHASE4":9641,"NA":9643},{"trials":9634,"activeCount":100},[],{"trials":9636,"activeCount":100},[],{"trials":9638,"activeCount":100},[],{"trials":9640,"activeCount":100},[],{"trials":9642,"activeCount":100},[],{"trials":9644,"activeCount":100},[9645],{"nctId":9114,"briefTitle":9115,"status":207,"phases":9646,"primaryCompletion":1294,"completion":531,"start":9117,"enrollment":19,"conditions":9647,"interventions":9648},[],[2839],[9120,9121,9122,9073],{"intervention":8878,"totalTrials":117,"cells":9650},{"EARLY_PHASE1":9651,"PHASE1":9653,"PHASE2":9655,"PHASE3":9657,"PHASE4":9659,"NA":9661},{"trials":9652,"activeCount":100},[],{"trials":9654,"activeCount":100},[],{"trials":9656,"activeCount":100},[],{"trials":9658,"activeCount":100},[],{"trials":9660,"activeCount":100},[],{"trials":9662,"activeCount":100},[9663],{"nctId":8869,"briefTitle":8870,"status":207,"phases":9664,"primaryCompletion":8872,"completion":8873,"start":8874,"enrollment":8875,"conditions":9665,"interventions":9666},[],[15],[575,8878],{"intervention":9668,"totalTrials":117,"cells":9669},"Oxycodone\u002Facetaminophen 5\u002F325 mg",{"EARLY_PHASE1":9670,"PHASE1":9672,"PHASE2":9674,"PHASE3":9676,"PHASE4":9678,"NA":9680},{"trials":9671,"activeCount":100},[],{"trials":9673,"activeCount":100},[],{"trials":9675,"activeCount":100},[],{"trials":9677,"activeCount":100},[],{"trials":9679,"activeCount":100},[],{"trials":9681,"activeCount":100},[9682],{"nctId":9683,"briefTitle":9684,"status":662,"phases":9685,"primaryCompletion":9686,"completion":9686,"start":9687,"enrollment":96,"conditions":9688,"interventions":9689},"NCT04194528","S1916 Digital Medicine Program for Pain Control in Cancer Patients",[92],"2020-09-16","2020-01-22",[1157],[9668],{"intervention":9691,"totalTrials":117,"cells":9692},"polyacrylamide gel electrophoresis",{"EARLY_PHASE1":9693,"PHASE1":9695,"PHASE2":9697,"PHASE3":9699,"PHASE4":9701,"NA":9703},{"trials":9694,"activeCount":100},[],{"trials":9696,"activeCount":100},[],{"trials":9698,"activeCount":100},[],{"trials":9700,"activeCount":100},[],{"trials":9702,"activeCount":100},[],{"trials":9704,"activeCount":100},[9705],{"nctId":9706,"briefTitle":9707,"status":207,"phases":9708,"primaryCompletion":6436,"completion":6436,"start":9709,"enrollment":9710,"conditions":9711,"interventions":9712},"NCT00899743","S9333A Study of Blood and Bone Marrow Samples From Patients With Previously Untreated Primary Acute Myeloid Leukemia",[],"2008-08",132,[24],[9691,9713],"western blotting",{"intervention":9713,"totalTrials":117,"cells":9715},{"EARLY_PHASE1":9716,"PHASE1":9718,"PHASE2":9720,"PHASE3":9722,"PHASE4":9724,"NA":9726},{"trials":9717,"activeCount":100},[],{"trials":9719,"activeCount":100},[],{"trials":9721,"activeCount":100},[],{"trials":9723,"activeCount":100},[],{"trials":9725,"activeCount":100},[],{"trials":9727,"activeCount":100},[9728],{"nctId":9706,"briefTitle":9707,"status":207,"phases":9729,"primaryCompletion":6436,"completion":6436,"start":9709,"enrollment":9710,"conditions":9730,"interventions":9731},[],[24],[9691,9713],{"intervention":9369,"totalTrials":117,"cells":9733},{"EARLY_PHASE1":9734,"PHASE1":9736,"PHASE2":9738,"PHASE3":9740,"PHASE4":9742,"NA":9744},{"trials":9735,"activeCount":100},[],{"trials":9737,"activeCount":100},[],{"trials":9739,"activeCount":100},[],{"trials":9741,"activeCount":100},[],{"trials":9743,"activeCount":100},[],{"trials":9745,"activeCount":100},[9746],{"nctId":9364,"briefTitle":9365,"status":241,"phases":9747,"primaryCompletion":8926,"completion":8926,"start":356,"enrollment":100,"conditions":9748,"interventions":9749},[],[15],[9339,9369,9357,9370,9358],{"intervention":9370,"totalTrials":117,"cells":9751},{"EARLY_PHASE1":9752,"PHASE1":9754,"PHASE2":9756,"PHASE3":9758,"PHASE4":9760,"NA":9762},{"trials":9753,"activeCount":100},[],{"trials":9755,"activeCount":100},[],{"trials":9757,"activeCount":100},[],{"trials":9759,"activeCount":100},[],{"trials":9761,"activeCount":100},[],{"trials":9763,"activeCount":100},[9764],{"nctId":9364,"briefTitle":9365,"status":241,"phases":9765,"primaryCompletion":8926,"completion":8926,"start":356,"enrollment":100,"conditions":9766,"interventions":9767},[],[15],[9339,9369,9357,9370,9358],{"intervention":8920,"totalTrials":117,"cells":9769},{"EARLY_PHASE1":9770,"PHASE1":9772,"PHASE2":9774,"PHASE3":9776,"PHASE4":9778,"NA":9780},{"trials":9771,"activeCount":100},[],{"trials":9773,"activeCount":100},[],{"trials":9775,"activeCount":100},[],{"trials":9777,"activeCount":100},[],{"trials":9779,"activeCount":100},[],{"trials":9781,"activeCount":100},[9782],{"nctId":8914,"briefTitle":8915,"status":207,"phases":9783,"primaryCompletion":5038,"completion":5038,"start":554,"enrollment":8917,"conditions":9784,"interventions":9785},[],[21],[8920,575,8887,8888,7933],{"intervention":9082,"totalTrials":117,"cells":9787},{"EARLY_PHASE1":9788,"PHASE1":9790,"PHASE2":9792,"PHASE3":9794,"PHASE4":9796,"NA":9798},{"trials":9789,"activeCount":100},[],{"trials":9791,"activeCount":100},[],{"trials":9793,"activeCount":100},[],{"trials":9795,"activeCount":100},[],{"trials":9797,"activeCount":100},[],{"trials":9799,"activeCount":100},[9800],{"nctId":9075,"briefTitle":9076,"status":207,"phases":9801,"primaryCompletion":9078,"completion":9078,"start":1209,"enrollment":9079,"conditions":9802,"interventions":9803},[],[15],[9082,576,8897]]